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ABSTRACT OF THE THESIS 
 
A Thesis on the Detection of Parkinson Disease Rest Tremor  
by 
Matthew Jonathan Johnson 
Master of Science in Electrical Engineering  
Washington University in St. Louis, 2014 
Research Advisor:  Dr. Arye Nehorai, Department Chair  
 
Parkinson Disease (PD) is a debilitating and progressive movement disorder that is 
estimated to affect over six million worldwide. One of the most characteristic symptoms of PD is 
resting tremor, which involves unintentional and rhythmic muscle oscillations of an afflicted 
extremity while the muscles of said extremity are relaxed. This study involved measuring the rest 
tremor of 10 PD subjects, 10 Essential Tremor subjects, and 10 healthy control subjects using two 
devices. One device was an FDA approved accelerometry system to measure human tremor known 
as the TremorometerTM and the other was a consumer three-dimensional camera known as the Leap 
MotionTM Controller. The study compares tremor characteristics calculated from both devices to 
compare the Leap Motion Controller to the Tremorometer System. The tremor characteristics 
obtained from the Leap Motion Controller were also used in an attempt to classify the subjects used 
in the study as either PD or non-PD subjects.  
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Chapter 1 
 
Introduction 
 
1.1 Purpose 
 
Parkinson Disease (PD) is a debilitating and progressive movement disorder 
that affects over one million people in the United States alone. One of the most 
characteristic symptoms of PD is resting tremor, as it has been shown that the 
proportion of patients with resting tremor ranged from 69-100% in 3 series of patients 
with autopsy-proven PD.1,2,3  Several methods currently exist to quantitatively measure 
tremor including accelerometry, electromyography, the spirogram, and most recently 
three-dimensional cameras.4  
 
This study involves measuring the rest tremor of 30 human subjects, consisting 
of 10 Parkinson’s subjects, 10 Essential Tremor subjects, and 10 healthy control 
subjects to classify test subjects as either Parkinson or non-Parkinson. The rest tremor 
was measured by recording the three-dimensional position and acceleration of their 
index finger while at rest over a set period of time using two devices. The first device, 
the TremorometerTM, has 510k clearance by the FDA to measure and quantify tremor 
by measuring acceleration in human patients. The second device, the Leap MotionTM 
Controller, is a three-dimensional camera that uses two CCD (Charged Coupled Device) 
cameras, three infrared Light Emitting Diodes (LEDs), and preprocessing in order to 
obtain position data.  
 
The study was split into two sections. The first section, involves comparing the 
Leap Motion Controller to the Tremorometer by calculating different tremor 
characteristics and comparing them to determine if the two devices are statistically 
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similar. The second part of the study involves using those same characteristics in an 
attempt to classify subjects as either Parkinson or non-Parkinson subjects. 
 
1.2 Motivation 
 
Advances in three-dimensional cameras have allowed for more accurate 
recordings and can now be used to provide much more accurate measurements in 
microdisplacements of upper extremities that are involved in movements such as resting 
tremor. The Leap Motion Controller produced by Leap Motion, Inc., has been shown 
to be capable of measuring changes in position of 0.2 mm for static setup and 1.2 mm 
for a dynamic setup.5 The Leap Motion Controller requires no external sensors or 
markers to be attached to the body unlike accelerometry, electromyography, and the 
spirogram. One possible disadvantage of having sensors attached to the body is that for 
every gram of additional mass a sensor adds, the peak frequency of finger tremor 
decreases by approximately 0.85 Hz and can also have an affect the amplitude of 
acceleration.6 Therefore the attached sensors may change the characteristics of the 
tremor and thus could alter the interpretation of tremor. Attaching sensors to the body 
can also be inconvenient, uncomfortable, and provide a margin of error if not done 
correctly. Another advantage of the Leap Motion Controller over accelerometry is that 
it does not require calibration, eliminating possible errors caused by consistent 
recalibration. Unlike electromyography, the Leap Motion Controller is not affected by 
interference from electrical sources, mechanical artifacts, stimulus artifacts, and the 
electrical activity of muscles that are not of interest. It is for these reasons that the Leap 
Motion Controller is of interest and may be a superior method for measuring tremor. 
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Chapter 2 
  
Background 
 
2.1 Parkinson Disease  
 
2.1.1 Prevalence 
 
According to the National Institute of Neurological Disorders and Stroke, at 
least 500,000 people suffer from Parkinson Disease (PD) in the United States with 
about 50,000 new cases reported annually.7 With more than 22,000 lives lost to PD in 
2010, it was claimed to be the 14th leading cause of death in the United States by the 
United States Centers for Disease Control and Prevention (CDC).8 As can be seen in 
Figure 2.1, the age-adjusted death rate for PD has steadily increased since 1958.  
 
Figure 2.1  Age-adjusted death rates for selected leading causes of death in the United 
States between 1958 and 2010. Figure obtained from the CDC.8 
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In fact, it has been projected that the estimate of people with Parkinson’s 
(PwPs) in 2005 is expected to double by 2030 in the world’s ten most populous nations 
as shown in Figure 2.2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 Symptoms  
 
Although symptoms can vary significantly between individuals, the primary 
motor symptoms involved with Parkinson Disease include: rigidity, postural instability, 
bradykinesia and tremor.10 
 
Figure 2.2  Projected number of People with Parkinson disease (PwP)  
in the most populous nations between 2005 and 2030. Figure obtained 
from Dorsey, et al (2007). 
     
 
5 
Bradykinesia  Bradykinesia refers to slowness of movement and 
initially manifests as slowness in performing activities associated with daily living, slow 
movement, and reaction times.10,11,12 Similar to other parkinsonian symptoms, 
bradykinesia is dependent on the emotional state of the patient and is the Parkinson 
characteristic that correlates best with the degree of dopamine deficiency.10,13 
 
Rigidity Rigidity is described as an increase in resistance while passively 
stretching a muscle, causing a feeling of stiffness.14 Rigidity is sometimes accompanied 
by the “cogwheel” phenomenon, which is the periodic interruption of rigidity on 
passive movement of the limbs.15 Rigidity of the neck and trunk eventually leads to 
changes in posture and postural deformities. 
 
Postural Instability  Postural instability usually occurs during the late 
stages of PD and typically after the onset of the other motor symptoms.10 It is the most 
common cause of falls and the late onset of falls can differentiate PD from other 
neurodegenerative disorders like progressive supranuclear palsy (PSP) and multiple 
system atrophy (MSA). 10,16  
 
Tremor Tremor is defined as an involuntary rhythmic oscillation of a 
body part. The characteristic tremor of PD, is usually a 3-6 Hz distal resting tremor, but 
patients with PD may also exhibit postural and kinetic tremors.17-19 Rest tremor occurs 
when a body part is at rest or relaxed while postural tremor occurs when a body part is 
maintained at a position against gravity, and kinetic tremor occurs during the movement 
of a body part. Rest tremor is such a characteristic feature of Parkinson’s that it has 
been shown that the proportion of patients with resting tremor ranged from 69-100% 
in three series of autopsy proven PD.1,2,3 In fact, rest tremor is the most common and 
most recognizable symptom of PD, and is, by itself, a positive diagnostic criterion for 
PD.10,20 
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2.2 Tremor Analysis 
 
New technologies and methods that complement the clinical neurologic 
evaluation are becoming more popular and useful by offering objective and quantitative 
data that can be analyzed. In fact, difficult medical diagnoses can even be confirmed or 
excluded on the basis of these additional tests. Since tremor is one of the most cardinal 
symptoms of PD, tremor analysis has become one of the most useful of these new 
methods to help differentiate tremor associated with PD from other types of tremor.21 
 
Tremor analysis refers to the method of recording certain identifiable 
characteristics of tremor and other involuntary movements through the use of 
computers and other hardware.  Since tremors are quasi-sinusoidal movements, they can 
be approached using a quantitative mathematical analysis.21 Two of the most important 
characteristics of tremor in tremor analysis, are the frequency and amplitude. Tremor 
frequency refers to the number of oscillations per second and is usually measured in 
cycles per second (Hz), while tremor amplitude refers to the degree of linear or angular 
displacement of the limb and is typically measured in degrees or millimeters. Tremor 
analysis is most useful when the clinical signs are subtle, such as distinguishing between 
Parkinsonian tremor and essential tremor.22 
 
2.2.1 Commonly Used Methods 
 
Accelerometry Accelerometry is accomplished through the use of 
accelerometers that measure static or dynamic acceleration forces. Miniature 
accelerometers can be attached to the afflicted body part, which are typically the limbs, 
and usually do not interfere with voluntary or involuntary movements. Mathematical 
integration is needed to determine the displacement of the oscillating body part and to 
better perceive the sinusoidal motion of the tremor.21 
 
Electromyography In electromyography (EMG), typically surface electrodes 
are fixed on the flexor and extensor muscles of the limb to measure the electrical 
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activity produced by the muscles involved in the generation of the tremor. However, 
EMG activity can also be measured using needle or wire electrodes.23 The EMG signal 
should be processed by rectification and integration or smoothing to properly place its 
frequency profile into the tremor range.24 
 
Spirogram Spirograms are less common than the other methods, but are 
performed by analyzing a drawing made by the patient of models of Archimedes’ 
spirals. This method is based on essentially “unraveling” the two-dimensional drawn 
spiral to determine kinematic data.  This kinematic data is collected in the X, Y, and 
pressure axes, which essentially provides a virtual tri-axial recording of data. By 
analyzing multiple trials together, tremor characteristics such as frequency, direction, 
and amplitude can be detected and quantified.  
 
Optical Systems Optical systems consist of a light source and an optical 
sensor. Some examples of laser-based systems are displacement lasers and velocity 
transducing lasers and have been previously used to record kinematic data associated 
with tremor in PD.25,26 Other optical systems include vision systems and essentially 
involve a sensor and an emitter, such as infrared cameras, which are used in many 
commercial motion capture systems.27,28  These vision systems can be used to measure 
and record the three-dimensional position of the body part exhibiting tremor with 
respect to time and can then be used to calculate velocity, acceleration, and other 
characteristic parameters. 
 
2.2.2 Tremorometer 
 
The Tremorometer is an accelerometer-based system produced by FlexAble 
Systems, Inc. that has received FDA 510 (k) approval to measure and quantify tremor in 
human patients. The system consists of two major components: the TremorScope and 
the TremorLab.  
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TremorScope®   The TremorScope, shown in Figure 2.3, consists 
of a tri-axial accelerometer integrated circuit that can measure precise changes in 
acceleration in three dimensions as well as a microcontroller that provides the precision 
timing necessary to take the measurements. These components are housed in a 15x20x9 
mm plastic case, weighing approximately 4 grams, and interface to any PC via a 
permanently attached USB cable. The triaxial accelerometer can measure 5 milli-g 
resolution, however it is recommended that the selectable measurement range of ± 2g at 
3 milli-g resolution is best for most tremors. The TremorScope samples at 100 Hz and 
the acceleration readings are converted from an analog to a digital output signal in 1 or 
3 milli-g units within the accelerometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
TremorLab® The TremorLab is a Windows-based PC program that reads the 
incoming data from the TremorScope and converts the acceleration into tremor 
statistics as seen in Figure 2.4, on the following page. The software is capable of running 
a standard set of tests for human tremor including active, resting, active with load, and 
intention tremor in order to obtain the frequency, amplitude, and tremor time percent 
among other measurements and results.  
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TremorScope Sensor 
The TremorScope sensor has a tri-axial accelerometer that measures in all three dimensions 
simultaneously without imposing restrictions  on  the  subject’s  orientation.  The  TremorScope interfaces to 
any PC through a standard USB port.  The USB provides the power for the accelerometer and the 
microcontroller in the TremorScope. 
The accelerometers can measure about 5 milli-g resolution (1 milli-g equals 1/1000th of Earth gravity 
acceleration constant) which is a very small acceleration not detectable by the human eye.  The selectable 
measurement range of +/- 2g at 3 milli-g resolution is best for most tremors with +/- 4g at 5 milli-g resolution 
for large tremors or motion.   Since these devices can withstand an acceleration of 1000g without 
damage, it is unlikely that they should ever be damaged by mechanical action. 
F r proper orientation, th  side of the label showing the word TremorScope and the FlexAble Systems logo is 
the top of the Sensor and should be facing up.  The sensor may be attached to the middle phalange of the index 
finger by wrapping surgical tape around the finger once, placing the sensor on the finger and wrapping the 
tape arou d both the sensor and fi ger t  secure in place.  The cable should extend out toward the wrist.  
The cable may be lightly taped to the wrist to keep it out of the way.  The TremorScope should fit snugly and not 
be able to move.   
  
 
 
The TremorScope samples at 100 Hz.  The range and sample rate are controlled by the TremorLab program 
that sends the current settings to the TremorScope via the USB.  The actual sample rate and amplitude are 
controlled by the calibration information that provides improved accuracy.    
The acceleration readings are converted from an analog to a digital signal within the accelerometer and 
the output is a digital value that is the acceleration in 1 or 3 milli-g units. 
The TremorScope weighs only 4 grams and is attached to the PC USB port by the USB cable.  The USB cable is 
permanently attached to the TremorScope sensor and must not be removed or damage to the device will occur. 
  
This photo shows the proper position of 
the TremorScope for all TremTest 
Protocols included with TremorLab. 
The accelerometers are permanently 
calibrated and should never need 
calibration, but may be recalibrated using 
the Calibrate Mode and selecting the 
Protocol – “Calibrate Amplitude”.  Refer 
to the Tutorial “Calibrate” for Test 
TremorScope Calibration to check the 
calibration without changing it.  
The TremorScope is housed in a  
0.6 x 0.8 x 0.4 inch (15 x 20 x 9 mm) plastic 
case. 
 
 
Figure 2.3  TremorScope. Image obtained from Tremorometer System 
Manual. 
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2.2.3 Leap Motion Controller 
 
The Leap Motion Controller, shown in Figure 2.5, is a USB 3D camera that 
connects to a computer and is claimed to measure positional data accurate to within 
0.01 mm. The device, made by Leap Motion, Inc., is very small with a height of 1.27 cm, 
a width of 3.05 cm, a depth of 7.62 cm, and only weighs 45.36 g. The Leap Motion 
Controller uses two CCD (Charged Coupled Device) cameras and three infrared LEDs 
to obtain depth information. As illustrated in Figure 2.6, on the following page, the 
device is capable of detecting a roughly hemispheric area of about 0.23 cubic meters.   
 
 
 
 
 
 
 Figure 2.5  The Leap Motion Controller. Image 
obtained from Leap Motion, Inc.29 
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TremorLab Screen and Control Basics 
  [These instructions will make more sense and be easier to follow if you have  
   TremorLab running on your computer as you go through the manual.] 
The Menu bar at the top of the screen changes with the TremorLab Mode currently selected.  TremTest has the 
basic set; Custom adds Control and Advanced adds Analysis. 
TremTest:      TremorLab Mode  |  Documentation    About TremorLab  |  Done 
Custom:         TremorLab Mode  Control  |  Documentation    About TremorLab  |  Done  
Advanced:     TremorLab Mode  Control  Analysis  |  Documentation    About TremorLab  |  Done                              
TremorLab Mode is used to Evaluate or Purchase the Custom or Advanced Modes 
Documentation displays a screen where Documents, Text, Tutorials and Web Sites may be accessed 
About TremorLab lists the TremorScope S/N and Program Revision and the TremorLab Version 
Done is used to exit from TremorLab as does the 'x' in the upper right corner of the screen  
Control (Custom/Advanced) supports Load and Save a Control File for easy test configuration 
Analysis (Advanced) runs the program that lets two sets of readings be compared in many formats 
Most of the work in TremorLab is done on the Main screen that consists of controls and indicators.  These are 
basically grouped into five color-coded categories: 
Test Controls (brown) are used to select Protocols, Start the test, Show Tremor and other operations. 
Display Controls (gold) select display resolution, type of display and readings mode.  
Report Controls (green) setup reports, control the report generation, show the TREM Table results. 
File Controls (yellow) include Patient ID, Record ID and other items relating to the report files. 
Prompts (blue) have information about running the system and Tutorials. 
 
 
  Main TremorLab Screen showing the Controls and Indicators.  Figure2.4  Screenshot of TremorLab. Image obtained from the Tremorometer System 
Manual. 
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Output The Leap Motion Controller is capable of detecting and tracking 
hands, fingers, and tools in its field of view. The device captures data one frame at a 
time and the rate at which this occurs, or frame-rate, can vary based on the lighting 
conditions, but typically occurs at approximately 100 frames per second (fps). The 
device is capable of recording the three dimensional fingertip positions, which is done 
in millimeters relative to the device’s origin. The Leap Motion Controller follows a 
right-handed Cartesian coordinate system, with the origin centered at the top and 
middle of the Leap Motion Controller as shown in Figure 2.7.  The data from the Leap 
Motion Controller is accessible using the Leap SDK and a supported programming 
language such as C++, C#, Objective-C, Java, JavaScript, and Python.  
 
 
 
 
 
 
 
Interaction Area
2 feet above the controller, by 2 feet wide on each side 
(150° angle), by 2 feet deep on each side (120° angle)
Figure 2.6 Interaction Area of Leap Motion Controller. 
Image obtained from Leap Motion, Inc.29 
Figure 2.7  The Leap Motion Controller right-
handed coordinate system. Image obtained from 
the Leap Motion Developer Portal.29 
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Chapter 3 
 
Methodology  
 
A description of the methodology will include information about the setup 
required for the devices used, the subject groups, the recruitment and consent process, 
as well as the ethical considerations involved. A more in-depth methodology of the 
study can be seen in the attached Protocol, located in the Appendix. 
 
3.1 Device Setup  
 
 The two devices that were used in this study were the Tremorometer and Leap 
Motion Controller. These devices required an initial setup, which will be described in 
this section. 
 
3.1.1 Tremorometer 
 
 For the purposes of this study, the Custom module of the TremorLab 2013 
Software Program was used. This module allows the user to use the system for custom 
controlled tremor experimentation and supports different lengths of recording (from 5 
to 180 seconds) as well as custom test protocols.  
 
 One custom test protocol was developed for this study, which involved 
measuring rest tremor of the index finger of the hand that exhibited the most severe 
rest tremor. This protocol consisted of two separate trials, each lasting for thirty 
seconds, and was run once for each participant. Once the protocol was run, the data 
was labeled to identify the participant number and whether the participant was part of 
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the healthy, Parkinson, or Essential Tremor group. This data was then saved to a 
HIPAA compliant secure flash drive for later analysis.  
 
3.1.2 Leap Motion Controller 
 
To use the Leap Motion Controller for the purposes of this study, a stand-alone 
Java program was written in order to access and record the positions detected by the 
Leap Motion Controller. The Leap Motion Skeletal V2 Beta SDK for Java, obtained 
through the Leap Motion Developer Portal, was used in writing the program to provide 
more robust hand tracking even if the fingers or hands were partially occluded.  The 
Leap Motion Java SDK utilizes a standard Jar file for Leap Motion API class definitions 
as well as a set of native libraries that allow the Leap-enabled Java program to exchange 
data with the Leap Motion Controller. The Eclipse platform was used to write the code 
necessary to access and record the data obtained from the device for thirty seconds.  
 
The stand-alone Java program that was written, recorded the position of each 
fingertip on the hand that exhibited the most tremor. The code was run twice for each 
participant and each time it was run, it saved a separate comma delimited CSV file to a 
HIPAA compliant secure flash drive with a filename that identified an arbitrary 
participant number, the trial number, and whether the data was from a participant from 
the Healthy Control, Parkinson Disease, or Essential Tremor group.  
 
The Leap Motion Controller itself was also attached to the ramp used to 
support the participants’ arm during the recordings. It was positioned approximately 6 
cm below where the base of the hand rested. The Leap Motion Controller was oriented 
such that the Z-axis was vertical and increased in the upward direction; the Y-axis was 
parallel with the horizon and increased moving away from the ramp.  
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3.2 Subject Selection  
 
There were a total of thirty individuals who participated in this study. These 
thirty individuals were divided up into the different groups as follows: 10 patients with 
Parkinsonism with tremor based on diagnostic criteria30, 10 patients with Essential 
Tremor based on diagnostic criteria31, and 10 healthy subjects. All potential participants 
had to be over the age of 18, could be either male or female, could be of any race or 
ethnicity, and had to have the ability to give informed consent. A history of stroke, 
cerebral palsy, additional neurological disorders, severe upper limb tremor, and 
cognitive impairment (A Mini-Mental State Score less than 19) were set as exclusion 
criteria for all participants since the possible inclusion of these criteria could negatively 
affect the data.  
 
3.3 Subject Recruitment and Consent Process 
 
Participants were recruited from the Movement Disorders Center at 
Washington University School of Medicine as well as the Volunteer for Health initiative 
of Barnes-Jewish Hospital, an affiliate of the Washington University School of Medicine 
with a pool of over 8,000 volunteers. The clinical database in the Washington University 
Movement Disorders Clinic follows a large number of patients that met the criteria set 
for the study, making it a practical choice for recruitment.  
 
Participants were recruited in person during their clinic visits with their 
physician or nurse. If the potential participant expressed interest in the study and fit all 
inclusion/exclusion criteria, informed consent materials were provided. A study team 
member reviewed the document with the potential participant, which gave the 
participant an opportunity to ask questions. Potential participants were then given time 
to read the document in its entirety, ask questions, and speak with friends/family 
members if they desired. If the potential participants agreed to participate in the study, 
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they signed the informed consent, and were offered a signed copy of the consent after 
both parties signed the document. 
 
3.4 Study Procedures 
 
All participants, including the control participants, followed the same procedure. 
Each participant was measured individually, twice with the Tremorometer and twice 
with the Leap Motion Controller. This occurred behind the closed doors of an 
examination room. First, a study member taped the accelerometer (from the 
Tremorometer system) to the index finger on the hand that they believe to exhibit the 
most symptomatic tremor. Each participant then rested their arm on a small slanted 
ramp and was asked to relax their fingers and hands. The acceleration of their index 
finger was then recorded for 30 seconds, while the participant counted down from 100. 
After the first Tremorometer recording, the subject was asked to re-adjust their arm on 
the slanted ramp and again relax their fingers. The participant was again asked to count 
down from 100 while the 30-second recording takes place for the second time. Once 
the second recording was complete, the accelerometer was removed.  
 
The participant was then asked to place the same arm on the small slanted ramp 
with their fingers relaxed, this time in front of the Leap Motion Controller. The position 
of each finger on the testing hand was then recorded for 30 seconds, while the 
participant again counted down from 100. After the first recording with the Leap 
Motion Controller, the subject was asked to re-adjust their hand and again place it on 
the slanted ramp with their fingers relaxed. Then the second 30-second recording with 
the Leap Motion Controller took place, while the participant again counted down from 
100. It was estimated that the time commitment for each participant was approximately 
10 minutes.  
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3.5 Ethical Considerations 
 
Each participant was an adult equal to or greater than 18 years of age and gave 
informed consent. To ensure all participants had the ability can give informed consent 
all participants had to have a Mini-Mental State Score greater than or equal to 19 and 
could not have any serious medical or psychiatric condition.  
 
3.5.1 Risks and Benefits 
 
The potential risks that were determined for the participants were mild and 
considered unlikely. The predetermined potential risks included: discomfort from 
attempting to hold one hand still, boredom or frustration during the recordings, and 
stress if the patient exhibits too severe of upper limb tremor to record the data. In order 
to reduce the potential risk to the subjects, a physician was present throughout all 
studies.  
 
The two devices that were used in this study, the Leap Motion Controller and 
the Tremorometer, met the Food and Drug Administration (FDA) definition of a Non-
Significant Risk Device (NSR).  This is because neither device was used as an implant, 
used in supporting or sustaining human life, was of substantial importance in 
diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment 
of human health, and neither presented a potential for serious risk to the health, safety, 
or welfare of a subject. 
 
The Leap Motion Controller is a consumer three-dimensional camera and was 
used in accordance with its purpose: to measure and record hand and finger motions. 
The Tremorometer has 510k clearance for measuring and quantifying tremor in human 
participants, which was its only use in this study. As a result, it can be concluded that 
the use of these devices in the study was safe for all those who participated in the study. 
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3.5.2 Early Withdrawal of Subjects  
 
None of the participants chose to or were withdrawn from the study. However, 
all of the participants were informed that they could withdraw from the study at any 
point and would not be penalized or lose any benefits that they would otherwise qualify 
for. In this case, the recordings would end and the data collected from the participant 
would have been deleted and not used in the study. Participants could have also been 
withdrawn from the study if they had exhibited upper limb tremor that was too severe 
to be recorded or if the participant could not spread their fingers enough to be detected 
by the Leap Controller. This withdrawal would have been based on the judgment of the 
study team member at the time of recording. Any data collected by a subject who had 
decided to withdraw or was withdrawn during the recording would not have been used 
and would have been deleted.  
 
3.5.3 Confidentiality and Security  
 
In order to protect the confidentiality of the patients, only study team members 
had access to the medical record of any of the potential and enrolled subjects. These 
records are password protected in the clinical movement disorders database (MARS) of 
Washington University in St. Louis, which is HIPAA compliant. This is the clinical 
database for which clinical information is entered for all patients seen in the movement 
disorders division of neurology. The collected data did not contain any identifiers and 
was stored on a LOK-IT Secure Flash Drive, which was automatically encrypted with 
military-grade 256-bit AES hardware encryption and is also HIPAA compliant.  
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Chapter 4 
 
Analysis 
 
4.1 Leap Motion Data Conditioning 
 
In order to calculate the necessary characteristics from the data of the Leap 
Motion Controller, a preliminary conditioning of the position data was performed. This 
position data was conditioned to reduce noise and eliminate errors in order to obtain 
the filtered displacement, which was later used to classify the Parkinson subjects.  The 
displacement was then further conditioned to derive the acceleration, in order to 
compare it to the acceleration from the Tremorometer.  
 
Upon collection of the Leap Motion Controller data, it was noticed that the 
Leap Motion Controller would not detect the hand unless the hand was moved into the 
field of view of the device after the test had begun. Although the code was written so 
that no data was recorded until the hand was detected, this still caused the first second 
or so of each data set to be recording the subject purposefully moving their hand into a 
relaxed position into the view of the Leap Motion Controller. It was determined that 
the removal of the first three seconds of the data from each recording was sufficient to 
eliminate any intentional movement of placing the hand in view of the Leap Motion 
Controller from the data.  
 
4.1.1 Positions 
 
The Leap Motion Controller provides three-dimensional coordinates of position 
for each finger in its field of view. The position of the index finger is recorded with 
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respect to the origin of the Leap Motion Controller, which is centered at the top and 
middle of the surface of the Leap and is assumed to remain stationary.29 Examples of 
these positions can be seen on the following pages for subjects with Parkinson Disease 
in Figure 4.1, Essential Tremor in Figure 4.2, and for a Healthy Control in Figure 4.3.  
.  
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Figure 4.2 Recorded positions in millimeters with respect to time for each 
axis (x,y, and z) of Patient 15, who has Essential Tremor (ET). 
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Figure 4.1 Recorded positions in millimeters with respect to time for each 
axis (x,y, and z) of Patient 10, who has Parkinson Disease (PD). 
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4.1.2 Displacements 
 
In order to analyze the data from the Leap Motion Controller, displacements of 
the positions (Eq. 4.1) and new associated times (Eq. 4.2) were calculated for each axis.  
 
 (4.1) 
        (4.2) 
Where:   
n is the frame number,  
 p is the x, y, or z coordinate associate with frame n, 
 tn+1 is the time associated with frame n+1,  
Tn is the new time associated with pn. 
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Figure 4.3  Recorded positions in millimeters with respect to time for each 
axis (x,y, and z) of Patient 22, who is a Healthy (HE) Control. 
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The displacements are indicative of the magnitude of movement in each axis of 
the index finger. A comparison between the positions and calculated displacements for 
Patient 22 are shown in Figure 4.4. As expected, the increase in oscillations of the 
position in the z-axis starting at around 20 seconds can be shown by the increases in 
magnitude of the displacements. The displacements were calculated, in part, to eliminate 
any large spikes in the position data, which will be discussed next. 
 
 
4.1.3 Spike Removal 
  
 Upon inspection of both the position and displacement data it was noticed that 
there were occasionally large spikes in the recorded positions and as a result, large 
magnitude spikes in the calculated displacements from the Leap Motion Controller.  
 
 An example of data containing these spikes can be seen in the position data and 
displacement data from Patient 18 with Essential Tremor in Figures 4.5, on the 
following page. As expected, a spike can be seen to occur on multiple axes and often 
can be seen more easily in one axis than another for both positions and displacements. 
It is apparent by observing the y-axis and z-axis positions that there are significant 
  
Figure 4.4  A side by side comparison of the positions and displacements for each axis of 
Patient 22, who is a Healthy (HE) control.  
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spikes around 5 seconds, but these spikes are not as visible in the x-axis. As shown 
below, it is much easier to visualize these spikes by observing the displacement data 
rather than just observing the position. 
 
 
 
The skeletal tracking V2 Beta Version of the SDK that was used in this study 
uses an anatomical model of the human hand to track 26 feature points of each hand. If 
one finger is not seen for a frame it is interpolated and considered as curled beneath the 
palm or the map of the entire hand is incorrectly recorded for that frame, returning an 
incorrect position. Another possible cause of these spikes could be a quick shift in the 
arm of the subject during the recording, such as a quick readjustment or a twitch, which 
would also return an erroneous position. When this occurs, the data was shown to have 
large magnitude spikes in the position, and more visibly in displacement as shown above 
in Figure 4.5.  
 
To compensate for this, any displacement with a magnitude of 4 mm or above 
was discarded. This value was chosen on the basis that a displacement of 4 mm between 
two frames approximately 0.01 milliseconds apart is too large of a magnitude for rest 
tremor since the magnitude of displacement from PD subjects has been shown to be 
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Figure 4.5  The positions and displacements for each axis of Patient 18, who has Essential 
Tremor (ET).  
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below 4 millimeters for similar sampling rates of high-amplitude rest tremor.32 Nearly all 
of the large magnitude spikes in the data that were larger than 4 millimeters between 
two frames were at least several magnitudes larger than 4 millimeters, supporting the 
argument that these large magnitude spikes are not a result of abnormally high-
amplitude tremor, but are incorrect readings. Therefore, it was concluded that 
displacement magnitudes greater than 4 mm between two frames on any axis indicated 
an incorrect reading and were thus removed from the data set. Eliminating these large 
displacement magnitudes from every axis ensured the removal of incorrect readings 
from an axis even when incorrect readings were not visible on that axis. Unfortunately, 
elimination of these data points does not exclude the possibility that an incorrect finger 
or an incorrect finger position could be tracked for several frames before the Leap 
Motion Controller returns the correct finger position. However, it was determined that 
the elimination of these large magnitude spikes in displacement was a better alternative 
than using a median filter since these spikes lasted for a different number of frames in 
different data sets. Therefore, in one data set a median filter using a given number of 
adjacent data points might work well while the same filter in another data set would not. 
A median filter would also face the same issue in that it would also not eliminate the 
possibility of an incorrect position reading for several frames. As a result, it was 
concluded it would be best to simply set a threshold with a displacement of 4 
millimeters between any two frames and remove any large magnitude spikes that were 
larger than this threshold.  
 
Figure 4.6, on the following page, shows a side-by-side comparison of the 
displacement data for Patient 18 before and after the removal of these large magnitude 
spikes. It can be seen that all of the spikes shown were several magnitudes larger than 4 
mm and are clearly incorrect recordings.  It can easily be seen that after the removal of 
these large magnitude spikes, the data is cleaner and more reasonable.  
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4.1.4 Euclidean Distance 
  
Once the spikes were removed from the displacement data, the Euclidean 
distance (Eq. 4.3) was calculated between the three-dimensional sampled position and 
the origin of the Leap Motion Controller.33 As previously mentioned, the origin of the 
coordinate system of the Leap Motion Controller is centered at the top and middle of 
the surface of the Leap and is assumed to remain stationary.29 The change in Euclidean 
Distance (Eq. 4.4) was calculated for each recorded frame in order to determine the 
magnitude of the change in distance of the index finger with the new associated time 
(Eq. 4.5).  
 
           (4.3) 
                   (4.4) 
            (4.5) 
 
  Where: 
 n is the frame number,  
dn is  the Euclidean distance, 
  
Figure 4.6  A side by side comparison of the displacements with respect to each axis of Patient 
18, who has Essential Tremor (ET), before and after the large magnitude spikes were removed. 
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(xn, yn, zn) are the positional coordinates associated with frame n, 
dn+1 is the Euclidean distance associated with frame n+1, 
tn+1 is the time associated with frame n+1,  
Tn is the new time associated with Dn. 
Dn is the new Euclidean distance associated with frame n. 
 
This new metric takes into account the magnitude of movement from each axis. 
As expected, if the spikes had not been removed they would have had a significant 
impact on the change in Euclidean Distance. The impact of the spikes can be seen in 
Figure 4.7, where a comparison between the change in Euclidean Distance with and 
without spike removal for Patient 18 with Essential Tremor is shown. When the spikes 
were removed, the actual magnitude of movement of the index finger can be seen much 
more clearly. 
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Figure 4.7  A side by side comparison of the change in Euclidean Distance of Patient 18, who 
has Essential Tremor (ET), before and after the large magnitude spikes were removed. 
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4.1.5 Non-Uniform Sampling  
 
As previously mentioned, the Leap Motion Controller has an inconsistent frame 
rate and so the collected data is non-uniform with respect to time. According to the 
Shannon sampling theory for non-uniform sampling, a band-limited signal can be 
reconstructed from its samples if the average sampling rate satisfies the Nyquist 
condition.34 The average sampling rate of the Leap Motion Controller during the study 
was approximately 100 Hz, which satisfies the Nyquist condition since the upper limit 
of the frequency that is of interest is no more than 25 Hz. As a result, the change in the 
Euclidean distance was interpolated with a cubic spine and resampled at a frequency of 
half of the average sampling rate, 50 Hz. 
 
4.1.6 Band-pass Butterworth Filter  
  
 The magnitudes of the Euclidean distance for the data from the Leap Motion 
Controller were then filtered using a 4th-Order band-pass Butterworth Filter. The 
Butterworth Filter that was used had a low-pass cutoff frequency of 20 Hz and a high-
pass cutoff of 2.5 Hz to eliminate frequencies that were not of interest, such as those 
due to physiological factors like breathing and heartrate.35 This approximation of the 
change in magnitude of displacement after band-pass filtering was used to classify 
Parkinson subjects, discussed later.   
 
4.1.7 Savitzky-Golay Filter  
 
 A 4th order Savitzky-Golay FIR filter, with a frame size of 11 points, was 
implemented in MATLAB using the sgolay function to smooth and perform a 2nd order 
differentiation on the band-pass filtered Euclidean distance.36 This allowed for an 
approximation of the change in magnitude of the acceleration while removing higher 
frequency noise that was amplified from differentiation. In Figure 4.8, the effects of the 
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Savitzky-Golay FIR filter can be seen on the magnitude of displacement, change in 
velocity, and change in acceleration of Patient 10, with Parkinson Disease.  
 
 
 
It can be more clearly seen that the amplification of higher frequency noise is 
greatly reduced when the Savitzky-Golay filter is applied in the frequency domain. 
Figure 4.9 shows Welch’s one-sided power spectral density estimate for acceleration 
with and without the Savitztky-Golay Filter using a Hanning window, averaging twenty 
sections with no overlap for Patient 10, with Parkinson Disease. 
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Figure 4.8  The displacement, change in velocity, and change in acceleration of Patient 10, who 
has Parkinson Disease, with and without the Savitzky-Golay FIR filter.  
Figure 4.9  Welch’s one-sided Power Spectral Density (PSD) estimate of Patient 10 who has 
Parkinson Disease, with and without the Savitzky-Golay FIR filter.  
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4.2 Tremorometer Data Conditioning  
 
Since the Tremorometer provides a uniform sampling rate of 100 Hz, the data 
from the Tremorometer did not have to be resampled since this rate is sufficient to 
analyze the frequencies of interest, those below 25 Hz.  
  
4.2.1 Change in Acceleration  
  
The Tremorometer provides changes in acceleration in three dimensions 
measured in milli-g (1/1000th of the acceleration due to gravity), with respect to time 
measured in seconds. Examples of these recorded accelerations can be seen on the 
following pages for subjects with Parkinson Disease in Figure 4.10, Essential Tremor in 
Figure 4.11, and for a Healthy Control subject in Figure 4.11.  
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Figure 4.10  Recorded changes in acceleration (milli-g) with respect to time for 
each axis (x,y,z) of Patient 10, who has Parkinson Disease (PD). 
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Figure 4.12  Recorded changes in acceleration (milli-g) with respect to time for 
each axis (x,y,z) of Patient 22, who is a Healthy (HE) Control.  
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Figure 4.11  Recorded changes in acceleration (milli-g) with respect to time for 
each axis (x,y,z) of Patient 15, who has Essential Tremor (ET). 
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4.2.2 Magnitude of Acceleration  
  
As previously mentioned, the Tremorometer records changes in acceleration in 
three different dimensions. These dimensions were used to calculate the total magnitude 
of the acceleration shown below, in Equation 4.6. 
 
     (4.6) 
 
Where: 
n is the frame number,  
||an|| is the magnitude of the acceleration associated with 
frame n,  
(ax, ay, az) are the changes in acceleration in each dimension with 
their associated frame n, 
 
An example of the calculated magnitude of acceleration for the three different 
axes can be seen in Figure 4.13 for Patient 10 who has Parkinson Disease (PD). It can 
be seen that in this case the largest changes in acceleration occur in the y-axis, which 
causes the greatest influence on the total magnitude of acceleration. However, it should 
be noted that the changes in acceleration from the other axes are also important and 
also contribute to the result of the total magnitude of the acceleration.  
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Figure 4.13  The accelerations (milli-g) for three axes of Patient 10, who has Parkinson Disease 
(PD) and the magnitude of acceleration (milli-g) calculated from the three axes.  
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4.2.3 Offset 
  
Although the accelerometer from the Tremorometer system was properly 
calibrated before the data was recorded, there was a significant offset in the data. As a 
result, the offsets in the data were removed by subtracting the mean value of each data 
set from the respective data set. The removal of a large offset can be seen in Figure 
4.14, where the magnitude of acceleration for Patient 10, who has Parkinson Disease, 
had an offset of approximately 1000 milli-g.  
 
 
4.2.4 Band-pass Butterworth Filter  
  
 The magnitudes of acceleration for each trial were also filtered using the same 
4th-Order band-pass Butterworth Filter with the same parameters used for the Leap 
Motion Controller. Again, the filter had a low-pass cutoff frequency of 20 Hz and a 
high-pass cutoff of 2.5 Hz to eliminate frequencies that are not of interest.35  
 
4.2.5 Savitzky-Golay Smoothing  
  
Once the frequencies not pertinent to the study were removed from the data 
obtained from the Tremorometer, the data was then smoothed using a Savitzky-Golay 
  
Figure 4.14  The magnitude of acceleration (milli-g) of Patient 10, who has Parkinson Disease 
(PD) with and without the offset.  
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smoothing filter. The same 4th order Savitzky-Golay FIR smoothing filter, with a frame 
size of 11 points that was used for the data from the Leap Motion Controller was used 
for the data from the Tremorometer in order to apply the same smoothing filter to the 
two devices.  
 
4.3 Frequency Domain Characteristics  
  
Once the data from the Leap Motion and Tremorometer were properly 
conditioned, various frequency domain characteristics were calculated.  This was done 
in order to analyze and compare the derived acceleration data from the Leap Motion 
Controller to the acceleration data of the Tremorometer. The derived accelerations 
from the Leap Motion Controller, measured in millimeters per second squared, and the 
acceleration from the Tremorometer, measured in milli-g, were converted into meters 
per second squared.  These same frequency domain characteristics were also used in an 
attempt to classify Parkinson subjects using the position data obtained from the Leap 
Motion Controller in Section 4.16, before the Savitzky-Golay 2nd order differentiation 
filter was applied.  
 
The Welch’s one-sided power spectral density estimate was calculated using a 
Hanning window averaging twenty sections with no overlap with the necessary 
correction factors applied.35 The following frequency domain characteristics were then 
determined based on this estimated power spectral density.  
 
4.3.1 Proportional Power between 4-6 Hz 
  
This characteristic quantifies the proportional power that is contained in the 
frequency range between 4-6 Hz and quantifies the approximate amount that this range 
contributes to the tremor.  In typical parkinsonian tremor, it is expected that there is a 
significant peak in this range, thus causing a large proportion of the power of the 
spectrum to also exist in this range.35 An example of this peak can be seen in Figure 
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4.15, which shows a large peak for the accelerations of both the Leap Motion Controller 
and the Tremorometer of Patient 10, who has Parkinson Disease. Although the peaks 
are seen to have slightly different magnitudes, it is clear that due to these peaks there is a 
large proportion of power in the 4-6 Hz range for Patient 10.  
 
 
 
 
As shown in Figure 4.16, it was found that many of the Healthy Controls also 
exhibited a large peak in both the Tremorometer acceleration data and the calculated 
accelerations from the Leap Motion Controller. This peak also caused an increase in the 
proportional power in the 4-6 Hz range for the Healthy Controls.  
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Figure 4.15  The Power Spectral Density (PSD) of Patient 10 with Parkinson Disease (PD). The 
large peaks in the 4-6 Hz range cause a large proportion of power to also exist in this range. 
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Figure 4.16  The Power Spectral Density (PSD) of Patient 22, a Healthy (HE) Control. The large 
peaks in the 4-6 Hz range causes a larger proportion of power to also exist in this range, but the 
peaks are less significant and have less power than those in the PD subjects. 
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However, the peaks of the Healthy Controls were proportionally smaller with 
respect to the power spectrum, than the peaks of the Parkinson subjects. This typically 
resulted in a smaller proportional power in the 4-6 Hz range for Healthy Controls than 
Parkinson subjects. The peaks from the Healthy Controls also tended to exist at a 
higher frequency than those of the Parkinson subjects, again resulting in a decreased 
proportional power in comparison to the Parkinson subjects.  
 
4.3.2 Proportional Power between 8-12 Hz  
 
This characteristic quantifies the proportional power that is contained in the 
frequency range between 8-12 Hz and quantifies the approximate amount that this 
range contributes to the tremor. Since normal physiological tremor is typically 
concentrated in the 8-12 Hz range, it was expected that the proportion of power in this 
range would be high in the absence of any low-frequency pathological tremor.35 As 
mentioned in the previous section, some Healthy Controls did exhibit a peak in the 4-6 
Hz range but this peak was proportionally smaller for the Healthy Control subjects than 
for the Parkinson subjects, typically resulting in a larger proportional power in the 8-12 
Hz range for the Healthy Control subjects than subjects with Parkinson Disease. An 
example of this can be seen by visually comparing the proportional power in the 8-12 
Hz range for subjects with Parkinson Disease in Figure 4.15 to Healthy Control subjects 
in Figure 4.16.  
 
4.3.3 Median Frequency  
 
This characteristic is indicative of the frequency at which there is a median of 
the area below the power spectrum, where there exists 50% of the power in the 
spectrum above and 50% below this frequency and has previously been used to 
characterize tremor.35,36 For power spectrums with one significantly large peak, the 
median frequency typically coincides with this peak as shown in Figure 4.17, on the 
following page. 
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4.3.4 Frequency Dispersion  
  
The frequency dispersion measures the width of an interval centered at the 
median frequency that contains 68% of the power in the spectrum and has also been 
previously used to characterize tremor.35,36 This characteristic can be used to quantify 
the harmonicity of oscillations. Typically, for regular oscillation such as parkinsonian or 
essential tremor the dispersion bandwidth is small due to a large peak while irregular 
tremors like physiological tremor, which usually have several peaks, tend to have a larger 
dispersion.35,38  
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Figure 4.17  The Power Spectral Density (PSD) of Patient 1 with 
Parkinson Disease (PD). The large peak in the 4-6 Hz range is 
so significant that the median frequency coincides with this 
peak, shown by the blue dot. 
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Figure 4.18  The Power Spectral Density (PSD) of Patient 3 with Parkinson Disease (PD) and 
Patient 30, a Healthy (HE) Control. As shown by the blue bars, the frequency dispersion for the 
subject with PD is narrower than that of the Healthy Control. The blue dot indicates the median 
frequency. 
0 5 10 15 20 250
0.005
0.01
0.015
0.02
0.025
Frequency (Hz)
Po
we
r (
m
/s2
)2
Leap M ti n Controller
Welch PSD for PD Patient 10
Student Version of MATLAB
     
 
35 
Figure 4.18, on the previous page, illustrates the difference in frequency 
dispersions by comparing Patient 3, with Parkinson Disease, and Patient 30, a Healthy 
Control, using the Tremorometer. The lower end of the frequency dispersion for 
Patient 3 is shown by the blue bar at 3.91 Hz, the blue bar at 5.08 Hz shows the upper 
end, and the median frequency is marked by a blue dot at 4.29 Hz.  Whereas Patient 30 
has a frequency dispersion with a lower end of 5.47 Hz, an upper end of 10.16 Hz, and 
a median frequency of 7.43 Hz. As shown, this results in a much more narrow 
frequency dispersion for Patient 3 who has Parkinson Disease, than Patient 30 who is a 
Healthy Control. 
 
4.3.5 Peak Frequency between 0-25 Hz  
  
This characteristic indicates the frequency of the highest peak power in the 
estimated power spectrum and also has been used to characterize tremor.35 It was 
expected that the frequency of this peak would be lower for typical parkinsonian 
tremor, typically between 4-6 Hz, and was expected to be higher for Healthy Controls, 
while subjects with Essential tremor would exist throughout the spectrum. Although 
this was not the case for all subjects, an example of a higher peak frequency in a Healthy 
Control subject compared to a Parkinson subject with a peak in the 4-6 Hz range, can 
be seen in Figure 4.18.   
 
4.3.6 Peak Power between 0-25 Hz  
  
The peak power between 0-25 Hz is indicative of the power at the highest peak 
in the estimated spectrum. It was expected that this peak would be larger for those with 
visible high-amplitude tremor, and significantly lower for Healthy Control subjects. This 
in seen by comparing the peak power of a subject with Parkinson Disease in Figure 4.15 
to the peak power of a Healthy Control subject in Figure 4.16. 
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4.3.7 Proportional Power of Peak between 0-25 Hz  
  
The proportional power of the peak between 0-25 Hz represents the proportion 
of power in the peak frequency of the estimated spectrum. It was expected that this 
peak would be larger for those with visible high-amplitude tremor such as Parkinson 
subjects and Essential Tremor subjects, and significantly lower for Healthy Control 
subjects. 
 
4.3.8 Total Power between 0-25 Hz  
  
This characteristic is indicative of the total power of the tremor that exists in the 
0-25 Hz range of the estimated spectrum. Those with high-amplitude tremor were 
expected to exhibit a larger value than those with low-amplitude or no visible tremor. 
This can be in Figure 4.18, where the magnitude of the area under the power spectrum 
for a Parkinson subject, Patient 3, is much larger than that of a Healthy Control, Patient 
30.  
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Chapter 5 
 
Results 
 
5.1 Device Comparison  
 
In order to compare the Leap Motion Controller to the Tremorometer, first the 
characteristics were tested in order to determine if the devices could be considered 
repeatable across trials. Once it was shown that both devices were not statistically 
different across trials, the two devices were compared.  To do this, the trials and subject 
groups were combined for each device and a statistical analysis was performed to 
compare the resulting characteristics from each device. Then, a statistical analysis was 
performed separately on each subject group, again with combined trials, to determine if 
there was a difference in characteristics between devices for each subject group.  
 
5.1.1 Repeatability  
 
To determine the repeatability of each device, a statistical analysis was 
performed across trials for each device on each characteristic. It was found that for both 
devices, the distributions of each characteristic for both trials did not follow a normal 
distribution as was expected.36,39 Therefore, the two trials for each device were first 
compared directly using the following nonparametric methods: the Wilcoxon Signed 
Ranks Test and the Sign Test.  
 
The Wilcoxon Signed Ranks Test was used as a two-sided test for the null 
hypothesis that the differences between trials come from a distribution with zero 
median. The Sign Test was also used to test the hypothesis that the differences in the 
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trials had a distribution with zero median against the alternative that the distribution did 
not have zero median. Again, the test failed to reject the null hypothesis of zero median 
in the differences of the trials for both devices for all, but one characteristic. The only 
null hypothesis that was rejected was the Peak Frequency between 0-25 Hz for the Leap 
Motion Controller using the Sign Test. The Wilcoxon Signed Ranks Test, however, did 
not reject the null hypothesis that the Peak Frequency between 0-25 Hz for the Leap 
Motion Controller between trials had a distribution with a zero median. The results of 
these two tests can be seen in Tables 5.1 and 5.2. Those characteristics with highlighted 
p-values are shown to have no significant difference between trials.   
 
 
 
 
 
 
 
 
 
 
 
Leap%Motion%Controller%
Differences%between%Trial%1%and%Trial%2 Z p%value Z p%value
Proportional*Power*between*4/6*Hz* /0.072 0.943 0 1
Proportional*Power*between*8/12*Hz* /0.751 0.453 /0.183 0.855
Median*Frequency* /0.671 0.502 / 0.523
Frequency*Dispersion /0.688 0.491 /0.588 0.556
Peak*Frequency*between*0/25*Hz* /1.435 0.151 / 0.023
Peak*Power*between*0/25*Hz* /0.504 0.614 /0.548 0.584
Proportional*Power*of*Peak*between*0/25*Hz* /1.08 0.28 /1.278 0.201
Total*Power*between*0/25*Hz* /0.956 0.339 /0.913 0.361
Wilcoxon%Signed%Ranks%Test Sign%Test
Tremorometer'
Differences'between'Trial'1'and'Trial'2 Z p'value Z p'value
Proportional*Power*between*4/6*Hz* /1.45 0.147 /0.548 0.584
Proportional*Power*between*8/12*Hz* /0.278 0.781 /0.183 0.855
Median*Frequency* /0.409 0.682 / 1
Frequency*Dispersion /0.258 0.797 / 1
Peak*Frequency*between*0/25*Hz* /0.653 0.514 / 1
Power*of*peak*between*0/25*Hz* /1.162 0.245 /0.913 0.361
Proportional*Power*of*Peak*between*0/25*Hz* /0.792 0.428 /0.183 0.855
Total*Power*between*0/25*Hz* /0.442 0.658 /0.183 0.855
Wilcoxon'Signed'Ranks'Test Sign'Test
Table 5.1  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the two trials of the Leap Motion Controller. Highlighted p-values indicate that there 
was no significant difference.  
Table 5.2  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the two trials of the Tremorometer. Highlighted p-values indicate that there was no 
significant difference.  
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The differences between trials were also tested to determine if they followed a 
normal distribution. To do so, a Kolmogorov-Smirnov One-Sample Test with Lilliefors’ 
Significance and a Shapiro-Wilk Test was run to test the null hypothesis that the 
differences in characteristics between trials for each device come from standard normal 
distributions against the alternative that they do not, at the 0.05 significance level. The 
results are shown in Table 5.3 and Table 5.4 on the next page, where highlighted p-
values indicate that the null hypothesis was not rejected and that the distribution was 
assumed to follow a normal distribution. As shown, not all characteristics were revealed 
to follow a normal distribution. However, for those characteristics that were shown to 
follow a normal distribution by just one of the normality tests, a one-sample t-test was 
performed. 
 
A one-sample t-test was used to test the null hypothesis that the differences in 
the trials come from normal distributions with means equal to zero and unknown 
variance for those characteristics that were assumed to follow a normal distribution 
from the normality tests. The alternative hypothesis was that the distributions of the 
differences in trials do not have means equal to zero. The results for the one-sample t 
test can be seen below, in Table 5.3 below and Table 5.4 on the following page, with 
highlighted p-values again indicating that there was no significant difference in the 
means of the two trials.   
 
 
 
 
 
 
 
Table 5.3  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the differences between trials for the Leap Motion Controller. 
Highlighted p-values for the Kolmogorov-Smirnov Test and the Shapiro-Wilk Test suggest that 
the characteristic follows a normal distribution. Highlighted p-values for the t-test indicate that 
there was no significant difference in the means of the two trials. 
Leap%Motion%Controller%
Differences%between%Trial%1%and%Trial%2 Kolmogorov<Smirnova
Shapiro<
Wilk t p%value
Proportional*Power*between*4/6*Hz* 0.052 0.007 0.065 0.949
Proportional*Power*between*8/12*Hz* 0.200 0.235 /1.098 0.281
Median*Frequency* 0.112 0.424 0.767 0.449
Frequency*Dispersion 0.200 0.497 /0.518 0.608
Peak*Frequency*between*0/25*Hz* 0.000 0.001 / /
Peak*Power*between*0/25*Hz* 0.000 0.000 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.013 0.005 / /
Total*Power*between*0/25*Hz* 0.000 0.000 / /
Normality t<test%
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5.1.2 Combined Subject Groups 
 
 Both trials and all subject groups were combined for each device and the 
differences between devices were calculated. Similar to the analysis between trials, the 
two devices were first compared directly using nonparametric methods. Again, the 
Wilcoxon Signed Ranks Test and Sign Test were used to test the null hypothesis that 
the differences between devices come from a distribution with a zero median. The 
results of the tests are shown in Table 5.5, where highlighted p-values indicate that the 
differences between the devices were not significant.  
Differences)between)
Leap)Motion)Controller)and)Tremorometer Z p)value Z p)value
Proportional*Power*between*4/6*Hz* /2.591 0.010 /1.678 0.093
Proportional*Power*between*8/12*Hz* /2.952 0.003 /2.969 0.003
Median*Frequency* /2.397 0.017 /2.806 0.005
Frequency*Dispersion /2.756 0.006 /2.649 0.008
Peak*Frequency*between*0/25*Hz* /1.328 0.184 /0.530 0.596
Peak*Power*between*0/25*Hz* /4.483 0.000 /5.035 0.000
Proportional*Power*of*Peak*between*0/25*Hz* /6.729 0.000 /7.359 0.000
Total*Power*between*0/25*Hz* /2.812 0.005 /2.969 0.003
Wilcoxon)Signed)Ranks)Test Sign)Test
Table 5.4  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the differences between trials for the Tremorometer. Highlighted p-
values for the Kolmogorov-Smirnov Test and the Shapiro-Wilk Test suggest that the 
characteristic follows a normal distribution. Highlighted p-values for the t-test indicate that 
there was no significant difference in the means of the two trials. 
 
Table 5.5  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the Leap Motion Controller and the Tremorometer. Highlighted values indicate that 
there was no significant difference.  
 
Tremorometer'
Differences'between'Trial'1'and'Trial'2 Kolmogorov8Smirnova
Shapiro8
Wilk t p'value
Proportional*Power*between*4/6*Hz* 0.026 0.095 /1.868 0.072
Proportional*Power*between*8/12*Hz* 0.2 0.637 0.244 0.809
Median*Frequency* 0.006 0.123 0.356 0.725
Frequency*Dispersion 0.2 0.304 /0.476 0.638
Peak*Frequency*between*0/25*Hz* 0 0.002 / /
Power*of*peak*between*0/25*Hz* 0 0 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.119 0.036 /1.161 0.255
Total*Power*between*0/25*Hz* 0 0 / /
Normality t8test
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The differences between the two devices were then tested to determine if they 
followed a normal distribution. The Kolmogorov-Smirnov One-Sample Test with 
Lilliefors’ Significance and Shapiro-Wilk Test were run to test the null hypothesis that 
the differences in characteristics between the two devices come from a standard normal 
distributions against the alternative that they do not, at the 5% significance level. The 
results of these tests can be seen in Table 5.6, where highlighted p-values indicate that 
the null hypothesis was not rejected and that the differences were assumed to follow a 
normal distribution. The one-sample t-test was then performed on those characteristics 
that were assumed to follow a normal distribution. This test was run in order to test the 
null hypothesis that the differences in the devices come from normal distributions with 
means equal to zero and unknown variance.  The results for the one-sample t test are 
shown in Table 5.6, with highlighted p-values indicating that there was no significant 
difference in the means of the difference between the two devices.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the difference between the Leap Motion Controller and the 
Tremorometer. Highlighted p-values for the Kolmogorov-Smirnov Test and the Shapiro-Wilk 
Test suggest that the characteristic follows a normal distribution. Highlighted p-values for the t-
test indicate that there was no significant difference in the means of the two trials. 
 
Differences)between))
Leap)Motion)Controller)and)Tremorometer Kolmogorov:Smirnova
Shapiro:
Wilk t p)value
Proportional*Power*between*4/6*Hz* 0.069 0.034 /2.919 0.005
Proportional*Power*between*8/12*Hz* 0.007 0.003 / /
Median*Frequency* 0.065 0.070 2.083 0.042
Frequency*Dispersion 0.200 0.098 2.745 0.008
Peak*Frequency*between*0/25*Hz* 0.082 0.258 1.170 0.247
Peak*Power*between*0/25*Hz* 0.000 0.000 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.017 0.004 / /
Total*Power*between*0/25*Hz* 0.000 0.000 / /
Normality t:test)
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5.1.3 Separate Subject Groups  
 
To compare the differences between the two devices, the same series of 
statistical analyses that were performed for all subjects in the previous section were also 
performed for each subject group. The results of the Wilcoxon Signed Ranks Test and 
the Sign Test are shown in Table 5.7 for the Parkinson Group, Table 5.8 for the 
Essential Tremor Group, and Table 5.9 for the Healthy Control Group. Following the 
same convention as before, highlighted p-values indicate that the differences between 
the devices were not significant for that characteristic.  
 
 
 
 
Table 5.7  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the Leap Motion Controller and the Tremorometer for the Parkinson Group. 
Highlighted values indicate that there was no significant difference.  
 
Table 5.8  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the Leap Motion Controller and the Tremorometer for the Essential Tremor Group. 
Highlighted values indicate that there was no significant difference.  
 
     
 
43 
 
 
 
 
The differences between the two devices for each group were then tested to 
determine if they followed a normal distribution using the Kolmogorov-Smirnov One-
Sample Test with Lilliefors’ Significance and Shapiro-Wilk Test. A one-sample t-test was 
performed on those characteristics that were assumed to follow a normal distribution. 
The results of the these tests are shown on the following pages in Table 5.10 for the 
Parkinson Group, Table 5.11 for the Essential Tremor Group, and Table 5.12 for the 
Healthy Control Group. Again, following the same convention as before, highlighted p-
values for the normality tests indicate that the differences were assumed to follow a 
normal distribution and a highlighted p-value for the t-test indicates that there was no 
significant difference in the means of the difference for that characteristic between the 
two devices. P-values with an asterisk for the Kolmogorov-Smirnov indicate that the 
value was a lower bound of the true significance.  
 
 
 
 
 
Healthy(Control(Group:(Differences(between(
Leap(Motion(Controller(and(Tremorometer Z p(value Z p(value
Proportional*Power*between*4/6*Hz* /0.747 0.455 /0.671 0.502
Proportional*Power*between*8/12*Hz* 0.149 0.881 0.671 0.502
Median*Frequency* 0.412 0.681 1.118 0.264
Frequency*Dispersion 1.250 0.211 0.918 0.359
Peak*Frequency*between*0/25*Hz* 0.112 0.911 0.671 0.502
Peak*Power*between*0/25*Hz* /2.763 0.006 /3.354 0.001
Proportional*Power*of*Peak*between*0/25*Hz* /3.920 0.000 /4.249 0.000
Total*Power*between*0/25*Hz* /1.045 0.296 /2.012 0.044
Wilcoxon(Signed(Ranks(Test Sign(Test
Table 5.9  The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference 
between the Leap Motion Controller and the Tremorometer for the Healthy Control Group. 
Highlighted values indicate that there was no significant difference.  
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Kolmogorov(
Smirnov Shapiro(Wilk t p2value
Proportional*Power*between*4/6*Hz* 0.200* 0.776 1.835 0.082
Proportional*Power*between*8/12*Hz* 0.200* 0.673 /0.916 0.371
Median*Frequency* 0.200* 0.841 /0.322 0.751
Frequency*Dispersion 0.200* 0.581 /1.117 0.278
Peak*Frequency*between*0/25*Hz* 0.077 0.105 0.195 0.848
Peak*Power*between*0/25*Hz* 0.000 0.000 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.200* 0.647 7.114 0.000
Total*Power*between*0/25*Hz* 0.000 0.000 / /
Parkinson2Group:2Differences2between2Leap2
Motion2Controller2and2Tremorometer2
Normality t(test2
Table 5.10  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the difference between the Leap Motion Controller and the 
Tremorometer for the Parkinson Group. Highlighted p-values for the Kolmogorov-Smirnov Test 
and the Shapiro-Wilk Test suggest that the characteristic follows a normal distribution. P-values 
with an asterick indicate the value is ta lower bound of the true significance. Highlighted p-
values for the t-test indicate that there was no significant difference in the means of the two 
trials. 
 
Kolmogorov(
Smirnova Shapiro(Wilk t p2value
Proportional*Power*between*4/6*Hz* 0.200* 0.058 2.341 0.030
Proportional*Power*between*8/12*Hz* 0.200* 0.987 /7.435 0.000
Median*Frequency* 0.078 0.159 /4.493 0.000
Frequency*Dispersion 0.200* 0.073 /2.278 0.034
Peak*Frequency*between*0/25*Hz* 0.200* 0.136 /3.037 0.007
Peak*Power*between*0/25*Hz* 0.000 0.000 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.200* 0.195 8.577 0.000
Total*Power*between*0/25*Hz* 0.000 0.000 / /
Essential2Tremor2Group:2Differences2between2
Leap2Motion2Controller2and2Tremorometer2
Normality t(test2
Table 5.11  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the difference between the Leap Motion Controller and the 
Tremorometer for the Essential Tremor Group. Highlighted p-values for the Kolmogorov-
Smirnov Test and the Shapiro-Wilk Test suggest that the characteristic follows a normal 
distribution. Highlighted p-values for the t-test indicate that there was no significant difference 
in the means of the two trials. 
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5.2 Classification of Parkinson Subjects  
 
To classify Parkinson Subjects, the band-pass filtered displacement data of the 
Leap Motion Controller from Section 4.1.6 were used. Only the Healthy Control group 
and the Parkinson Disease group were used in the classification of Parkinson subjects, 
due to the statistical differences found between devices that are discussed later in 
Section 6.1.3. Also based on the statistical differences between devices for the 
Parkinson and Healthy Control groups, only six of the eight characteristics were used to 
classify the Parkinson subjects. These six characteristics were used for both supervised 
and unsupervised learning and include: Proportional Power between 4-6 Hz, 
Proportional Power between 8-12 Hz, Median Frequency, Frequency Dispersion, Peak 
Frequency between 0-25 Hz, and the Total Power between 0-25 Hz. For unsupervised 
learning, a K-means cluster analysis was performed to determine how well underlying 
patterns or groupings in the characteristics separated the subjects. For supervised 
learning, a Support Vector Machine (SVM) was used to train and classify the Parkinson 
subjects.  
Kolmogorov(
Smirnova Shapiro(Wilk t p2value
Proportional*Power*between*4/6*Hz* 0.200* .438 1.034 0.314
Proportional*Power*between*8/12*Hz* 0.144 .093 0.013 0.990
Median*Frequency* 0.009 .010 / /
Frequency*Dispersion 0.139 .406 /1.585 0.129
Peak*Frequency*between*0/25*Hz* 0.018 .009 / /
Peak*Power*between*0/25*Hz* 0.000 .000 / /
Proportional*Power*of*Peak*between*0/25*Hz* 0.200* .266 11.767 0.000
Total*Power*between*0/25*Hz* 0.000 .000 / /
Healthy2Control2Group:2Differences2between2
Leap2Motion2Controller2and2Tremorometer2
Normality t(test2
Table 5.12  The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, Shapiro-
Wilk Test, and t-test for the difference between the Leap Motion Controller and the 
Tremorometer for the Healthy Control Group. Highlighted p-values for the Kolmogorov-
Smirnov Test and the Shapiro-Wilk Test suggest that the characteristic follows a normal 
distribution. Highlighted p-values for the t-test indicate that there was no significant difference 
in the means of the two trials. 
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5.2.1 K-means Cluster Analysis  
  
To determine how well underlying patterns and groupings in the characteristics 
separated subjects into their respective groups, K-means cluster analysis was used to 
partition the subjects into 2 clusters. First both trials from both subject groups were 
combined and normalized. Then the K-means cluster analysis was performed using the 
city-block distance measure, where each centroid was the component-wise median of 
the points in that cluster. Since the true clinical diagnosis for each subject was known, 
the validity of the clustering was verified by comparing the true diagnosis to the cluster 
results. The results for each subject can be seen in Table 5.13, where Cluster 2 was 
chosen to be representative of the Parkinson group and Cluster 1 was representative of 
the Healthy group. The green highlight indicates a correct classification and a red 
highlight indicates an incorrect classification. It was found that there were 9 
misclassifications out of the 40 subjects, an error rate of 0.225.   
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Patient'Group Subject Trial Cluster
1 2
2 2
1 2
2 2
1 2
2 2
1 1
2 2
1 1
2 1
1 2
2 2
1 1
2 1
1 2
2 1
1 1
2 1
1 2
2 2
1 1
2 1
1 1
2 1
1 1
2 1
1 1
2 1
1 1
2 1
1 1
2 1
1 1
2 1
1 1
2 2
1 1
2 1
1 1
2 1
29
24
25
26
27
28
PD
HE
1
2
3
4
5
6
7
8
30
9
10
21
22
23
Table 5.13  The results of the K-means 
cluster analysis using the city-block 
distance measure for the Parkinson 
Disease (PD) Group and Healthy 
(HE) Control Group. 
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5.2.2 Support Vector Machine  
 
In an attempt to classify Parkinson subjects, the binary support vector machine 
(SVM) classifier function fitcsvm within MATLAB was used. Both trials from the two 
subject groups were combined, normalized and labeled with their respective class. The 
default parameters of the function were used to train the classifier using a linear kernel 
for the six standardized predictors. Once trained, the model was cross-validated using 
the leave-one-out method and the cross-validation loss of the model was calculated 
using the function kfoldLoss, which was found to be 0.2. This SVM classifier was then 
tuned by adjusting the box constraint and kernel scale parameters to optimize this 
performance estimation. The best parameters for the kernel scale and the box 
constraints were found to be 0.1 and 1, respectively. The tuned SVM classifier was again 
cross-validated using the leave-one-out method and the new cross-validation loss was 
recalculated to be 0.15. The predicted response for the cross-validated classification 
model was then calculated and the resulting predicted class labels are shown in Table 
5.14. Again, the green highlight indicates a correct classification and a red highlight 
indicates an incorrect classification.   
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Patient'Group Subject Trial SVM'Model
1 PD
2 PD
1 PD
2 PD
1 PD
2 PD
1 HE
2 PD
1 HE
2 HE
1 PD
2 PD
1 HE
2 HE
1 PD
2 PD
1 PD
2 PD
1 PD
2 PD
1 PD
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
1 HE
2 HE
PD
HE
1
2
3
4
5
6
7
8
30
9
10
21
22
23
29
24
25
26
27
28
Table 5.14  The predicted response for 
the tuned cross-validated SVM 
classification model for the Parkinson 
Disease (PD) Group and Healthy (HE) 
Control Group. 
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Chapter 6 
 
Discussion and Conclusion  
 
6.1 Device Comparison 
  
 To compare the Leap Motion Controller to the Tremorometer, several analyses 
were performed. First each device was tested to determine if the trials were statistically 
different or if they could be repeatable, then statistical analyses of the differences 
between devices for all subject groups were performed, and finally statistical analyses of 
the differences between devices for each separate subject group was presented. A 
discussion and the conclusions drawn from the results of these analyses are presented in 
this section. 
 
6.1.1 Repeatability  
  
The first step in comparing the two devices was to determine if they provide 
characteristics that could be repeatable. It was found that the Leap Motion Controller 
and Tremorometer were both shown to not statistically different across trials for all 
characteristics, which suggest that the devices could be repeatable. This is supported by 
results of the Wilcoxon Signed Ranks Test, which indicated that there were no 
significant differences between trials. The results of the Sign Test also indicated that 
there were no differences between trials for all characteristics in the Tremorometer and 
all but one characteristic in the Leap Motion Controller, the Peak Frequency between 0-
25 Hz. However, it can be argued that the Wilcoxon Signed Ranks Test was a stronger 
indicator since it took into account the magnitudes and signs of the observations rather 
than just the signs. As a result, if there was a discrepancy between the results of the 
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Wilcoxon Signed Ranks Test and the Sign Test, the results of the Wilcoxon Signed 
Ranks Test were used to determine statistical difference. Since the Wilcoxon Signed 
Ranks Test suggested that there was no significant difference between trials for the Peak 
Frequency between 0-25 Hz for the Leap Motion Controller, it was concluded that this 
characteristic was also not different between trials for the Leap Motion Controller. The 
difference between trials were also tested for normality to see if a more powerful 
parametric test, such as the t-test, could also be used to determine if there was a 
statistical difference between the trials for each device. The results of the t-test 
supported the results of the Wilcoxon Signed Ranks Test, where all those characteristics 
shown to follow a normal distribution were shown to not be statistically different 
between trials for either device. As a result, the results of the t-test also support the 
argument that the two devices could be repeatable for measuring all eight characteristics 
and that the two trials are not statistically different for either device. In conclusion, it 
was found that the two devices could be considered repeatable for the purposes of this 
study. 
 
6.1.2 Combined Subject Groups  
 
The results of combining subject groups and comparing the devices revealed 
that characteristics for the two devices were statistically different for all but one 
characteristic. The only characteristic that was shown to not be statistically different 
between devices from the Wilcoxon Signed Ranks Test and Sign Test was the Peak 
Frequency between 0-25 Hz. This result was confirmed by the t-test, which indicated 
that out all of the characteristics that were shown to possibly follow a normal 
distribution by the normality tests, the only one that was not significantly different was, 
in fact, the Peak Frequency between 0-25 Hz. The end results of the relevant statistical 
tests are summarized on the following page in Table 6.1 where the characteristics 
highlighted in green indicate that they are not statistically different between devices, 
while a red highlight indicates that the characteristic is statistically different between 
devices. In conclusion, only the Peak Frequency between 0-25 Hz was shown to not be 
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statistically different between the Leap Motion Controller and Tremorometer when 
testing the combined subject groups. 
 
 
 
 
 
 
 
 
 
 
 
Initially this was a little discouraging, but it is also very important to note. The 
statistical differences are most likely due to the consequences of pre-processing of the 
data previously mentioned in Chapter 4. When comparing the Leap Motion to the 
Tremorometer, the displacement data from the Leap Motion Controller had to be 
differentiated to calculate acceleration and was then filtered to eliminate the 
amplification of the high frequency noise. The differentiation and filtering likely affected 
many of the characteristics that depended on the power in the higher frequencies, such 
as the Total Power between 0-25 Hz. This most likely resulted in the distortion of many 
of these characteristics resulting in a statistical difference between devices. It is also 
possible that upon calculating the Welch’s one-sided power spectral density estimate 
with the Hanning window averaging twenty sections, the shape of the power spectral 
density for some of the trials were not preserved and could influence some of these 
resulting characteristics such as the Median Frequency and Frequency Dispersion. 
Unfortunately, some of these pre-processing issues were very difficult to avoid because 
the data from each trial would have to be conditioned individually, which would be 
incredibly time-consuming and could introduce bias into the results since the study was 
not blinded. Several methods to improve the pre-processing of the data are discussed in 
more detail in the Future Works Section. 
Table 6.1  Summary of characteristics that are not  
statistically different between devices for the 
combined subject groups. Green indicates not 
statistically different. Red indicates statistically 
different. 
 
 
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak%Frequency%between%0125%Hz%
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*
!Combined!Subject!Groups:!!!Summary!of!characteristics!
not!statistically!different!between!devices!
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6.1.3 Separate Subject Groups  
 
Once it was found that there was only one characteristic that was not 
significantly different between devices for all subject groups, the groups were separated 
and reexamined to determine if there were any differences for particular groups. The 
trials were combined per subject group due to the small sample size of each group. A 
summary of the conclusions drawn from the results can be seen on the following pages 
in Table 6.2 for the Parkinson group, Table 6.3 for the Essential Tremor group, and 
Table 6.4 for the Healthy Control group. In the summaries, characteristics highlighted 
in green indicate that they were not statistically different between devices, while 
characteristics with a red highlight indicate that they were statistically different between 
devices.  
 
Parkinson Group The results of the Wilcoxon Signed Ranks Test indicated 
that there was no significant difference between devices for the majority of 
characteristics. The only two characteristics that were shown to be statistically different 
between devices were the Peak Power between 0-25 Hz and the Proportional Power of 
Peak between 0-25 Hz. The results of the t-test were shown to support these results for 
those characteristics that were shown to follow a normal distribution. It was therefore 
concluded that all of the characteristics were shown to not be statistically different 
between devices except for Peak Power between 0-25 Hz and Proportional Power of 
Peak between 0-25 Hz for the Parkinson group.  
 
 
 
 
 
 
 
 
 
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak%Power%between%0-25%Hz%
Proportional%Power%of%Peak%between%0-25%Hz%
Total*Power*between*0/25*Hz*
!Parkinson!Subject!Group:!!!Summary!of!characteristics!
not!statistically!different!between!devices!
Table 6.2  Summary of characteristics that are not  
statistically different between devices for the Parkinson 
subject group. Green indicates not statistically 
different. Red indicates statistically different. 
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Essential Tremor Group The Essential Tremor group, however, only had 
two characteristics that were not statistically significant based on the results of the 
Wilcoxon Signed Ranks Test. These two characteristics were the Proportional Power 
between 4-6 Hz and Frequency Dispersion. It was noted that these two characteristics 
were also not statistically different for the Healthy Control group and the Parkinson 
Group, suggesting that these characteristics may be most similar between devices for 
the different groups. The Essential Tremor group was also shown to have many of the 
characteristics follow a normal distribution, but the t-test revealed that all of these 
characteristics were also shown to be statistically different between devices. Therefore, it 
was found that all of the characteristics were concluded to be statistically different 
between the Tremorometer and Leap Motion Controller for the Essential Tremor 
group.  
 
 
 
 
 
 
 
 
 
 
Healthy Control Group The Wilcoxon Signed Ranks Test for the Healthy 
Control Group indicated that there were no significant differences between devices for 
most of the characteristics. Similar to the Parkinson group, the only two characteristics 
that were shown to be statistically different between devices were the Peak Power 
between 0-25 Hz and the Proportional Power of Peak between 0-25 Hz. Again like the 
Parkinson group, the t-test supported the results from the Wilcoxon Signed Rank Test 
for the normally distributed. It was concluded that all of the characteristics were shown 
to not be statistically different except for Peak Power between 0-25 Hz and 
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*
Essential)Tremor)Subject)Group:))Summary)of)
characteristics)not)statistically)different)between)devices)
Table 6.3  Summary of characteristics that are not  
statistically different between devices for the Essential 
Tremor subject group. Green indicates not statistically 
different. Red indicates statistically different. 
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Proportional Power of Peak between 0-25 Hz for the Healthy Control group, which 
were the same results as the Parkinson group. 
 
 
 
 
 
 
 
 
 
 
 
 It is clear that the results for the Parkinson group and Healthy Control group 
agree, where the same six characteristics are shown to not be statistically different 
between devices. This supports the claim that for these six characteristics, the two 
devices are not statistically different. However, these six characteristics were revealed to 
not be statistically similar for the Essential Tremor group. The statistical differences in 
the characteristics measured from the Essential Tremor group could be due to the 
nature of the disorder.  It is known that the amplitude of Essential Tremor tends to be 
fairly variable and thus changes in the amplitude of the tremor between device 
recordings may have influenced the results, especially since many of the characteristics 
depend on the amplitude of this tremor. Another possibility for the statistical difference 
in characteristics for the Essential Tremor group is that during the pre-processing of the 
data, such as during the differentiation and filtering of the displacement data from the 
Leap Motion Controller, the characteristics unique to subjects with Essential Tremor 
were more greatly affected than the Parkinson and Healthy Control subjects. Similarly, 
upon calculating the Welch’s one-sided power spectral density estimate using a Hanning 
window with an average of twenty sections, the shape of the power spectral density for 
the Essential Tremor subjects could have been more distorted than the Healthy Control 
subjects or the Parkinson subjects due to features unique to Essential Tremor.  
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak%Power%between%0-25%Hz%
Proportional%Power%of%Peak%between%0-25%Hz%
Total*Power*between*0/25*Hz*
!Healthy!Control!Groups:!!!Summary!of!characteristics!not!
statistically!different!between!devices!
Table 6.4  Summary of characteristics that are not  
statistically different between devices for the Healthy 
Control subject group. Green indicates not statistically 
different. Red indicates statistically different. 
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6.2 Classification of Parkinson Subjects   
  
Due to the statistical differences in characteristics between devices for the 
Essential Tremor group, only the Healthy Control and Parkinson groups were used for 
the classification of Parkinson subjects. Likewise, only those six characteristics that were 
not shown to be statistically different between the Leap Motion Controller and the 
Tremorometer were used as features to classify the Parkinson subjects. Again, those six 
characteristics were Proportional Power between 4-6 Hz, Proportional Power between 
8-12 Hz, Median Frequency, Frequency Dispersion, Peak Frequency between 0-25 Hz, 
and the Total Power between 0-25 Hz. Since these characteristics were not statistically 
different by device for the Healthy Control group and Parkinson group, it was assumed 
that the characteristics provided by the Leap Motion Controller were correct and that 
they would be the most useful features to classify the Parkinson subjects.  
 
6.2.1 K-means Cluster Analysis  
 
The K-means Cluster analysis, as a method of classifying Parkinson subjects 
from Healthy Control subjects, was found to be fairly successful. It was found that 
there were 9 misclassifications out of the 40 subjects, an error rate of 0.225.  To evaluate 
the performance of the classification, a confusion matrix was created and is shown in 
Table 6.5. The label True Positive represents the subjects that were from the Parkinson 
group, True Negative represents the subjects that were from the Healthy Control group, 
the label Predicted Positive represents the subjects that were classified as Parkinson 
subjects, and the Predicted Negative label represents the subjects that were classified as 
Healthy Control subjects. 
 
 
 
 
 
 True Positive True Negative 
Predicted Positive 12 1 
Predicted Negative 8 19 
Table 6.5  The confusion matrix for the K-means cluster analysis 
as a means of classification.  
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Based on the confusion matrix, the accuracy, sensitivity, and specificity were 
calculated and are shown in Table 6.6. The precision is indicative of the percentage of 
the positive cluster labels that were correct, the recall/sensitivity represents the 
percentage of True Positive subjects that were correctly clustered, the specificity 
represents the percentage of True Negative subjects that were correctly clustered, and 
the accuracy represents the percentage of the clustering that were correct. The overall 
accuracy for classifying Parkinson subjects from Healthy Control subjects using K-
means Clustering was found to be 77.5%. 
 
 
 
 
 
 
 
 
 
A visualization of the K-means cluster analysis was also created for several of 
the characteristics and can be seen in Figure 6.1 on the following page. Blue data points 
indicate the data that were classified into Cluster 1 and red data points are those that 
were classified of Cluster 2. The data points labeled with an asterisk are diagnosed 
Parkinson Disease subjects and the data points labeled by a circle are Healthy Controls. 
Those points labeled with an “X” represent the centroid of the cluster. This figure 
allows for a better visualization of the performance of the K-means cluster analysis in 
terms of classifying the Healthy Controls and Parkinson subjects. It also allows one to 
visually compare the characteristics of individual subjects per subject group. It can be 
seen that some of the Parkinson subjects exhibited a higher Proportion of Power 
between 4-6 Hz as expected and it is hypothesized that these Parkinson subjects had 
visible or high-amplitude tremor. This is supported by the fact that the same Parkinson 
subjects had a much higher Proportional Power of Peak between 0-25 Hz than other 
Parkinson subjects. However, other Parkinson subjects were shown to have a lower 
 K-means Clustering  
Precision 92.3% 
Recall/Sensitivity 60% 
Specificity 95% 
Accuracy 77.5 % 
Table 6.6  The precision, recall/sensitivity, 
specificity, and accuracy to evaluate the K-means 
cluster analysis as a means of classification.  
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Proportional Power between 4-6 Hz that were more similar to the Healthy Controls. 
This most likely indicates that these subjects did not exhibit any visible high amplitude 
tremor and were possibly being treated using Deep Brain Stimulation (DBS) or were 
taking medications to suppress the severity of the tremor.  
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Figure 6.1  The K-means cluster analysis for several characteristics. The data points in blue 
represent Cluster 1, the red data points represent Cluster 2. The data points labeled with an 
asterisk are Parkinson Disease (PD) subjects and those labeled with a circle are Healthy (HE) 
Controls. The points labeled with an “X” represent the centroid of the cluster. 
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6.2.2 Support Vector Machine  
 
The original SVM classifier was also found to be fairly successful in classifying 
the Parkinson subjects. When cross-validated using the leave-one-out method, the 
misclassification rate was calculated to be 0.2, which was slightly better than the error 
rate of 0.225 from the K-means cluster analysis. However, once the SVM classifier was 
tuned, the misclassification rate was reduced from 0.2 down to 0.15. To evaluate the 
performance of this classification the confusion matrix was created and the accuracy, 
sensitivity, and specificity were calculated and can be shown in Table 6.7 and Table 6.8, 
respectively. The same labels used in the K-cluster analysis confusion matrix were used 
for the SVM confusion matrix. As shown, the precision, recall/sensitivity, and accuracy 
were all higher for the tuned SVM classifier than for the K-means clustering, while the 
specificity remained the same. The resulting overall accuracy of the tuned SVM classifier 
for classifying Parkinson subjects from Healthy Controls was found to be 85%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 True Positive True Negative 
Predicted Positive 15 1 
Predicted Negative 5 19 
 SVM Classifier  
Precision 93.75% 
Recall/Sensitivity 75% 
Specificity 95% 
Accuracy 85% 
Table 6.7  The confusion matrix for the predicted response of 
the cross-validated SVM classification model  
 
Table 6.8  The precision, recall/sensitivity, 
specificity, and accuracy for the tuned SVM 
Classifier.  
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6.3 Concluding Remarks 
  
In conclusion, the study was fairly successful in comparing the Leap Motion 
Controller to the Tremorometer. All eight characteristics were found to not be 
statistically different across trials for either device, suggesting that both devices may be 
repeatable. It was concluded that when comparing the differences between devices for 
the combined subject groups, only the Peak Frequency between 0-25 Hz was found to 
not be statistically different. This suggests that the Leap Motion Controller may be 
capable of obtaining the same Peak Frequency between 0-25 Hz as the Tremorometer 
for subjects with Parkinson Disease, subjects with Essential Tremor, and Healthy 
subjects. However, for all other characteristics, the characteristics between devices were 
shown to be statistically different. These statistically different characteristics could be 
attributed to the pre-processing of the Leap Motion Controller displacement data that 
was performed to obtain acceleration. When the devices were compared within each 
subject group, evidence was found that the Leap Motion Controller could be capable of 
obtaining the same Proportional Power between 4-6 Hz, Proportional Power between 
8-12 Hz, Median Frequency, Frequency Dispersion, Peak Frequency between 0-25 Hz, 
and Total Power as the Tremorometer in Parkinson subjects as well as Healthy Control 
subjects. However, it was found that the Leap Motion Controller did not obtain similar 
characteristics to the Tremorometer for the Essential Tremor subjects. This could also 
be attributed to the pre-processing of the data, where perhaps characteristics unique to 
subjects with Essential Tremor were more greatly affected than the Parkinson and 
Healthy Control subjects. It has also been shown that some accelerometers do not 
correspond well to the data obtained from devices that record displacement, except for 
cases of high-amplitude tremors even though the devices that measure displacement are 
shown to be fairly precise.32 Possible improvements to the pre-processing methods are 
discussed in the next section. It was noted that in subjects with high-amplitude tremor, 
consisting of a very large peak with small frequency dispersion, the resulting 
characteristics of the Tremorometer and Leap Motion Controller were very similar. The 
power spectral density estimate of such a subject can be seen in Figure 4.15. 
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Although only Parkinson subjects and Healthy Controls were used for 
classification, the study was still successful in that Parkinson subjects were accurately 
differentiated from the Healthy Controls. The Proportional Power between 4-6 Hz, 
Proportional Power between 8-12 Hz, Median Frequency, Frequency Dispersion, Peak 
Frequency between 0-25 Hz, and the Total Power between 0-25 Hz were all used as 
features for classification, based on the results of the statistical differences between the 
Leap Motion Controller and Tremorometer for the Parkinson and Healthy Control 
groups. The K-means cluster analysis, as a method of classification, was found to have 
an accuracy of 77.5%, while the tuned cross-validated SVM classifier was found to have 
an accuracy of 85%. It should be noted that another SVM classifier was also trained 
using all eight characteristics and while the results are not mentioned in this study, it was 
interesting to find that using all eight decreased the overall accuracy even after tuning. 
This suggests that perhaps the Peak Power between 0-25 Hz and the Proportional 
Power of Peak between 0-25 Hz are either not good predictors or are not consistent 
across recordings. Although not perfect, the SVM classifier reported in this study was 
more successful in classifying Parkinson subjects than simply using K-means clustering.  
Based on these results, it can be concluded that overall the study was successful in 
classifying Parkinson subjects from Healthy Control subjects.  
 
It is important to keep in mind that not all of the Parkinson and Essential 
Tremor subjects displayed high-amplitude tremor. Many of the subjects were likely 
taking medication or undergoing Deep Brain Stimulation (DBS) that could have greatly 
suppressed their tremor. This would most likely detriment the accuracy of the 
classifications, making it much more difficult to discern subjects Parkinson from 
Healthy Controls. Methods to account for cases where patients are undergoing 
treatment for their disorder are mentioned in Future Works. 
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6.4 Future Works 
   
In future works, it would be interesting to investigate a variety of different 
methods to go about comparing the Leap Motion Controller with the Tremorometer to 
measure human tremor. It is suggested that rather than performing two separate trials 
with the two devices individually, to perform one trial with the two devices 
simultaneously as done in other similar studies.32 This would ensure that the same 
tremor was recorded rather than tremor from the same individual at two different 
points in time. Since tremor can significantly vary at different times, especially for those 
with movement disorders, it would be ideal to perform the recordings of both devices 
simultaneously. It is also recommended that postural tremor be recorded rather than 
rest tremor, since it is less likely that the Leap Motion Controller will incorrectly record 
the index finger. This is because if the hand is outstretched, fingers are more spread 
apart than they would be at rest. When the Leap Motion Controller can distinguish 
individual fingers as is the case when fingers are more spread apart, it is much more 
likely to obtain an accurate recording of the index finger. It would also be useful to 
implement the confidence level method, available in the Leap Motion Skeletal V2 Beta 
SDK for Java, in the code used to record the Leap Motion data. This method rates how 
well the internal hand model fits the observed hand and would be useful to ensure that 
the recordings are as accurate as possible.  
   
 It is suggested that to improve the pre-processing of the data an alternative 
approach be taken to estimate the spectra on the data. One method is to blind the study 
to eliminate bias and pre-process each tremor signal individually, applying different 
filters and windowing to best estimate the power spectral density. This would eliminate 
the possibility of distorting the shape of power spectral density estimate by applying the 
same filtering and windowing to all tremor signals. Another method would be an 
adaptive approach specifically for tremor, such as the one suggested by Timmer, Lauk, 
and Deuchl (1996).40 In future works, a Kalman Filter could also be implemented during 
the pre-processing of data. 
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Although not performed in this study, it would have been interesting to 
determine how well the Parkinson subjects could be classified, if the Essential subjects 
had been included in the classifications. Likewise, it would also be interesting to 
determine if abnormal tremors could be correctly classified out of the Healthy Control 
subjects, Parkinson subjects, and Essential Tremor subjects. It is also suggested that 
more subjects and possibly more trials be recorded in future works. This would increase 
the power of the study and add more validity to the results. It would also be beneficial 
to include the UPDRS score at the time of the recording, recorded by a clinician. This   
would provide better true indication of the severity of tremor and determine if similar 
scores can be derived based on the tremor measurements and characteristics. 
Comments as to whether the subjects are currently taking medication or if they are 
undergoing treatment for the tremor would also be useful as this could greatly affect the 
presence of tremors characteristic to Parkinson Disease and Essential Tremor. The 
identification and calculation of more potential features could also prove to be useful 
along with an implementation of a feature selection algorithm to identify the most 
deterministic features that could be used in the classification. Although only one 
unsupervised and one supervised learning methods were implemented in this study, it is 
suggested that others alternatives may provide better results. 
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Appendix B 
 
IRB Application  
 
Tremor Detection 
PI: Matthew Johnson 
IRB ID #: 201404034 
 
Project Details 
I. Demographics 
 I.1 Project Title: 
  Detection of Parkinson Disease Rest Tremor   I.2 Short Title (required): 
  Tremor Detection   I.3 Project is primarily: 
  Biomedical   I.4 Do you want the IRB to give this project 
  Regular (expedited or full board) review   I.7 Enter the estimated date you will be ready to begin 
recruiting participants or collecting data for this project. 
  
04/2014 
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 I.8 Provide a short summary of the purpose and procedures of 
the study proposed in this IRB application. 
• DO NOT include information on studies not proposed 
in this application. (If your source of support 
proposal describes multiple aims, refer to the 
information button for an example on how to 
complete this question.) 
• Use LAY terminology only. This must be easily 
understandable by IRB community members and 
nonscientists. 
• DO NOT cut and paste technical abstracts from 
source of support applications that may not be 
understood by a general audience. 
  
The main purpose of this study is to determine whether it is 
possible to predict, with reasonable accuracy, if a patient has 
Parkinson Disease based on their rest tremor. The rest tremor 
will be measured by recording the three-dimensional position 
and acceleration of their index finger while at rest over a set 
period of time. This will be done using two devices. The first 
device, the Tremorometer, uses a three-dimensional 
accelerometer(a device that measures changes in acceleration) 
and has 510k clearance by the FDA to measure and quantify 
tremor by measuring acceleration and calculating tremor 
statistics in human patients. The second device, the Leap 
Motion Controller, is a three-dimensional camera that uses 
two CCD (Charged Coupled Device) cameras and three 
infrared LEDs to obtain position data. Tremor statistics 
obtained and calculated from both devices will be compared to 
determine if data obtained from the Leap Motion Controller 
are substantially equivalent to that obtained from the 
Tremorometer. The data obtained from the Leap Motion 
Controller will then be used to determine the characteristic 
features of rest tremor in Parkinson Disease and then be used 
to create an algorithm that can predict whether a patient has 
Parkinson disease.  
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 I.9 Specify your research question(s), study aims or hypotheses 
(do not indicate "see protocol") 
  
Hypothesis 1: The Leap Motion Controller can be used in 
place of a triaxial accelerometer to record rest tremor in 
Parkinson Disease.  
Aim 1: Determine whether the Leap Motion Controller can be 
used to obtain similar tremor statistics as those obtained from 
a triaxial accelerometer (Tremorometer).  
 
Hypothesis 2: The data obtained from the Leap Motion 
Controller can be used to identify characteristic features of rest 
tremor in Parkinson Disease that will distinguish PD patients 
from patients with Essential Tremor.  
Aim 2: Determine whether patients with rest tremor in 
Parkinson disease can be identified when compared to patients 
with Essential Tremor, using the positional data collected by 
the Leap Motion Controller.  
 
 I.10 Background and significance and/or Preliminary studies 
related to this project. 
(do not indicate "see protocol") 
  
Parkinson Disease (PD) is a debilitating and progressive 
movement disorder that affects over one million people in the 
United States alone. One of the most characteristic symptoms 
of PD is resting tremor, as it has been shown that the 
proportion of patients with resting tremor ranged from 69-
100% in 3 series of patients with autopsy-proven PD[1,2,3]. 
Several methods currently exist to quantitatively measure 
tremor including accelerometry, electromyography, the 
spirogram, and most recently three-dimensional cameras [4]. 
Advances in three-dimensional cameras have allowed for 
more accurate recordings and can now be used to provide 
much more accurate measurements in microdisplacements of 
upper extremities that are involved in movements such as 
resting tremor. One such three-dimensional camera is the Leap 
Motion Controller, produced by Leap Motion, Inc. The device 
is a small USB three-dimensional camera that utilizes two 
CCD (Charged Coupled Device) cameras and three infrared 
LEDs to obtain depth information, and is capable of 
measuring changes in position to within 0.01 mm, and requires 
no external sensors or markers unlike accelerometry, 
electromyography, and the spriogram. The advantage of 
having no sensors attached to the body is that the mass of the 
sensors decrease the peak frequency of finger tremor by 
approximately 0.85 Hz for every gram of additional mass with 
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no solid data for its effects on the amplitude of acceleration 
[5]. Therefore the attached sensors may change the 
characteristics of the tremor, thus altering interpretation of 
tremor. Unlike accelerometers, the Leap Motion Controller 
does not require calibration eliminating possible errors caused 
by recalibrating. Unlike electromyography, the Leap Motion 
Controller is not affected by interference from electrical 
sources, mechanical artifacts, stimulus artifacts, and the 
electrical activity of muscles that are not of interest. This is 
why the Leap Motion Controller is of interest and may be 
superior in measuring tremor. 
 
 
 I.11 Literature cited / references (if attaching a grant or protocol 
enter N/A). 
  
1. Hughes AJDaniel SELees AJ The clinical features of 
Parkinson's disease in 100 histologically proven cases. Adv 
Neurol. 1993;60595- 599  
 
2. Louis EDKlatka LALiu YFahn S Comparison of 
extrapyramidal features in 31 pathologically confirmed cases 
of diffuse Lewy body disease and 34 pathologically confirmed 
cases of Parkinson's disease. Neurology. 1997;48376- 380  
 
3.Rajput AHRozdilsky BAng L Occurrence of resting tremor 
in Parkinson's disease. Neurology.1991;411298- 1299  
4. Wenzelburger, R., Raethjen, J., Löffler, K., Stolze, H., 
Illert, M. and Deuschl, G. (2000), Kinetic tremor in a reach-to-
grasp movement in Parkinson's disease. Mov. Disord., 15: 
1084–1094.  
 
5. Stiles RN, Randall JE; Mechanical factors in human tremor 
frequency; J Appl Physiol 1967;23(3):324-30  
 
 
 I.12 Select up to three key words below that best describe this 
research study: 
  
• Engineering 
  • Electrical 
• Investigational Devices 
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II. Research Team 
 II.1 The Principal Investigator of this study is: 
  Graduate student/Medical Student   II.3 Do you want to add a team member who is a WUSTL 
faculty, student or staff member? 
  Yes   II.4 Do you want to add a team member who is not a WUSTL 
faculty, student or staff member? 
  
No 
 
 
 II. 
5 
Team Members 
 
WUSTL Team Members 
Role Name E-mail College Department Contact WUSTL COI 
Consent 
Process 
Involvement 
PI 
Matthew Johnson, 
Biomedical  
Engineering, BS 
johnson.m@wustl.edu 
School Of 
Engineering 
And 
Applied 
Science 
General 
Engineering Yes  Yes 
FS Arye Nehorai,  PHD nehorai@ese.wustl.edu 
School Of 
Engineering 
Electrical & 
Systems 
Engineering 
Yes  No 
 
Scott Norris, 
 MD, BA norriss@npg.wustl.edu 
School Of 
Medicine Neurology Yes  Yes 
 
Mwiza Ushe,  
MD, MA- ushem@neuro.wustl.edu 
School Of 
Medicine Neurology Yes  Yes 
Name Financial Interests 
Matthew Johnson, Biomedical Engineering, BS none 
Arye Nehorai, PHD none 
Scott Norris, MD, BA none 
Mwiza Ushe, MD, MA- none 
 
 
 
Non-WUSTL Team Members 
Name Institution Location FWA Role DHHS Contact WUSTL COI 
Consent Process 
Involvement 
Nothing found to display 
Name Financial Interests 
Nothing found to display 
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III. Source(s) of Support 
 III.1 Source(s) of Support 
  
 Type Source 
Grant 
Title 
Name of 
PI on 
Grant 
Status Status Description 
 No Support      
 
* new source name 
 
 
IV. Waiver of Consent 
 IV.1 Are you requesting a waiver of informed consent 
(participants will not be given any oral or written 
information about the study prior to their participation)? 
  No  
 
V. Other Institutional Reviews/Requirements 
 V.1 Do you or a family member have within the past twelve 
months or anticipate having within the next twelve months 
any financial interests in the company/organization 
providing support for this research or from a 
company/organization that owns or licenses the drug, 
device, or intellectual property being utilized in this 
research? 
  
Name Financial Interests 
Matthew Johnson, Biomedical Engineering, BS none 
Arye Nehorai, PHD none 
Scott Norris, MD, BA none 
Mwiza Ushe, MD, MA- none 
  
  
V.4 
 
Do any of the objectives of this study involve the diagnosis, 
prevention, screening, evaluation, treatment or support of 
cancer patients? 
  No   V.5 Are more than 30% of the patients involved in this study 
likely to have an active cancer diagnosis? 
  No  
     
 
74 
 V.7 Will any subject be asked to undergo a radiation therapy 
procedure (including external beam therapy, brachytherapy, 
or radiopharmaceutical therapy)? 
  No   V.10 Does your study involve the administration of 
radiopharmaceuticals (radioactive drugs) for research 
purposes? 
  No   V.12 Will any participant be asked to undergo any of the 
following: 
• a standard radiology procedure involving ionizing 
radiation (includes X-rays, fluoroscopy, DEXA, CT) 
OR 
• a standard nuclear medicine examination with FDA-
approved radioactive drugs (including bone scans, 
radionuclide ventriculogram (RVG or MUGA), 
myocardial perfusion imaging, FDG-PET) 
• DO NOT include MRI or ultrasound 
  No   V.17 Will the study involve any of the following activity at WUSM 
or any BJC hospitals, even if subjects or their insurance will 
not be billed for the item or service, and regardless of the 
study funding source (including studies with departmental 
or no funding)? 
• Procedures, tests, examinations, hospitalizations, use 
of Pathology services, use of clinic facilities or 
clinical equipment, or any patient care services, 
including services conducted in the Clinical 
Research Unit; or 
• Physician services or services provided by non-
physicians who are credentialed to bill (ARNPs, 
Physician Assistants, etc.) 
  Yes   V.18 Does this project involve administration of recombinant 
DNA (gene therapy) or microorganisms? 
  No   V.19 Does this study involve the use of human embryonic stem 
cells or human induced pluripotent stem cells? 
  No  
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 V.20 Does this study involve research in which a human embryo 
or embryos are destroyed, discarded, or knowingly subjected 
to risk of injury or death greater than that allowed for 
research on fetuses in utero? 
  No   V.21 Will you be utilizing participants, data or tissue from the 
Memory & Aging Project (MAP) or Alzheimer's Disease 
Research Center (ADRC)? 
  No   V.22 Is the PI of this study a BJH Registered nurse or a staff 
member of Patient Care Services (Pharmacy, PT/OT/, 
Respiratory, Rehabilitation, and Social work)? 
  No   V.23 Will any portion of this project be conducted in any Center 
for Applied Research Sciences Units, Clinical Research Unit 
(CRU), Clinical Trials Unit (CTU) and/or the Pediatric 
Research Unit (PCRU)? 
  No   V.24 Will this research be performed in the Neonatal Intensive 
Care Unit (NICU)? 
  No   V.25 Is this research being conducted in the Emergency 
Department? 
  No   V.26 Are you recruiting or screening patients in the Emergency 
Department? 
  No  
 
VI. Participants 
 VI.1 How many adult participants do you expect to consent for 
this project? 
  30   VI.2 What is the age of the youngest adult participant? 
  18.0   VI.3 What is the age of the oldest adult participant? 
  No age limit   VI.4 How many minor participants do you expect to consent for 
this project? 
  0  
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 VI.7 Describe EACH of your participant populations 
• Include description of any control group(s) 
• Specify the Inclusion/Exclusion criteria for EACH 
group 
  
Study patient groups:  
1) 10 patients diagnosed with Parkinsonism with tremor  
 
Inclusion criteria:  
a. age greater than or equal to 18  
b. male or female  
c. any race or ethnicity  
d. physician confirmed Parkinsonism, with tremor as a 
symptom, based on diagnostic criteria (Calne DB, Snow BJ, 
Lee C. Criteria for Diagnosing Parkinson's Disease. Annals of 
Neurology 1992; 32:S125-S127.)  
e. ability to give informed consent  
 
Exclusion criteria:  
a. History of stroke, seizure, cerebral palsy, or additional 
neurological diagnosis  
b. Severe upper limb tremor  
c. Any serious medical or psychiatric condition  
d. Age less than 18  
e. Cognitive impairment (Mini-Mental State Score <19)  
 
2)10 patients diagnosed with Essential Tremor  
 
Inclusion criteria:  
a. age greater than or equal to 18  
b. male or female  
c. any race or ethnicity  
d. physician confirmed essential tremor based on diagnostic 
criteria (Bain P, Brin M, Deuschl G, Elble R, Jankovic J, 
Findley L, Koller B, Pahwa R. Criteria for the diagnosis of 
essential tremor. Neurology 2000;54(Suppl. 4):57.)  
e. ability to give informed consent  
 
 
 
 
 
 
 
     
 
77 
Exclusion criteria:  
a. History of stroke, seizure, cerebral palsy, or other major 
psychiatric illness  
b. Severe upper limb tremor  
c. Any serious medical or psychiatric condition  
d. Age less than 18  
e. Cognitive impairment (Mini-Mental State Score <19)  
 
3) 10 normal control subjects  
 
Inclusion criteria:  
a. age greater than or equal to 18  
b. male or female  
c. any race or ethnicity  
d. ability to give informed consent  
 
Exclusion criteria:  
a. History of stroke, seizure, cerebral palsy, or other major 
psychiatric illness  
b. Severe upper limb tremor  
c. Any serious medical or psychiatric condition  
d. Age less than 18  
e. Cognitive impairment (Mini-Mental State Score <19)  
 
 VI.8 Describe why you believe there is a sufficient number of 
potential participants available to meet your recruitment 
goals. 
  
Over one million people in the United States suffer from 
Parkinson disease alone. The clinical database in the 
Washington University Movement Disorders Clinic follows a 
large number of patients with Parkinsonism with tremor as a 
symptom as well as patients with Essential Tremor. 
Therefore, the 10 subjects with Parkinsonism with tremor and 
the 10 subjects with Essential Tremor required for this study 
represents a very small proportion of the potential participants 
within this database. 10 healthy control subjects will be 
recruited among the spouses or from the Volunteer for Health 
initiative of Barnes-Jewish Hospital and Washington 
University School of Medicine's Research Participant 
Registry with a pool of over 8000 volunteers. 
 
 VI.9 Describe how you will have access to each of your study 
populations in sufficient number to meet your recruitment 
goals. 
  
Participants with Parkinsonism and Essential Tremor will be 
recruited from the Movement Disorders Center at Washington 
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University School of Medicine. Healthy control subjects will 
be recruited among their spouses or from the Volunteer for 
Health initiative of Barnes-Jewish Hospital, an affiliate of the 
Washington University School of Medicine with a pool of 
over 8000 volunteers. 
 
 VI.10 Choose the appropriate description of the disease/condition 
under study (for example consider race, ethnicity, gender, 
socioeconomic status etc.) 
  
The disease/condition under study is represented equally 
throughout the population 
 
 VI.13 Will participants provide any information about their 
relatives or another person (third party)? 
  No   VI.16 Will any individual(s), other than the participant, provide 
you with information about the participant (e.g. proxy 
interviews)? 
  No   VI.21 Do you plan to recruit/enroll non-English speaking people? 
  No   VI.24 Do you propose to enroll any of the following in this study 
as participants? 
• Employee of the PI or employee of a research team 
member 
• Individual supervised by PI or supervised by member 
of research team 
• Individual subordinate to the PI or subordinate to 
any member of the research team 
• Student or trainee under the direction of the PI or 
under the direction of a member of the research team 
  No   VI.26 Is this project about pregnant women? 
  No   VI.27 Will this project involve fetuses? 
  No   VI.28 Does this project involve adult participants who may be 
incompetent or have limited decision-making capacity on 
initial enrollment into the study? 
  No   VI.34 Does this project involve participants whose capacity to 
consent may change over the course of the study? 
  No  
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 VI.38 Does this project involve prisoners as participants? 
  No  
 
VII.A. Basic Project Information 
 VII.A.1 Is there a separate, written protocol that will be submitted in 
addition to this IRB New Project form? (Note: a grant 
application is not considered to be a protocol) 
  Yes   VII.A.2 Who initiated/provided the protocol? 
  WUSTL Investigator   VII.A.4 Protocol#: 
   
 
 VII.A.5 Protocol Version#: 
   
 
 VII.A.6 Protocol Date: 
   
 
 VII.A.7 Provide a list of the amendments for this study (this may be 
left blank if none). Any amendments previously listed should 
not be removed. 
  
Amend. # Amend. Date 
Nothing found to display 
  
 VII.A.8 Where will project procedures take place (check all that 
apply)? 
  
• Barnes Jewish Hospital (BJH) 
• Washington University School of Medicine (WUSM) 
 
 VII.A.9 Is this project also being conducted by other researchers at 
their own sites (e.g. a multi-site collaborative project)? 
  No  
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VII.B. Drugs/Devices 
 VII.B.1 Does this project involve any of the following: 
• clinical intervention 
• pharmacologic intervention 
• therapeutic intervention 
• physiology studies (e.g. studying the functions of 
organs, tissues, or cells) 
  Yes   VII.B.2 Does this project involve any substance ingested, injected, or 
applied to the body? 
  No   VII.B.9 Are any contrast agents used for any purpose in this study? 
  No   VII.B.11 Does this project involve a drug washout (asking participant 
to stop taking any drugs s/he is currently taking)? 
  No   VII.B.15 Will any participants receive a placebo in this study when, if 
they were not participating, they could be receiving an FDA-
approved treatment for their condition? 
  No   VII.B.20 Does this project involve testing the safety and/or efficacy of 
a medical device? 
  Yes   VII.B.21 Describe in detail procedures in place for maintaining device 
shipment and receipt records: 
  
N/A since the devices are currently marketed and currently on 
hand. 
 
 VII.B.22 Who will be responsible for maintaining these shipment and 
receipt records? 
  N/A   VII.B.23 Describe in detail procedures in place for tracking use and 
disposition of devices described in this study: 
  N/A   VII.B.24 Who will be responsible for maintaining these use and 
disposition tracking records? 
  
N/A 
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 VII.B.25 Describe in detail procedures in place to limit access to 
authorized study personnel for the storage, control, and 
dispensing of the investigational devices. 
  N/A   VII.B.26 Is the device FDA-approved for the way it will be used in this 
study? 
  No   VII.B.27 Is there an IDE (Investigational Device Exemption) for this 
device in this research project? 
  No   VII.B.31 Indicate the appropriate FDA status you and/or the sponsor 
are requesting for the use of this device in this study. 
  Non-Significant Risk (NSR) device/software   VII.B.33 Provide a detailed rationale for why this device meets the 
FDA definition of a Non-Significant Risk Device (NSR) 
  
The Leap Motion Controller meets the FDA definition of a 
Non-Significant Risk Device (NSR) because:  
1. It is not an implant  
2. It will not be used in supporting or sustaining human life  
3. Is not for a use of substantial importance in diagnosing, 
curing, mitigating, or treating disease, or otherwise preventing 
impairment of human health  
4. It does not present a potential for serious risk to the health, 
safety, or welfare of a subject  
 
The Leap Motion Controller is a consumer three-dimensional 
camera and will be used in accordance with its purpose: to 
measure and record hand and finger motions.  
 
The Tremorometer meets the FDA definition of a Non-
Significant Risk Device (NSR) because:  
1. It is not an implant  
2. It will not be used in supporting or sustaining human life  
3. Is not for a use of substantial importance in diagnosing, 
curing, mitigating, or treating disease, or otherwise preventing 
impairment of human health  
4. It does not present a potential for serious risk to the health, 
safety, or welfare of a subject  
 
The Tremorometer has 510k clearance for measuring and 
quantifying tremor in human participants, which will be its 
only use in this study. 
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 VII.B.34 Provide a summary of prior investigations with this device. 
  
Prior investigations with the Leap Motion Controller  
 
Mauser, Stanis & Burgert, Oliver. (2014, Feb. 12) Touch-Free 
GestureBased Control of Medical Devices and Software 
Based on the Leap Motion Controller. In J.D Westwood, S. 
W. Westwood, and L. Felländer-Tsai, eds. Medicine Meets 
Virtual Reality 21: NextMed/MMVR21. Paper presented at 
21st NextMed/MMVR conference, Manhattan Beach, 
California. (pp. 265-270) Vol. 196. IOS Press, 2014.  
 
F. Weichert, D. Bachmann, B. Rudak, D. Fisseler  
Analysis of the accuracy and robustness of the leap motion 
controller  
Sensors, 13 (5) (2013), pp. 6380–6393 
http://dx.doi.org/10.3390/s130506380  
 
I. Tarnanas, W. Schlee, M. Tsolaki, R. Müri, U. Mosimann, T. 
Nef  
Ecological validity of virtual reality daily living activities 
screening for early dementia: longitudinal study  
JMIR Serious Games, 1 (1) (2013) 
http://dx.doi.org/10.2196/games.2778 e1, 1–13  
 
Guna J, Jakus G, Pogačnik M, Tomažič S, Sodnik J. An 
Analysis of the Precision and Reliability of the Leap Motion 
Sensor and Its Suitability for Static and Dynamic Tracking. 
Sensors. 2014; 14(2):3702-3720.  
 
Taha Khan, Dag Nyholm, Jerker Westin, Mark Dougherty, A 
computer vision framework for finger-tapping evaluation in 
Parkinson's disease, Artificial Intelligence in Medicine, 
Volume 60, Issue 1, January 2014, Pages 27-40, ISSN 0933-
3657, http://dx.doi.org/10.1016/j.artmed.2013.11.004.  
(http://www.sciencedirect.com/science/article/pii/S093336571
3001565)  
 
 
Prior investigations with the Tremorometer  
 
Aasef G. Shaikh, Kenichiro Miura, Lance M. Optican, Stefano 
Ramat, Robert M. Tripp and David S. Zee, “Hypothetical 
membrane mechanisms in essential tremor”, Journal of 
Translational Medicine, 2008, 6:68  
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Aasef G. Shaikh, H. A. Jinnah, Robert M. Tripp, Lance M. 
Optican, Stefano Ramat, Frederick A. Lenz, David S. Zee, 
“Irregularity distinguishes limb tremor in cervical dystonia 
from essential tremor”, Journal Neurology, Neurosurgery, 
Psychiatry, (2008), 79, 187-189; originally published online 
14 Sep 2007, doi: 10.1136/JNNP.2007.131110  
 
Aasef G. Shaikh, Kenichiro Miura, Lance M. Optican, Stefano 
Ramat, R. John Leigh, David S. Zee, “A new familial disease 
of saccadic oscillations and limb tremor provides clues to 
mechanisms of common tremor disorders”, Brain (2007), 130, 
3020-3011  
 
S. M. Bowyer, K. Mason, B. Weiland, J. E. Moran, G. L. 
Barkley, N. Tepley, “Localization of Motor Cortex by MEG 
Using a Tremorometer”, International Congress Series, 
Elsevier (2007) doi: 10.1016/j.ics.2007.02.001  
 
Khalafalla O. Bushara, Taimur Malik, Rupert E. Exconde, 
“The Effect of Levetiracetam on Essential Tremor”, 
Neurology 2005; 64;1078-1080; doi: 
10.1212/01.WNL.0000154596.21335.2E  
 
Michael P. Caligiuri, Robert M. Tripp, “A portable hand-held 
device for quantifying and standardizing tremor assessment”, 
Journal of Medical Engineering and Technology (2004), 
28(6):254-262  
 
Michael P. Caligiuri, Robert M. Tripp, “The 
TremorometerTM: A Portable Instrument for Quantifying 
Hand Tremor”, Biol Psychiatry Abstr (2000), 47:142S 
 
 
 VII.B.35 Have there been any prior IRB reviews (at WUSTL or 
elsewhere) and/or determinations made with regard to this 
device? 
  No   VII.B.37 Has the FDA made an assessment of risk with regard to this 
device? 
  Yes   VII.B.38 Has this device/software been approved by the FDA for 
another indication or in another form from its use in this 
project? 
  No  
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VII.C. Genetic Research 
 VII.C.1 Does this project involve any research on genes or genetic 
testing/research? 
  No  
 
VII.D. Recruitment & Consent 
 VII.D.1 Check all materials/methods that will be used in recruiting 
participants (you will need to attach copies of all materials 
at the end of the application): 
  
• Existing Registry/database , Describe 
Washington University Movement Disorders 
electronic medical record (MARS) clinical database. 
This is the clinical database for which clinical 
information is entered for all patients seen in the 
movement disorders division of neurology. We may 
utilize the Washington University School of Medicine 
Research Participant Registry powered by the 
Volunteer for Health to recruit normal control 
subjects. 
 
• PHI 
o Use of any information available to the 
researchers or their colleagues because this 
person is a patient OR use of any 
information considered to be Protected 
Health Information (PHI) OR review of 
patient/clinic records , Describe source of 
records 
We will review patient records in the Washington 
University Movement Disorders electronic 
medical record clinical database (MARS) to 
identify potential participants. 
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• Referral from colleague , Describe 
Physician colleagues within the division of Movement 
Disorders at Washington University School of 
Medicine will be verbally notified of the ongoing 
study. If they evaluate a patient in clinic that fits 
inclusion criteria, they may provide potential 
participants with contact information for the research 
team or direct them directly to the testing room on the 
day of study. 
 
 VII.D.2 List the individual data elements you will need to access/use 
from the patient or clinic records to identify potential 
participants for recruitment 
  
1. Definite diagnosis of Parkinsonism or Essential Tremor  
2. Mini-mental Status Exam  
3. Information regarding examination findings with regard to 
tremor (i.e. whether present, degree of severity, etc). 
 
 VII.D.3 Describe why you could not practicably recruit participants 
without access to and use of the information described above 
  
The above information is critical inclusion/exclusion criteria 
which must be confirmed from the medical record. 
 
 VII.D.4 Describe why you could not practicably obtain authorization 
from potential participants to review their patient or clinic 
records for recruitment purposes. 
  
Without knowing the definite diagnosis and medical history 
of a patient, it is not possible to identify appropriate subjects 
to recruit based on specific inclusion criteria. 
 
 VII.D.5 Describe plans to protect the identifiers from improper use 
or disclosure 
  
Only study team members will have access to the medical 
record of any potential and/or enrolled subjects. These records 
are password protected in the clinical movement disorders 
database (MARS) which is HIPAA compliant. Any data 
collected will not contain any identifiers, except for what is 
mentioned in the inclusion and exclusion criteria for each 
group and will only be stored on a LOK-IT Secure Flash 
Drive, which is automatically encrypted with military-grade 
256-bit AES hardware encryption, which is HIPAA 
compliant. 
 
 VII.D.6 Describe plans to destroy identifiers at the earliest 
opportunity consistent with conduct of the research 
  There will be no need to utilize any identifiers in this study.   VII.D.7 Does the research team agree that the requested information 
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will not be reused or disclosed to any other person or entity, 
except as required by law, for authorized oversight of the 
study, or for other research for which the use or disclosure 
of the requested information would be permitted by the 
HIPAA Privacy Rule 
  Yes   VII.D.8 Will a member of the research team discuss the study with 
the participant in person prior to the participant agreeing to 
participate? 
  Yes   VII.D.9 Describe the physical location where the consent process 
will take place: 
  
Meetings with participants will occur in the following 
location within the Washington University School of 
Medicine:  
1) The movement disorder clinic in the lower level of 
McMillan Building. The study will be performed behind 
closed doors in an examination room.  
 
 VII.D.10 Will a member of the research team discuss the study with 
the participant by phone prior to the participant agreeing to 
participate? 
  No   VII.D.12 Who will be involved in the consent process (including 
review of consent document, answering participants' 
questions)? 
  
Name Consent Process Involvement 
Matthew Johnson,  
Biomedical Engineering, BS 
Yes 
Arye Nehorai, PHD No 
Scott Norris, MD, BA Yes 
Mwiza Ushe, MD, MA- Yes 
  
 VII.D.13 Check all materials that will be used to obtain/document 
informed consent: 
  
• Consent Document 
 
 VII.D.14 Does the study include any form of deception (e.g., 
providing participants with false information, misleading 
information, or withholding information about certain study 
procedures)? 
Examples: 
• Procedure includes a cover story that provides a 
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plausible but inaccurate account of the purposes of 
the research. 
• Participants will be provided with false information 
regarding the particular behaviors of interest in the 
research. 
• Procedures include a confederate pretending to be 
another participant in the study. 
• Participants will be told that the research includes 
completion of a particular task, when in fact, that 
task will not be administered. 
• Study is designed to introduce a new procedure (or 
task) that participants are not initially told about. 
  No   VII.D.25 Are you requesting a waiver of documentation of consent 
(either no participant signature or no written document)? 
  No   VII.D.28 Before the participant gives consent to participate are there 
any screening questions that you need to directly ask the 
potential participant to determine eligibility for the study? 
  Yes   VII.D.29 List any screening questions you will directly ask the 
potential participant to determine eligibility. 
  
1. What is your current age?  
2. Have you every been diagnosed with any serious medical 
or psychiatric conditions?  
 
 VII.D.30 Will you keep a screening log or other record that would 
include information on people who do not consent to 
participate in the study? 
  No   VII.D.34 After the participant agrees to participate (signs consent), 
are there any screening procedures, tests, or studies that 
need to be done to determine if the participant is eligible to 
continue participating? 
  No   VII.D.36 Discuss how much time a potential participant will have to 
agree to consider participation and whether or not they will 
be able to discuss the study with family/friends before 
deciding on participation. 
  
The potential participant will have as much time as necessary 
(or until completion of the project, whichever comes first) to 
consider participation in the study. They will be allowed to 
discuss the study with family/friends before deciding on 
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participation. 
 
 VII.D.37 How long after the participant agrees to participate do study 
procedures begin? 
  
The study procedure can begin as soon as the participant signs 
the consent form. 
 
 VII.D.38 Provide a description of the enrollment and consent process 
for adult participants 
• Describe each study population separately including 
control population 
• Include when recruitment and consent materials are 
used 
• Use THIRD person active voice. For example, "the 
principal investigator will identify potential 
participants, the study coordinator will discuss the 
study with participants over the telephone and 
schedule the first study visit, etc..." 
• Describe the steps that will be taken by the research 
team to minimize the possibility of coercion or undue 
influence during the consent process 
  
Ten subjects with clinical diagnostic criteria for 
Parkinsonism, 10 subjects with clinical diagnostic criteria for 
Essential Tremor, and 10 normal control subjects will be 
enrolled in this study. The study team will identify potential 
participants from the clinical database in the movement 
disorder clinic at WUSM. Patients will be recruited in person 
in the movement disorder clinic at WUSM during clinic visits 
with their physician or nurse. The study team member will 
determine the capacity of the potential participant to consent 
for her/himself during initial contact and ask screening 
questions to determine if the potential participant fits the 
inclusion/exclusion criteria for the study. If the subject 
expresses interest in the study and is deemed to fit all 
inclusion/exclusion criteria, informed consent materials will 
be provided to the patient. A study team member will review 
the document with the potential participant to answer any 
questions or explain any unclear points. Potential participants 
will be given time to read the document in its entirety, ask 
questions, and speak with friends/family members if they so 
desire. Study participants will sign the informed consent, and 
will be offered a signed copy of the consent after both parties 
sign the document. 
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VII.E. Methods 
 VII.E.1 Will participants be randomized? 
  No   VII.E.3 Will any questionnaires, surveys, or written assessments be 
used to obtain data directly from participants in this study? 
  No   VII.E.5 Does this project involve creating any audiotapes, 
videotapes, or photographs? 
  No   VII.E.6 Provide a detailed description in sequential order of the 
study procedures following the consent process - DO NOT 
cut and paste from the Consent Document. 
 
Describe study populations separately if they will be 
participating in different procedures - include CONTROL 
population if applicable. 
 
DESCRIBE: 
• What participants will be asked to do/what happens 
in the study (in sequential order) 
• The time period over which procedures will occur 
• The time commitment for the participant for 
individual visits/procedures 
• Long-term followup and how it occurs 
  
All participants, including the control participants, will follow 
the same procedure. Each participant will be measured twice 
and be measured individually. First, the participant will be 
asked to allow a study member to affix with tape the 
accelerometer (from the Tremorometer system) to the index 
finger on the hand that they believe to exhibit the most 
symptomatic tremor. The participant will then be asked to 
place said hand on a small slanted box and asked to spread 
their fingers so that no fingers are touching another finger. 
The participant will again be asked to allow their fingers to 
relax and drape over the edge of the box, still ensuring that 
their fingers are not touching each other. Once the participant 
has their hand in a comfortable position, they will be verbally 
alerted that the measurement will start and be asked to silently 
countdown from 100. After 30 seconds, the participant will be 
verbally alerted that the measurement is over and the 
accelerometer will be removed. The participant will then be 
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asked to again place the same hand on the small slanted box, 
this time in front of the Leap Motion Controller. The 
participant will again be asked to attempt to spread their 
fingers so that no fingers are touching another finger and then 
allow their fingers to relax and drape over the edge of the box, 
ensuring that their fingers are still not touching one another. 
Once the participant has their hand in a comfortable position, 
they will be verbally alerted that the measurement will start 
and be asked to silently countdown from 100. After 30 
seconds, the participant will be alerted that the measurement 
is over. Once complete, the participant will be finished and 
thanked for their time. It is estimated that the time 
commitment for the individual visit will be approximately 10 
minutes, which includes a short explanation of the study along 
with recordings of the individual participant. There will be no 
attempt at a long-term followup. Each participant will be 
given an option to be contacted with the results of the study, 
once the study is complete. 
 
 VII.E.7 Will you attempt to recontact participants who are lost to 
follow-up? 
  No - followup is not required in this study   VII.E.9 Will participants be provided any compensation for 
participating in this study? 
  No  
 
VIII. Risks 
 VIII.1 What are the risks to participants including 
- emotional or psychological 
- financial 
- legal or social 
- physical? 
  
1. Attempting to hold one hand still in one position may be 
uncomfortable.  
2. Participants may become uncomfortable, frustrated, or 
bored during the recording.  
3. Participants may become stressed if they exhibit too severe 
of upper limb tremor to record the data.  
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VIII.2 What have you done to minimize the risks? 
• If applicable to this study ALSO include: 
o How you (members of your research team at 
WUSTL) will monitor the safety of individual 
participants. 
o Include a description of the availability of 
medical or psychological resources that 
participants might require as a consequence 
of participating in this research and how 
referral will occur if necessary (e.g. 
availability of emergency medical care, 
psychological counseling, etc.) 
  
To reduce the risks to the subjects, a physician will be present 
throughout all studies. Confidentiality will be maintained in 
accordance with applicable state and federal laws and all 
study data will be identified only by a code number. 
Personally identifying data will not be recorded or collected. 
 
 VIII.3 Does this study have a plan to have an individual or 
committee review combined data from all participants on a 
periodic basis (such as summary or aggregate safety and/or 
efficacy data)? 
  No  
 
IX. Benefits 
 IX.1 What are the direct benefits to the participant (do not 
include compensation)? 
  There is no direct benefit to participants.   IX.2 What are the potential benefits to society in terms of 
knowledge to be gained as a result of this project? 
  
This study may help provide a better understanding of the 
characteristic features of rest tremor in Parkinsonism. It may 
also provide a better alternative method to record and measure 
rest tremor that may aid in the differentiation of Parkinsonism 
from Essential Tremor. 
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X. Privacy & Confidentiality 
 X.1 Describe your plans to protect the privacy interests of the 
participants during the conduct of the study including: 
• How will you provide a private setting during the 
recruitment process 
• How will you provide a private setting for the consent 
process including an opportunity for the participant 
to ask questions privately 
• Describe how interventions occur in a private setting 
and/or how information will be collected using 
methods that protect the participant's privacy. 
• Discuss why the information collected during the 
study is necessary to the conduct of the study and 
does not unnecessarily invade the rights of 
participants to privacy of their personal information. 
  
The potential subjects will be escorted into a separate 
examination room with closed doors in the clinic, after seeing 
their physician. The potential subjects will be given the 
opportunity to ask questions privately within the examination 
room.  
 
The acceleration information collected using the 
Tremorometer and the position information collected using 
the Leap Motion Controller is necessary because it serves as a 
quantitative representation of tremor, which is needed for this 
study. This quantitative data is needed in order to compare the 
Leap Motion Controller and the Tremorometer for measuring 
tremor. It is also needed in order to identify, calculate, and use 
features of rest tremor that are characteristic of subjects with 
Parkinson Disease. The collection of this data does not invade 
the rights of participants to privacy of their personal 
information because the data being collected is not 
identifiable and cannot be used to identify the patient. The 
data will be used to extract underlying characteristics that are 
unique to their group (Parkinson Disease participants, 
Essential Tremor participants, healthy participants) and are 
not unique to the participants themselves. 
 
 X.2 Are you collecting or using the Social Security Number of 
any participants for any purpose? 
  No     
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X.4 
 
How will information/data be collected and stored for this 
study (check all that apply): 
  
• Electronic records (computer files, electronic 
databases, etc.) - The data that will be recorded will be 
fully de-identified and will not include names, dates of 
birth, or clinic numbers. The only data that will be 
recorded will be the positional and acceleration data of 
the fingers for each subject and whether or not they 
have Parkinsons Disease. This data will only be saved 
on a LOK-IT Secure Flash Drive, which is 
automatically encrypted with military-grade 256-bit 
AES hardware encryption. This level of encryption is 
HIPAA compliant and ensures that the data is 
unreadable if the flash memory were to be physically 
accessed. 
 
 X.5 Do the confidentiality protections indicated above allow only 
members of the research team to access identified 
data/specimens? 
  Yes  
 
XI. Data Analysis 
 XI.1 Provide a summary of the analysis methods you will use, 
including, if applicable, the data points or outcomes you will 
analyze. 
  
Tremorometer:  
All participants will use the Tremorometer system, which will 
record the three-dimensional acceleration of one finger of the 
patient over a set period of time. This acceleration data will 
then be analyzed by the software included in the system to 
provide the frequency and intensity of the tremor.  
 
Leap Motion Controller:  
All participants will use the Leap Motion Controller, which 
will record the three-dimensional position of the one finger of 
the patient over a set period of time. This raw position data 
will then be analyzed using MATLAB in order to calculate 
the tremor frequency as well as the intensity of the tremor. 
These calculations will then be compared to those obtained 
from the Tremorometer system. The position data will further 
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be used to calculate other characteristics of tremor that will be 
used as features in creating an algorithm to predict whether a 
patient has Parkinson's disease.  
 
  
XI.2 
 
Provide the rationale or power analysis to support the 
number of participants proposed to complete this study. 
  
In a previous study entitled the Effect of deep brain 
stimulation on amplitude and frequency characteristics of rest 
tremor in Parkinson's disease by Beuter et al (2001), 8 
Parkinsons subjects were used to determine some of the same 
characteristics that will also be calculated in this study. 
Likewise, in The dynamics of resting and postural tremor in 
Parkinson's disease by Vaillancourt et al (2000), 8 Parkinsons 
subjects and 8 healthy subjects were used to again obtain the 
time and frequency structure of tremor. Similarly, in a study 
that used a 3D motion analysis system to measure tremor, 6 
Parkinson subjects were used (A novel quantitative method 
for 3D measurement of Parkinsonian tremor by Rajaraman et 
al. 1999). Based on these previous studies, we will recruit 10 
healthy subjects, 10 Parkinsons subjects, and 10 Essential 
Tremor subjects. We expect that the number of participants 
will provide enough data to adequately examine tremor and to 
provide enough characteristic features involved in the rest 
tremor of Parkinsonism to create a predictive algorithm. 
 
 
XII. Future Research 
 XII.1 Do you wish to keep any information about participants 
involved with this research project so that other researchers 
outside the current study team may contact them for future 
research? 
  No   XII.3 Does this project involve storing any data for future 
research? 
  
Yes – contribution for future use is mandatory for 
participation in the study 
 
 XII.4 Does this project involve storing any tissues or specimens for 
future research? 
  No  
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Appendix C 
 
Informed Consent 
 
 
 
  
FOR IRB USE ONLY 
IRB ID #: 201404034 
APPROVAL DATE: 05/27/14 
RELEASED DATE: 05/28/14 
EXPIRATION DATE: 05/26/15 
 
 
INFORMED CONSENT DOCUMENT 
 
Project Title: Detection of Parkinson Disease Rest Tremor 
 
Principal Investigator: Matthew Johnson 
 
Research Team Contact: Matthew Johnson: (561) 906-1671 
 
 
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights as a research participant. By signing this form you are 
agreeing to participate in this study. 
• If you have any questions about anything in this form, you should ask the research team for 
more information.   
• You may also wish to talk to your family or friends about your participation in this study. 
• Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
This is a research study.  We invite you to participate in this research study because you: have been 
diagnosed with Parkinson Disease and have tremor as a symptom, have been diagnosed with Essential 
Tremor, or are healthy with no symptoms of tremor.  
 
The purpose of this research study is to create an algorithm that will predict, with reasonable accuracy, if 
a patient has Parkinson Disease based on their rest tremor. To create this algorithm, rest tremor data will 
be collected by recording the three-dimensional position and acceleration of the index finger using two 
different devices. The first device, the Tremorometer, uses a three-dimensional accelerometer (a device 
that measures changes in acceleration) and is cleared by the FDA to measure and quantify tremor by 
measuring acceleration and calculating tremor statistics in human patients. The second device, the Leap 
Motion Controller, is a three-dimensional camera that can obtain position data and is considered 
investigational, which means that it has not been approved by the U.S. Food and Drug Administration. 
The data collected and analyzed by the Tremorometer will be compared to that of the Leap Motion 
Controller to determine whether the Leap Motion Controller can be used to obtain similar results as the 
Tremorometer. The data from the Leap Motion Controller will be analyzed and used to create an 
algorithm that can predict whether a patient has Parkinson Disease. It is hypothesized that the Leap 
Motion Controller will provide similar results as the Tremorometer and that the data from the Leap 
Motion Controller can be used to create a reasonably accurate algorithm that can identify a patient with 
Parkinson Disease from a patient with Essential Tremor or a healthy patient.   
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WHAT WILL HAPPEN DURING THIS STUDY? 
 
The study will occur in an examination room behind closed doors in the movement disorders clinic 
within the Washington University School of Medicine. The data that will be recorded will consist of the 
position and acceleration of your fingers over time and whether you have Parkinson Disease, Essential 
Tremor, or are healthy with no symptoms of tremor.  
 
You will first be asked to allow a study member to tape a small sensor (the accelerometer from the 
Tremorometer system) to your index finger on the hand that you exhibit the most symptomatic tremor. 
You will then be asked to place said hand on a small slanted box and be asked to spread your fingers so 
that no fingers are touching another finger. You will then be asked to allow your fingers to relax and 
drape over the edge of the box, still ensuring that your fingers are not touching. Once your hand is in a 
comfortable position, you will be warned that the recording will start and be asked to silently countdown 
from 100. After 30 seconds, you will be told that the recording is over and the sensor will be removed. 
You will then be asked to place the same hand on the small slanted box in front of the Leap Motion 
Controller (a small three-dimensional camera that tracks hand and finger movements and has not yet 
been used to measure hand or finger tremors.) You will again be asked to allow your fingers to relax and 
drape over the edge of the box, still ensuring that no fingers are touching another finger. Once your hand 
is in a comfortable position, you will be told that the recording will begin and be asked to silently 
countdown from 100. After 30 seconds, you will be told that the recording is over and the you will be 
finished with your participation in the study. 
 
 
Will you save my samples or research data to use in future research studies?  
 
As part of this study, we are obtaining tremor data (in the form of position and acceleration over time) 
from you. By agreeing to be part of this study you give up any property rights you may have in the 
tremor data. We would like to use your tremor data for other research projects in the future. These future 
studies may provide additional information that will be helpful in understanding Parkinson's Disease, 
but it is unlikely that what we learn from these studies will have a direct benefit to you. It is possible that 
your tremor data might be used to develop tests, treatments or cures. There are no plans to provide 
financial compensation to you should this occur. If you agree, this means we will store your tremor data 
and may use it for studies going on right now as well as studies that are conducted in the future. 
 
I would also like your permission to share your tremor data with other investigators doing research in 
similar fields such as other diseases where tremor is a common symptom.  These investigators may be at 
Washington University or at other research centers.  We may also share you research data with large 
data repositories (a repository is a database of information) for broad sharing with the research 
community.  If your individual research data is placed in one of these repositories only qualified 
researchers, who have received prior approval from individuals that monitor the use of the data, will be 
able to look at your information.   
 
Your tremor data will be stored without your name or any other kind of link that would enable us to 
identify which data are yours.  Therefore, if you give permission to store and use your tremor data, it 
will be available for use in future research studies indefinitely and cannot be removed. 
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HOW MANY PEOPLE WILL PARTICIPATE? 
Approximately 30 people will take part in this study conducted by investigators at Washington 
University.   
 
 
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to take part in this study, your involvement will last for approximately 10 minutes.  
 
 
WHAT ARE THE RISKS OF THIS STUDY? 
 
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
study.  
 
Less Likely / Less Common 
 
Mild 
• Risk 1: Attempting to hold one hand still in one position may be physically uncomfortable. 
• Risk 2: Become fatigued, frustrated, or bored during the recording. 
• Risk 3: Become stressed if you exhibit too severe of upper limb tremor to record the data. 
 
One risk of participating in this study is that confidential information about you may be accidentally 
disclosed.  We will use our best efforts to keep the information about you secure, and we think the risk 
of accidental disclosure is very small.  Please see the section in this consent form titled “How will you 
keep my information confidential?” for more information. 
 
 
WHAT ARE THE BENEFITS OF THIS STUDY? 
 
You will not benefit from being in this study. 
 
However, we hope that, in the future, other people might benefit from this study because the study may 
help provide a better understanding of the characteristic features of rest tremor in Parkinsonism as well 
as provide a better alternative to record and measure rest tremor that may aid in the differentiation of 
Parkinsonism from Essential Tremor.  
 
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
You will not have any additional costs for being in this research study.  You and/or your 
medical/hospital insurance provider will remain responsible for your regular medical care expenses. 
 
 
     
 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FOR IRB USE ONLY 
IRB ID #: 201404034 
APPROVAL DATE: 05/27/14 
RELEASED DATE: 05/28/14 
EXPIRATION DATE: 05/26/15 
 
  Page 4 of 7 
WILL I BE PAID FOR PARTICIPATING? 
You will not be paid for being in this research study.   
        
 
WHO IS FUNDING THIS STUDY? 
 This study is not being funded. 
 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator at 
(561) 906-1671 and/or the Human Research Protection Office at (314) 633-7400 or 1-(800)-438-0445.  
 
Decisions about payment for medical treatment for injuries relating to your participation in research will 
be made by Washington University. If you need to seek medical care for a research-related injury, please 
notify the investigator as soon as possible.  
 
 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
We will keep your participation in this research study confidential to the extent permitted by law.  
However, it is possible that other people such as those indicated below may become aware of your 
participation in this study and may inspect and copy records pertaining to this research.  Some of these 
records could contain information that personally identifies you.  
• Government representatives, (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• The U.S. Food and Drug Administration 
• People who use the Washington University School of Medicine's Research Participant Registry 
or the clinical movement disorders database (MARS)  
• Hospital or University representatives, to complete Hospital or University responsibilities 
• Information about your participation in this study may be documented in your health care records 
and be available to your health care providers who are not part of the research team.  
• Washington University’s Institutional Review Board (a committee that oversees the conduct of 
research involving human participants.) The Institutional Review Board has reviewed and 
approved this study.  
 
To help protect your confidentiality, we will have you escorted into a separate examination room with 
closed doors in the clinic, after seeing your physician. The data that will be recorded will be fully de-
identified and will not include your name, date of birth, clinic number, or any other identifiable 
information. The only data that will be recorded will be the positional and acceleration data of your 
finger and whether or not you have Parkinson Disease. This data will only be saved on a LOK-IT Secure 
Flash Drive, which is automatically encrypted with military-grade 256-bit AES hardware encryption. 
This level of encryption is HIPAA compliant and ensures that the data is unreadable if the flash memory 
were to be physically accessed. If we write a report or article about this study or share the study data set 
with others, we will do so in such a way that you cannot be directly identified. 
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Are there additional protections for my health information? 
 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?”.  
Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form.  When possible, 
the research team will make sure information cannot be linked to you (de-identified).  Once information 
is de-identified, it may be used and shared for other purposes not discussed in this consent form. If you 
have questions or concerns about your privacy and the use of your PHI, please contact the University’s 
Privacy Officer at 866-747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to your health 
care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
 
If you sign this form: 
• You authorize the use of your PHI for this research 
• Your signature and this form will not expire as long as you wish to participate. 
• You may later change your mind and not let the research team use or share your information 
(you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the Participant section 
of the Human Research Protection Office website at http://hrpo.wustl.edu (or use the direct 
link: http://hrpohome.wustl.edu/participants/WithdrawalTemplate.rtf) or you may request 
that the Investigator send you a copy of the letter.       
o If you revoke your authorization: 
! The research team may only use and share information already collected for 
the study. 
! Your information may still be used and shared if necessary for safety reasons.  
! You will not be allowed to continue to participate in the study. 
 
 
IS BEING IN THIS STUDY VOLUNTARY? 
 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
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you decide to be in this study, you may stop participating at any time.  If you decide not to be in this 
study, or if you stop participating at any time, you won’t be penalized or lose any benefits for which you 
otherwise qualify. 
 
What if I decide to withdraw from the study? 
You may withdraw by telling the study team you are no longer interested in participating in the study or 
you may send in a withdrawal letter. A sample withdrawal letter can be found at http://hrpo.wustl.edu 
under Information for Research Participants. 
 
Will I receive new information about the study while participating? 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
 
Can someone else end my participation in this study? 
Under certain circumstances, the researchers might decide to end your participation in this research 
study earlier than planned.  This might happen because in our judgement you are exhibiting upper limb 
tremor too severe to be recorded or if you have too much trouble keeping your fingers separated during 
the recording.  
 
 
WHAT IF I HAVE QUESTIONS? 
 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Matthew Johnson, (561) 906-1671. If you experience a research-related injury, please contact: 
Dr. Arye Nehorai, (314) 935-5565.  
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office, 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO  
63110, (314) 633-7400, or 1-(800)-438-0445 or email hrpo@wusm.wustl.edu.   General information 
about being a research participant can be found by clicking “Participants” on the Human Research 
Protection Office web site, http://hrpohome.wustl.edu.  To offer input about your experiences as a 
research subject or to speak to someone other than the research staff, call the Human Research 
Protection Office at the number above. 
 
 
 
This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.  
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Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 
 
Do not sign this form if today’s date is after EXPIRATION DATE: 05/26/15. 
 
 
__________________________________________ _______________________________ 
(Signature of Participant)     (Date) 
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A Introduction 
 
A1 Study Abstract 
 
This study is exploratory in nature and its purpose is to attempt to classify, with 
reasonable accuracy, if a subject can be classified as a Parkinson or non-Pakinson 
subject based on their rest tremor. The rest tremor will be measured by recording the 
three-dimensional position and acceleration of their index finger while at rest over a set 
period of time. This will be done using two devices. The first device, the Tremorometer, 
uses a three-dimensional accelerometer (a device that measures changes in 
acceleration) and has 510k clearance by the FDA to measure and quantify tremor by 
measuring acceleration and calculating tremor statistics in human patients. The second 
device, the Leap Motion Controller, is a three-dimensional camera that uses two CCD 
(Charged Coupled Device) cameras and three infrared LEDs to obtain position data. 
Tremor statistics obtained and calculated from both devices will be compared to 
determine if data obtained from the Leap Motion Controller are statistically similar to the 
data obtained from the Tremorometer. The data obtained from the Leap Motion 
Controller will then be used to determine the characteristic features of rest tremor in 
Parkinson Disease and be used to classify subjects used in the study as Parkinson or 
non-Parkinson subjects.  
 
A2 Primary Hypothesis 
The primary hypothesis is that the positional data from the Leap Motion Controller will be 
statistically similar to that of the Tremorometer, showing that the Leap Motion Controller 
has the potential to accurately quantify and record tremor. It is also hypothesized that 
the position data from the Leap Motion Controller can be used to identify characteristic 
features of rest tremor in Parkinson Disease that can be used to classify subjects as 
either Parkinson Disease or non-Parkinson Disease subjects.  
 
A3 Purpose of the Study Protocol 
The purpose of the protocol is to be used by all study team members as the approved 
procedures for conduct of the study. 
 
B Background 
 
B1 Prior Literature and Studies 
Parkinson Disease (PD) is a debilitating and progressive movement disorder that affects 
over one million people in the United States alone. One of the most characteristic 
symptoms of PD is resting tremor, as it has been shown that the proportion of patients 
with resting tremor ranged from 69-100% in 3 series of patients with autopsy-proven 
PD.1,2,3  Several methods currently exist to quantitatively measure tremor including 
accelerometry, electromyography, the spirogram, and most recently three-dimensional 
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 4 
cameras4. This study involves the use of accelerometry as well as a three-dimensional 
camera.  
B2 Rationale for this Study 
Advances in three-dimensional cameras have allowed for more accurate recordings and 
can now be used to provide much more accurate measurements in microdisplacements 
of upper extremities that are involved in movements such as resting tremor. One such 
three-dimensional camera is the Leap Motion Controller, produced by Leap Motion, Inc. 
The device is a small USB three-dimensional camera that utilizes two CCD (Charged 
Coupled Device) cameras and three infrared LEDs to obtain depth information, and is 
capable of measuring changes in position to within 0.01 mm, and requires no external 
sensors or markers unlike accelerometry, electromyography, and the spriogram. One 
advantage of having no sensors attached to the body is that the mass of the sensors 
decrease the peak frequency of finger tremor by approximately 0.85 Hz for every gram 
of additional mass, and also effect the amplitude of acceleration.5 Therefore the attached 
sensors may change the characteristics of the tremor, thus altering interpretation of 
tremor. Attaching sensors to the body can also be inconvenient, uncomfortable, and 
provide a margin of error if not done correctly. Another advantage of the Leap Motion 
Controller over accelerometry is that it does not require calibration eliminating possible 
errors caused by consistent recalibration. Unlike electromyography, the Leap Motion 
Controller is not affected by interference from electrical sources, mechanical artifacts, 
stimulus artifacts, and the electrical activity of muscles that are not of interest. It is for 
these reasons that the Leap Motion Controller is of interest and may be superior in 
measuring tremor. 
 
C Study Objectives 
 
C1 Primary Aim 
The primary aim of the study is to determine whether the Leap Motion Controller can be 
used to obtain similar tremor statistics as those obtained from a triaxial accelerometer 
(Tremorometer).   
 
C2 Secondary Aim 
The secondary aim is to determine whether patients with rest tremor in Parkinson 
disease can be classified differently when compared to patients with Essential Tremor, 
using positional data collected by the Leap Motion Controller. 
 
C3 Rationale for the Selection of Outcome Measures 
The rationale for the selection of outcome measures is that the outcome measures are 
able to provide characteristic features of tremor such as peak frequency and amplitude, 
which are typically used when describing and quantifying tremor. The Tremorometer 
provides measurements of acceleration over time and the Leap Motion Controller 
provides measurements of position over time, both of which can provide the typical 
characteristics used in measuring and quantifying tremor. 
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D Study Design  
 
D1 Overview or Design Summary 
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 6 
A total of thirty (30) subjects will be recruited for participation in this study and will 
consist of: 10 subjects diagnosed with Parkinsonsim with tremor, 10 subjects diagnosed 
with Essential Tremor, and 10 normal healthy control subjects. These subjects will be 
recruited in person through the Washington University Movement Disorders electronic 
medical record (MARS) clinical database, among the spouses of the subjects, and from 
the Volunteer for Health initiative of Barnes-Jewish Hospital. If the potential participant 
expresses interest in the study and is deemed to fit all inclusion/exclusion criteria, 
informed consent materials will be provided to the subject. A study team member will 
review the study and the informed consent materials with the potential participant, and 
provide the participant an opportunity to ask any questions or request further 
elaboration. If the potential participant agrees and signs the consent document, the data 
collection process can begin.  
 
Each participant will be measured individually, twice with the Tremorometer and twice 
with the Leap Motion Controller. First, the participant will have the accelerometer from 
the Tremorometer taped to the index finger of the hand that they believe to exhibit the 
most symptomatic tremor. The participant will rest their hand on a small slanted box and 
be asked to relax their fingers and hands. The acceleration of their index finger will then 
be recorded for 30 seconds, while the participant counts down from 100. After the first 
Tremorometer recording, the subject will be asked to re-adjust their hand on the slanted 
box and again relax their fingers. The participant will again be asked to count down from 
100 while the 30-second recording takes place for the second time. Once the second 
recording is complete, the accelerometer will be removed. The participant will then be 
asked to place the same hand on the small slanted box with their fingers relaxed, this 
time in front of the Leap Motion Controller. The position of each finger on the testing 
hand will then be recorded for 30 seconds, while the participant counts down from 100. 
After the first recording with the Leap Motion Controller, the subject will be asked to re-
adjust their hand and again place it on the slanted box with their fingers relaxed. The 
second 30-second recording with the Leap Motion Controller will then take place, while 
the subject again counts down from 100. Once complete, the data collection for that 
participant will be over and the participant will be finished with the study and thanked for 
their time. It is estimated that the time commitment for each participant will be 
approximately 10 minutes.  
 
Once the data for all subjects has been collected, the data analysis can begin. For the 
first part of the data analysis, the data from the Leap Motion and Tremorometer will be 
analyzed to compare several important characteristic features, such as peak frequency 
and amplitude of the tremor. To do this, the position data from the Leap Motion 
Controller will be converted to acceleration data to compare it to the acceleration data 
from the Tremorometer. Tremor statistics, such as peak frequency and amplitude, from 
the Leap Motion Controller and the Tremorometer will be calculated and compared. For 
the second portion of the data analysis, the position data from the Leap Motion 
Controller will be used to identify characteristic features that could be used to 
differentiate the Parkinson subjects from the other subjects. To do this, characteristic 
features will be selected that differentiate the Parkinson subjects from the normal healthy 
subjects. From there, the same features, and possibly more, will be used in an attempt 
to differentiate the Parkinson subjects from the Essential Tremor subjects since it is 
expected that it will be harder to differentiate Parkinson tremor from Essential tremor, 
based on past time-frequency analyses of tremor.8 These features will then be used in 
an attempt to classify, as accurately as possible, all subjects from the study as either 
Parkinson or non-Parkinson.  
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 7 
D2 Subject Selection and Withdrawal  
2.a Inclusion Criteria  
1) 10 patients diagnosed with Parkinsonism with tremor 
a. age greater than or equal to 18 
b. male or female 
c. any race or ethnicity 
d. physician confirmed Parkinsonism, with tremor as a symptom, based 
on diagnostic criteria6 
e. ability to give informed consent 
2) 10 patients diagnosed with Essential Tremor  
a. age greater than or equal to 18 
b. male or female 
c. any race or ethnicity 
d. physician confirmed essential tremor based on diagnostic criteria7  
e. ability to give informed consent 
3) 10 normal control subjects 
a. age greater than or equal to 18 
b. male or female 
c. any race or ethnicity 
d. ability to give informed consent 
2.a Exclusion Criteria  
1) 10 patients diagnosed with Parkinsonism with tremor 
a. History of stroke, seizure, cerebral palsy, or additional neurological 
diagnosis 
b. Severe upper limb tremor 
c. Any serious medical or psychiatric condition 
d. Age less than 18 
e. Cognitive impairment (Mini-Mental State Score <19) 
2) 10 patients diagnosed with Essential Tremor  
a. History of stroke, seizure, cerebral palsy, or other major psychiatric 
illness 
b. Severe upper limb tremor  
c. Any serious medical or psychiatric condition 
d. Age less than 18 
e. Cognitive impairment (Mini-Mental State Score <19) 
3) 10 normal control subjects 
a. History of stroke, seizure, cerebral palsy, or other major psychiatric 
illness 
b. Severe upper limb tremor 
c. Any serious medical or psychiatric condition 
d. Age less than 18 
e. Cognitive impairment (Mini-Mental State Score <19) 
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2.b Ethical Considerations  
Each participant will be an adult equal to or greater than 18 years of age and will have 
the ability to give informed consent. To ensure that the participant can give informed 
consent, they must not have a Mini-Mental State Score less than 19 or any serious 
medical or psychiatric condition. Only study team members will have access to the 
medical record of any potential and/or enrolled subjects. These records are password 
protected in the clinical movement disorders database (MARS), which is HIPAA 
compliant. Any data that will be collected will not contain any identifiers. The collected 
data will only be stored on a LOK-IT Secure Flash Drive, which is automatically 
encrypted with military-grade 256-bit AES hardware encryption and is HIPAA compliant. 
2.c Subject Recruitment Plans and Consent Process 
10 subjects with clinical diagnostic criteria for Parkinsonism, 10 subjects with clinical 
diagnostic criteria for Essential Tremor, and 10 normal control subjects will be enrolled in 
this study. The Washington University Movement Disorders electronic medical record 
(MARS) clinical database is the clinical database for which clinical information is entered 
for all patients seen in the movement disorders division of neurology. The database 
follows a large number of patients with Parkinsonism with tremor as a symptom as well 
as patients with Essential Tremor. Therefore, the 10 subjects with Parkinsonism with 
tremor and the 10 subjects with Essential Tremor will be recruited from this database. 
The 10 healthy control subjects will be recruited among their spouses or from the 
Volunteer for Health initiative of Barnes-Jewish Hospital, an affiliate of the Washington 
University School of Medicine with a pool of over 8000 volunteers. The study team will 
identify potential participants from this database and participants will be recruited in 
person in the movement disorder clinic at Washington University School of Medicine 
during clinic visits with their physician or nurse. The study team member will determine 
the capacity of the potential participant to consent for her/himself during initial contact 
and ask screening questions to determine if the potential participant fits the 
inclusion/exclusion criteria for the study. If the subject expresses interest in the study 
and is deemed to fit all inclusion/exclusion criteria, informed consent materials will be 
provided to the subject. A study team member will review the document and the study 
with the potential participant to answer any questions or explain any unclear points. 
Potential participants will be given time to read the document in its entirety, ask 
questions, and speak with friends/family members if they so desire. If the potential 
participant agrees, the participant will sign the informed consent and will be offered a 
signed copy of the consent after both parties sign the document. 
2.d Randomization Method and Blinding 
The participants will not be randomized and this study is not blinded. 
2.e Risks and Benefits 
The only potential risks for the participants are mild and considered unlikely. These risks 
include: 
1. Attempting to hold one hand still in one position may be uncomfortable. 
2. Participants may become uncomfortable, frustrated, or bored during the 
recording. 
3. Participants may become stressed if they exhibit too severe of upper limb 
tremor to record the data. 
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To reduce any potential risk to the subjects, a physician will be present throughout all 
studies. Confidentiality will also be maintained in accordance with applicable state and 
federal laws and all study data will be identified only by a code number. Personally 
identifying data will not be recorded or collected. 
 
The two devices being used, the Leap Motion Controller and the Tremorometer, meet 
the FDA definition of a Non-Significant Risk Device (NSR) because: 
1. Neither is an implant  
2. Neither will be used in supporting or sustaining human life  
3. Neither will be of substantial importance in diagnosing, curing, mitigating, or 
treating disease, or otherwise preventing impairment of human health 
4. Neither presents a potential for serious risk to the health, safety, or welfare of 
a subject 
 
The Leap Motion Controller is a consumer three-dimensional camera and will be used in 
accordance with its purpose: to measure and record hand and finger motions. The 
Tremorometer has 510k clearance for measuring and quantifying tremor in human 
participants, which will be its only use in this study. 
 
While there are no direct benefits to participants, this study may provide potential 
benefits to society by possibly providing a better understanding of the characteristic 
features of rest tremor in Parkinsonism. It may also provide a better alternative method 
to record and measure rest tremor that may aid in the differentiation of Parkinsonism 
from Essential Tremor.  
2.f Early Withdrawal of Subjects  
Potential participants will be informed that they may withdraw from the study at any point 
and that they will not be penalized or lose any benefits that they would otherwise qualify 
for.  
2.g When and How to Withdraw Subjects  
If a participant decides to withdraw, they may inform the study team member during the 
recording. In this case, the recordings will end and the data collected from the participant 
will be deleted and not used in the study. Participants may also be withdrawn from the 
study if they exhibit upper limb tremor too severe to be recorded or cannot spread their 
fingers enough to be detected by the Leap Controller. This withdrawal will be based on 
the judgment of the study team member at the time of recording. If the participant 
decides to withdraw from the study or if they are withdrawn due to severe upper limb 
tremor, the participant will be escorted out of the examination room and thanked for their 
time.  
2.h Data Collection and Follow-up for Withdrawn Subjects  
Any data collected by a subject who has decided to withdraw or is withdrawn during the 
recording will not be used and deleted. There will be no follow-up for withdrawn subjects.  
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E Study Procedures  
 
E1 Screening for Eligibility 
The Washington University Movement Disorders electronic medical record (MARS) 
clinical database will be used to recruit and screen potential participants for eligibility. 
This is the clinical database for which clinical information is entered for all patients seen 
in the movement disorders division of neurology. The Washington University School of 
Medicine Research Participant Registry powered by the Volunteer for Health may also 
be used to recruit normal control subjects. The study team members will review patient 
records in the Washington University Movement Disorders electronic medical record 
clinical database (MARS) will be reviewed to identify potential participants. The patient 
records will be used to screen for eligibility by reviewing the existence of a definite 
diagnosis of Parkinsonism or Essential Tremor, the Mini-Mental Status Exam, and 
information regarding examination findings with regards to tremor (i.e. whether present, 
the degree of severity, etc.)  This information is critical inclusion/exclusion criteria that 
must be confirmed from the medical record. Without confirming the definite diagnosis 
and medical history of a patient, it is not possible to identify appropriate participants to 
recruit based on specific inclusion criteria.  
 
E2 Schedule of Measurements 
Once both parties sign the consent form, the study can begin that same day. All 
participants, including the control participants, will follow the same procedure. Each 
participant will be measured twice and be measured individually. First, the participant will 
be asked to allow a study member to affix with tape the accelerometer (from the 
Tremorometer system) to the index finger on the hand that they believe to exhibit the 
most symptomatic tremor. The participant will then be asked to place said hand on a 
small slanted box and asked to spread their fingers so that no fingers are touching 
another finger. The participant will again be asked to allow their fingers to relax and 
drape over the edge of the box, still ensuring that their fingers are not touching each 
other. Once the participant has their hand in a comfortable position, they will be verbally 
alerted that the measurement will start and be asked to silently countdown from 100. 
After 30 seconds, the participant will be verbally alerted that the measurement is over 
and the subject will be asked to readjust their hand and the recording will be repeated 
following the same procedure. Once the second recording using the Tremorometer is 
complete, the accelerometer will be removed. The participant will then be asked to again 
place the same hand on the small slanted box, this time in front of the Leap Motion 
Controller. The participant will again be asked to attempt to spread their fingers so that 
no fingers are touching another finger and then allow their fingers to relax and drape 
over the edge of the box, ensuring that their fingers are still not touching one another. 
Once the participant has their hand in a comfortable position, they will be verbally alerted 
that the measurement will start and be asked to silently countdown from 100. After 30 
seconds, the participant will be alerted that the measurement is over. The participant will 
then be asked to readjust their hand and fingers and the second recording of the data 
using the Leap Motion Controller will then occur using the same procedure. Once 
complete, the participant will be finished and thanked for their time. It is estimated that 
the time commitment for each individual visit will be approximately 10 minutes, which 
includes a short explanation of the study along with recordings of the individual 
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participant. There will be no attempt at a long-term follow-up. Each participant will be 
given an option to be contacted with the results of the study, once the study is complete. 
 
E3 Study Outcome Measurements and Ascertainment 
The study outcome measurements will consist of the position and acceleration 
measurements from the Leap Motion and from the Tremorometer. These measurements 
will be used to calculate tremor statistics to compare the measurements from the two 
devices. The positional measurements from the Leap Motion Controller will then be used 
to determine characteristic features that will classify subjects in the study as either 
Parkinson subjects or non-Parkinson subjects. The positional data from the Leap Motion 
Controller will be obtained using Java code and the Leap Motion SDK and saved as a 
tab-delimited .txt file. The data would be recorded at a rate of approximately 150 frames 
per second, with each frame consisting of a timestamp and the three dimensional 
position of each of the five fingers of the hand being recorded. The acceleration data 
from the Tremorometer would be obtained using the program TremTest, a part of the 
Tremorometer package, which would collect data at 100 frames per second and save 
the three-dimensional acceleration every 10 milliseconds. The data will be saved to a 
LOK-IT Secure Flash Drive, which is automatically encrypted with military-grade 256-bit 
AES hardware encryption, which is HIPAA compliant.  
 
F Statistical Plan  
 
F1  Sample Size Determination and Power 
In a previous study entitled the Effect of deep brain stimulation on amplitude and 
frequency characteristics of rest tremor in Parkinson's disease by Beuter et al (2001), 8 
Parkinsons subjects were used to determine some of the same characteristics that will 
also be calculated in this study.9 In a similar study, 8 Parkinsons subjects and 8 healthy 
subjects were used to again obtain the time and frequency structure of tremor.10 Also, in 
a study that used a 3D motion analysis system to measure tremor, 6 Parkinson subjects 
were used.11 Based on these similar studies, we will recruit 10 healthy subjects, 10 
Parkinson subjects, and 10 Essential Tremor subjects. We expect that the number of 
participants will provide enough data to adequately examine tremor and to provide 
enough characteristic features involved in the rest tremor of Parkinsonism to classify 
subjects with Parkinsons differently than healthy subjects and subjects with Essential 
Tremor.  
 
Each subject will be recorded twice for 30 seconds using the Leap Motion Controller and 
twice for 30 seconds using the Tremorometer. The Leap Motion Controller records data 
at an approximate rate of 150 times per second, while the Tremorometer records data at 
a rate of 100 times per second. Therefore, each subject will provide approximately 9,000 
position measurements and 6,000 acceleration measurements from the Leap Motion 
and Tremorometer, respectively. Given that there will be 10 subjects per group, this will 
result in approximately 90,000 position measurements and 60,000 acceleration 
measurements per group. 
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F2  Analysis Plan 
The primary aim of the study is to determine whether the Leap Motion Controller can be 
used to obtain similar tremor statistics as those obtained from a triaxial accelerometer 
(Tremorometer). To do this, the three-dimensional positional data from the Leap Motion 
Controller will be used to derive three-dimensional acceleration data in order to compare 
it to the acceleration data obtained from the Tremorometer. To compare the data, certain 
tremor statistics will be calculated and compared in MATLAB. These tremor statistics 
consist of parameters obtained from a power distribution of the tremor within a certain 
frequency band, some of which include the peak tremor intensity and the peak tremor 
frequency along with other statistics used in previous studies.9,10,11  
The secondary aim of this study is to determine whether subjects with Parkinson disease 
can be classified differently from healthy patients and patients with Essential Tremor by 
using positional data collected by the Leap Motion Controller. To do this, positional data 
collected by the Leap Motion Controller will be imported using Java and the LeapSDK 
and analyzed in MATLAB. A variety of tremor statistics will be calculated and used to 
determine characteristic features that identify each group of subjects. These 
characteristic features will again stem from a power distribution of the tremor and be 
chosen based on how well they differentiate the different groups of subjects.  
  
F3  Statistical Methods  
The position data from the Leap Motion Controller will be converted into acceleration 
data. The tremor parameters from the Tremorometer and the Leap Motion Controller will 
then be obtained from the power distribution of the tremor within a certain frequency 
band. The tremor parameters, such as peak frequency and amplitude, from the 
Tremorometer will be compared against the tremor parameters from the Leap Motion 
Controller using a Bland-Altman plot as well as a paired t-test. The position data from the 
Leap Motion Controller will also be used to identify different tremor statistics that can be 
used to classify subjects as Parkinson or non-Parkinson subject.  
F4  Missing Outcome Data 
Missing outcome data will be approached using listwise deletion, also known as 
complete case analysis. If one sample of a recording does not return an acceleration or 
position, that sample will be deleted from the recording. This will have virtually no effect 
on the data due to the high sampling rate of the devices.  
 
 
G Data Handling and Record Keeping  
 
G1 Confidentiality and Security 
Only study team members will have access to the medical record of any potential and/or 
enrolled subjects. These records are password protected in the clinical movement 
disorders database (MARS), which is HIPAA compliant. Any data that will be collected 
will not contain any identifiers. This collected data will only be collected to and stored on 
a LOK-IT Secure Flash Drive, which is automatically encrypted with military-grade 256-
bit AES hardware encryption, which is HIPAA compliant.  
     
 
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
______________________________________________________________________________________ 
 13 
 
 
 
H Study Administration 
 
H1 Organization and Participating Centers 
The coordinating site will be the Movement Disorders Clinic at the Washington University 
School of Medicine with the lead PI being Matthew Johnson. 
 
 
 
H2  Study Timetable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portion of Study Estimated Duration 
Subject Recruitment/Data Collection 2 months 
Data Analysis/Study Report 2 months 
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I  Attachments  
I1  Informed consent documents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
 
INFORMED CONSENT DOCUMENT 
 
Project Title: Detection of Parkinson Disease Rest Tremor 
 
Principal Investigator: Matthew Johnson 
 
Research Team Contact: Matthew Johnson: (561) 906-1671 
 
 
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights as a research participant. By signing this form you are 
agreeing to participate in this study. 
• If you have any questions about anything in this form, you should ask the research team for 
more information.   
• You may also wish to talk to your family or friends about your participation in this study. 
• Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
This is a research study.  We invite you to participate in this research study because you: have been 
diagnosed with Parkinson Disease and have tremor as a symptom, have been diagnosed with Essential 
Tremor, or are healthy with no symptoms of tremor.  
 
The purpose of this research study is to create an algorithm that will predict, with reasonable accuracy, if 
a patient has Parkinson Disease based on their rest tremor. To create this algorithm, rest tremor data will 
be collected by recording the three-dimensional position and acceleration of the index finger using two 
different devices. The first device, the Tremorometer, uses a three-dimensional accelerometer (a device 
that measures changes in acceleration) and is cleared by the FDA to measure and quantify tremor by 
measuring acceleration and calculating tremor statistics in human patients. The second device, the Leap 
Motion Controller, is a three-dimensional camera that can obtain position data. The data collected and 
analyzed by the Tremorometer will be compared to that of the Leap Motion Controller to determine 
whether the Leap Motion Controller can be used to obtain similar results as the Tremorometer. The data 
from the Leap Motion Controller will be analyzed and used to create an algorithm that can predict 
whether a patient has Parkinson Disease. It is hypothesized that the Leap Motion Controller will provide 
similar results as the Tremorometer and that the data from the Leap Motion Controller can be used to 
create a reasonably accurate algorithm that can identify a patient with Parkinson Disease from a patient 
with Essential Tremor or a healthy patient.   
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WHAT WILL HAPPEN DURING THIS STUDY? 
 
The study will occur in an examination room behind closed doors in the movement disorders clinic 
within the Washington University School of Medicine. The data that will be recorded will consist of the 
position and acceleration of your fingers over time and whether you have Parkinson Disease, Essential 
Tremor, or are healthy with no symptoms of tremor.  
 
You will first be asked to allow a study member to tape a small sensor (the accelerometer from the 
Tremorometer system) to your index finger on the hand that you exhibit the most symptomatic tremor. 
You will then be asked to place said hand on a small slanted box and be asked to spread your fingers so 
that no fingers are touching another finger. You will then be asked to allow your fingers to relax and 
drape over the edge of the box, still ensuring that your fingers are not touching. Once your hand is in a 
comfortable position, you will be warned that the recording will start and be asked to silently countdown 
from 100. After 30 seconds, you will be told that the recording is over and the sensor will be removed. 
You will then be asked to place the same hand on the small slanted box in front of the Leap Motion 
Controller (a small three-dimensional camera that tracks hand and finger movements and has not yet 
been used to measure hand or finger tremors.) You will again be asked to allow your fingers to relax and 
drape over the edge of the box, still ensuring that no fingers are touching another finger. Once your hand 
is in a comfortable position, you will be told that the recording will begin and be asked to silently 
countdown from 100. After 30 seconds, you will be told that the recording is over and the you will be 
finished with your participation in the study. 
 
 
Will you save my samples or research data to use in future research studies?  
 
As part of this study, we are obtaining tremor data (in the form of position and acceleration over time) 
from you. By agreeing to be part of this study you give up any property rights you may have in the 
tremor data. We would like to use your tremor data for other research projects in the future. These future 
studies may provide additional information that will be helpful in understanding Parkinson's Disease, 
but it is unlikely that what we learn from these studies will have a direct benefit to you. It is possible that 
your tremor data might be used to develop tests, treatments or cures. There are no plans to provide 
financial compensation to you should this occur. If you agree, this means we will store your tremor data 
and may use it for studies going on right now as well as studies that are conducted in the future. 
 
I would also like your permission to share your tremor data with other investigators doing research in 
similar fields such as other diseases where tremor is a common symptom.  These investigators may be at 
Washington University or at other research centers.  We may also share you research data with large 
data repositories (a repository is a database of information) for broad sharing with the research 
community.  If your individual research data is placed in one of these repositories only qualified 
researchers, who have received prior approval from individuals that monitor the use of the data, will be 
able to look at your information.   
 
Your tremor data will be stored without your name or any other kind of link that would enable us to 
identify which data are yours.  Therefore, if you give permission to store and use your tremor data, it 
will be available for use in future research studies indefinitely and cannot be removed. 
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Please place your initials in the blank next to Yes or No for each of the questions below: 
 
My tremor data may be stored and used for future research as described above. 
 
_____ Yes _____ No 
Initials  Initials 
 
My tremor data may be shared with other investigators and used by these investigators for the 
future research as described above. 
 
_____ Yes  _____ No 
Initials  Initials 
 
 
HOW MANY PEOPLE WILL PARTICIPATE? 
Approximately 30 people will take part in this study conducted by investigators at Washington 
University.   
 
 
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to take part in this study, your involvement will last for approximately 10 minutes.  
 
 
WHAT ARE THE RISKS OF THIS STUDY? 
 
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
study.  
 
Less Likely / Less Common 
 
Mild 
• Risk 1: Attempting to hold one hand still in one position may be physically uncomfortable. 
• Risk 2: Become fatigued, frustrated, or bored during the recording. 
• Risk 3: Become stressed if you exhibit too severe of upper limb tremor to record the data. 
 
One risk of participating in this study is that confidential information about you may be accidentally 
disclosed.  We will use our best efforts to keep the information about you secure, and we think the risk 
of accidental disclosure is very small.  Please see the section in this consent form titled “How will you 
keep my information confidential?” for more information. 
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WHAT ARE THE BENEFITS OF THIS STUDY? 
 
You will not benefit from being in this study. 
 
However, we hope that, in the future, other people might benefit from this study because the study may 
help provide a better understanding of the characteristic features of rest tremor in Parkinsonism as well 
as provide a better alternative to record and measure rest tremor that may aid in the differentiation of 
Parkinsonism from Essential Tremor.  
 
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
You will not have any additional costs for being in this research study.  You and/or your 
medical/hospital insurance provider will remain responsible for your regular medical care expenses. 
 
 
WILL I BE PAID FOR PARTICIPATING? 
You will not be paid for being in this research study.   
        
 
WHO IS FUNDING THIS STUDY? 
 This study is not being funded. 
 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator at 
(561) 906-1671 and/or the Human Research Protection Office at (314) 633-7400 or 1-(800)-438-0445.  
 
Decisions about payment for medical treatment for injuries relating to your participation in research will 
be made by Washington University. If you need to seek medical care for a research-related injury, please 
notify the investigator as soon as possible.  
 
 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
 
We will keep your participation in this research study confidential to the extent permitted by law.  
However, it is possible that other people such as those indicated below may become aware of your 
participation in this study and may inspect and copy records pertaining to this research.  Some of these 
records could contain information that personally identifies you.  
• Government representatives, (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• People who use the Washington University School of Medicine's Research Participant Registry 
or the clinical movement disorders database (MARS)  
• Hospital or University representatives, to complete Hospital or University responsibilities 
• Information about your participation in this study may be documented in your health care records 
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and be available to your health care providers who are not part of the research team.  
• Washington University’s Institutional Review Board (a committee that oversees the conduct of 
research involving human participants.) The Institutional Review Board has reviewed and 
approved this study.  
 
To help protect your confidentiality, we will have you escorted into a separate examination room with 
closed doors in the clinic, after seeing your physician. The data that will be recorded will be fully de-
identified and will not include your name, date of birth, clinic number, or any other identifiable 
information. The only data that will be recorded will be the positional and acceleration data of your 
finger and whether or not you have Parkinson Disease. This data will only be saved on a LOK-IT Secure 
Flash Drive, which is automatically encrypted with military-grade 256-bit AES hardware encryption. 
This level of encryption is HIPAA compliant and ensures that the data is unreadable if the flash memory 
were to be physically accessed. If we write a report or article about this study or share the study data set 
with others, we will do so in such a way that you cannot be directly identified. 
 
 
Are there additional protections for my health information? 
 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?”.  
Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form.  When possible, 
the research team will make sure information cannot be linked to you (de-identified).  Once information 
is de-identified, it may be used and shared for other purposes not discussed in this consent form. If you 
have questions or concerns about your privacy and the use of your PHI, please contact the University’s 
Privacy Officer at 866-747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to your health 
care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
 
If you sign this form: 
• You authorize the use of your PHI for this research 
• Your signature and this form will not expire as long as you wish to participate. 
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• You may later change your mind and not let the research team use or share your information 
(you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the Participant section 
of the Human Research Protection Office website at http://hrpo.wustl.edu (or use the direct 
link: http://hrpohome.wustl.edu/participants/WithdrawalTemplate.rtf) or you may request 
that the Investigator send you a copy of the letter.       
o If you revoke your authorization: 
! The research team may only use and share information already collected for 
the study. 
! Your information may still be used and shared if necessary for safety reasons.  
! You will not be allowed to continue to participate in the study. 
 
 
IS BEING IN THIS STUDY VOLUNTARY? 
 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
you decide to be in this study, you may stop participating at any time.  If you decide not to be in this 
study, or if you stop participating at any time, you won’t be penalized or lose any benefits for which you 
otherwise qualify. 
 
What if I decide to withdraw from the study? 
You may withdraw by telling the study team you are no longer interested in participating in the study or 
you may send in a withdrawal letter. A sample withdrawal letter can be found at http://hrpo.wustl.edu 
under Information for Research Participants. 
 
Will I receive new information about the study while participating? 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
 
Can someone else end my participation in this study? 
Under certain circumstances, the researchers might decide to end your participation in this research 
study earlier than planned.  This might happen because in our judgement you are exhibiting upper limb 
tremor too severe to be recorded or if you have too much trouble keeping your fingers separated during 
the recording.  
 
 
WHAT IF I HAVE QUESTIONS? 
 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Matthew Johnson, (561) 906-1671. If you experience a research-related injury, please contact: 
Dr. Arye Nehorai, (314) 935-5565.  
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office, 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO  
63110, (314) 633-7400, or 1-(800)-438-0445 or email hrpo@wusm.wustl.edu.   General information 
about being a research participant can be found by clicking “Participants” on the Human Research 
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Protection Office web site, http://hrpohome.wustl.edu.  To offer input about your experiences as a 
research subject or to speak to someone other than the research staff, call the Human Research 
Protection Office at the number above. 
 
 
 
This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.  
 
Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 
 
Do not sign this form if today’s date is after $STAMP_EXP_DT. 
 
 
__________________________________________ _______________________________ 
(Signature of Participant)     (Date) 
 
 
____________________________________________ 
(Participant's name – printed) 
 
 
 
 
 
 
 
Statement of Person Who Obtained Consent 
 
The information in this document has been discussed with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The participant has indicated that he or she understands 
the risks, benefits, and procedures involved with participation in this research study. 
 
 
__________________________________________ _______________________________ 
(Signature of Person who Obtained Consent)  (Date) 
 
 
___________________________________________ 
(Name of Person who Obtained Consent - printed) 
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I2 Device Documentation 
2.a The Leap Motion Controller 
i EU Declaration of Conformity 
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ii Safety and Compliance 
 
 
 
 
 
 
 
 
 
 
This Important Information Guide contains safety, handling, 
disposal, recycling and regulatory information, as well as the 
limited hardware warranty for your Leap Motion Controller.
Important Safety and Handling Information
High-risk activities 
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. 
Operating environment 
Operating your Leap Motion Controller outside these ranges 
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or 
where bright light sources or reflective surfaces (including 
exposed metal vents) are above the device, will impact 
performance. In order to improve performance, move to a less 
bright or reflective environment.
For best performance, maintain a clear field of view between 
your Leap Motion Controller and your hands and fingers. Loose 
sleeves, large or loose jewelry, and non-transparent objects or 
materials that are near the device, or between the device and 
your hands, or right above your hands, may impact 
performance. In addition, avoid wearing dark gloves, or using 
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may 
degrade the performance of your Leap Motion Controller.  
When cleaning the outside of the device, first unplug the cable. 
Then use a dry cloth to wipe the surface. Do not use 
detergents, abrasive cleaners or other cleaners, which may 
scratch the surface, and harm performance. Do not allow the 
device to become wet. 
Proper handling 
The surface of your Leap Motion Controller may become warm 
during normal use. The Leap Motion Controller complies with 
the user-accessible surface temperature limits defined by the 
International Standard for Safety of Information Technology 
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is 
comfortable to use.  Center your controller in front of your 
keyboard or laptop. Adjust your chair or work surface so that 
your elbows are near your side and your forearms are roughly 
parallel to the floor.  Your chair may need to be slightly higher 
or your work surface slightly lower than usual.
You should sit at such a height so that your forearms extend at 
roughly a right angle from your body to a position slightly 
above your Leap Motion Controller, with your wrist and hands 
in roughly a straight line. Your hands should be just above the 
device, and your shoulders should be relaxed. You can rest your 
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the 
controller again, change your arm posture. If you have 
persistent or recurrent discomfort after use, stop use and see a 
physician.
Disposal and Recycling Information
This symbol on the product (and on its packaging) is in 
accordance with the European Union's Waste Electrical and 
Electronic Equipment (WEEE) Directive. The symbol indicates 
that this product must be recycled/disposed of separately from 
other household waste. It is the end user’s responsibility to 
dispose of this product by taking it to a designated WEEE 
collection facility for the proper collection and recycling of the 
waste equipment. The separate collection and recycling of 
waste equipment will help to conserve natural resources and 
protect human health and the environment.  For more 
information about recycling, please contact your local 
environmental office, an electrical/electronic waste disposal 
company or the store where you purchased the product. 
Device Information
To get information about your Leap Motion Controller, use the 
“About” box in your Leap Motion software. It shows you what 
software is installed, the serial number, and more. 
Compliance
FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE 
USE.
This device complies with Part 15 of the FCC Rules. Operation is 
subject to the following two conditions: 1) this device may not 
cause harmful interference, and 2) this device must accept any 
interference received, including interference that may cause 
undesired operation. 
This equipment has been tested and found to comply with the 
limits for a Class B digital device, pursuant to part 15 of the FCC 
Rules. These limits are designed to provide reasonable 
protection against harmful interference in a residential 
installation. This equipment generates, uses and can radiate 
radio frequency energy. And, if not installed and used in 
accordance with the instructions, may cause harmful 
interference to radio communications. However, there is no 
guarantee that interference will not occur in a particular 
installation. If this equipment does cause harmful interference 
to radio or television reception, which can be determined by 
turning the equipment off and on, the user is encouraged to try 
to correct the interference by one or more of the following 
measures:
-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different 
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for 
help.
Warning: Where shielded interface cables or accessories have 
been provided with the product or specified additional 
components or accessories elsewhere defined to be used with 
the installation of the product, they must be used in order to 
ensure compliance with FCC limits. Changes or modifications to 
the product not expressly approved by Leap Motion, Inc. could 
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with 
Canadian ICES – 003. 
Déclaration IC: Cet appareil numérique de catégorie B est 
conforme à la norme canadienne NMB-003.
European Compliance Statement
A copy of the EU Declaration of Conformity is available at: 
www.leapmotion.com/legal
Read all safety information and operating instructions 
below before using your Leap Motion Controller to 
avoid injury. For user instructions for the Leap Motion 
Controller and the latest version of this Important 
Information Guide visit:  leapmotion.com/support
Software License Agreement
Use of the Leap Motion Controller constitutes acceptance of 
the Leap Motion and third-party software license terms found 
at:  www.leapmotion.com/legal
Leap Motion Hardware Limited Warranty
Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap 
Motion hardware product against material defects in materials 
and workmanship for a period of one year from the date of 
purchase (“Warranty Period”) by the original end user 
purchaser (“you”). Except where prohibited by applicable law, 
this warranty is nontransferable and is limited to the original 
purchaser. This warranty gives you specific legal rights, and you 
may also have other rights that vary under local laws.
Software distributed by Leap Motion with or without the Leap 
Motion brand name (including, but not limited to, the software 
that interacts with or that is pre-installed in the product) is not 
covered under this limited warranty. Refer to the licensing 
agreement accompanying the software for details of your 
rights with respect to its use. Leap Motion does not warrant 
that the operation of the product will be uninterrupted or 
error-free. Leap Motion is not responsible for damage arising 
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during 
the Warranty Period, Leap Motion will (at its option) (1) repair or 
replace the product, or (2) refund the price paid, provided that 
the product is returned to the point of purchase or such other 
place as Leap Motion may direct with a copy of the sales receipt 
or dated itemized receipt. Shipping and handling charges may 
apply except where prohibited by applicable law. Leap Motion 
may, at its option, use new or refurbished or used parts in good 
working condition to repair or replace any product. Any 
replacement product will be warranted for the remainder of the 
original warranty period or thirty (30) days, whichever is longer 
or for any additional period of time that may be applicable in 
your jurisdiction.
This warranty does not cover problems or damage resulting 
from (1) accident, abuse, misapplication, or any unauthorized 
repair, modification or disassembly; (2) improper operation or 
maintenance, usage not in accordance with product 
instructions or connection to improper voltage supply; (3) use 
of cables or other equipment not supplied by Leap Motion; or 
(4) other causes that are not defects in material and 
workmanship except where such restriction is prohibited by 
applicable law. This warranty additionally does not cover 
products marked as “sample” or sold “AS IS”.
How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit 
the support section at www.leapmotion.com for technical 
assistance. Valid warranty claims are generally processed 
through the point of purchase during the first 30 days after 
purchase; however, this period of time may vary depending on 
where you purchased your product – please check with Leap 
Motion or the retailer where you purchased your product for 
details. Warranty claims that cannot be processed through the 
point of purchase and any other product related questions 
should be addressed directly to Leap Motion. The addresses 
and customer service contact information for Leap Motion can 
be found in the documentation accompanying your product 
and on the web at:  www.leapmotion.com/support
Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT, 
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES 
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE 
PRODUCT.  IN ADDITION, LEAP MOTION WILL NOT BE LIABLE 
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER 
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF 
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT 
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH  DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE 
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN 
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND 
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY 
OR IMPLIED.  Any recovery is limited to repair, replacement, or 
refund as described above.  Some jurisdictions do not allow the 
exclusion or limitation of special, indirect, incidental or 
consequential damages, so the above limitation or exclusion 
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE 
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS 
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH 
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION 
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES 
RESULTING FROM SUCH USE. 
Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP 
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY 
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY 
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED 
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS 
FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN 
DURATION TO THE DURATION OF THE WARRANTY PERIOD 
ABOVE. Some jurisdictions do not allow limitations on how 
long an implied warranty lasts, or do not allow exclusions or 
limitations on certain damages, including damages for death or 
personal injury caused by negligence, so the above limitation 
may not apply to you.  
National Statutory Rights
Consumers in some jurisdictions may have legal rights 
under applicable national legislation governing the sale of 
consumer goods. These rights are not affected by the 
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to 
make any modification, extension, or addition to this warranty.  
Your seller is solely responsible for any other warranties.
Service and Support
Your Leap Motion Controller does not contain any 
user-serviceable parts. If you need service, contact Leap Motion 
at one of the numbers below. Helpful information is also 
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges 
apply - please contact your telecom service provider for 
details).
The hours our customer support is available may be found at: 
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107 
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic
                            46-0006
Leap Motion Controller
Important Information Guide
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This Important Information Guide contains safety, handling, 
disposal, recycling and regulatory information, as well as the 
limited hardware warranty for your Leap Motion Controller.
Important Safety and Handling Information
High-risk activities 
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. 
Operating environment 
Operating your Leap Motion Controller outside these ranges 
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or 
where bright light sources or reflective surfaces (including 
exposed metal vents) are above the device, will impact 
performance. In order to improve performance, move to a less 
bright or reflective environment.
For best performance, maintain a clear field of view between 
your Leap Motion Controller and your hands and fingers. Loose 
sleeves, large or loose jewelry, and non-transparent objects or 
materials that are near the device, or between the device and 
your hands, or right above your hands, may impact 
performance. In addition, avoid wearing dark gloves, or using 
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may 
degrade the performance of your Leap Motion Controller.  
When cleaning the outside of the device, first unplug the cable. 
Then use a dry cloth to wipe the surface. Do not use 
detergents, abrasive cleaners or other cleaners, which may 
scratch the surface, and harm performance. Do not allow the 
device to become wet. 
Proper handling 
The surface of your Leap Motion Controller may become warm 
during normal use. The Leap Motion Controller complies with 
the user-accessible surface temperature limits defined by the 
International Standard for Safety of Information Technology 
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is 
comfortable to use.  Center your controller in front of your 
keyboard or laptop. Adjust your chair or work surface so that 
your elbows are near your side and your forearms are roughly 
parallel to the floor.  Your chair may need to be slightly higher 
or your work surface slightly lower than usual.
You should sit at such a height so that your forearms extend at 
roughly a right angle from your body to a position slightly 
above your Leap Motion Controller, with your wrist and hands 
in roughly a straight line. Your hands should be just above the 
device, and your shoulders should be relaxed. You can rest your 
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the 
controller again, change your arm posture. If you have 
persistent or recurrent discomfort after use, stop use and see a 
physician.
Disposal and Recycling Information
This symbol on the product (and on its packaging) is in 
accordance with the European Union's Waste Electrical and 
Electronic Equipment (WEEE) Directive. The symbol indicates 
that this product must be recycled/disposed of separately from 
other household waste. It is the end user’s responsibility to 
dispose of this product by taking it to a designated WEEE 
collection facility for the proper collection and recycling of the 
waste equipment. The separate collection and recycling of 
waste equipment will help to conserve natural resources and 
protect human health and the environment.  For more 
information about recycling, please contact your local 
environmental office, an electrical/electronic waste disposal 
company or the store where you purchased the product. 
Device Information
To get information about your Leap Motion Controller, use the 
“About” box in your Leap Motion software. It shows you what 
software is installed, the serial number, and more. 
Compliance
FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE 
USE.
This device complies with Part 15 of the FCC Rules. Operation is 
subject to the following two conditions: 1) this device may not 
cause harmful interference, and 2) this device must accept any 
interference received, including interference that may cause 
undesired operation. 
This equipment has been tested and found to comply with the 
limits for a Class B digital device, pursuant to part 15 of the FCC 
Rules. These limits are designed to provide reasonable 
protection against harmful interference in a residential 
installation. This equipment generates, uses and can radiate 
radio frequency energy. And, if not installed and used in 
accordance with the instructions, may cause harmful 
interference to radio communications. However, there is no 
guarantee that interference will not occur in a particular 
installation. If this equipment does cause harmful interference 
to radio or television reception, which can be determined by 
turning the equipment off and on, the user is encouraged to try 
to correct the interference by one or more of the following 
measures:
-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different 
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for 
help.
Warning: Where shielded interface cables or accessories have 
been provided with the product or specified additional 
components or accessories elsewhere defined to be used with 
the installation of the product, they must be used in order to 
ensure compliance with FCC limits. Changes or modifications to 
the product not expressly approved by Leap Motion, Inc. could 
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with 
Canadian ICES – 003. 
Déclaration IC: Cet appareil numérique de catégorie B est 
conforme à la norme canadienne NMB-003.
European Compliance Statement
A copy of the EU Declaration of Conformity is available at: 
www.leapmotion.com/legal
Read all safety information and operating instructions 
below before using your Leap Motion Controller to 
avoid injury. For user instructions for the Leap Motion 
Controller and the latest version of this Important 
Information Guide visit:  leapmotion.com/support
Software License Agreement
Use of the Leap Motion Controller constitutes acceptance of 
the Leap Motion and third-party software license terms found 
at:  www.leapmotion.com/legal
Leap Motion Hardware Limited Warranty
Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap 
Motion hardware product against material defects in materials 
and workmanship for a period of one year from the date of 
purchase (“Warranty Period”) by the original end user 
purchaser (“you”). Except where prohibited by applicable law, 
this warranty is nontransferable and is limited to the original 
purchaser. This warranty gives you specific legal rights, and you 
may also have other rights that vary under local laws.
Software distributed by Leap Motion with or without the Leap 
Motion brand name (including, but not limited to, the software 
that interacts with or that is pre-installed in the product) is not 
covered under this limited warranty. Refer to the licensing 
agreement accompanying the software for details of your 
rights with respect to its use. Leap Motion does not warrant 
that the operation of the product will be uninterrupted or 
error-free. Leap Motion is not responsible for damage arising 
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during 
the Warranty Period, Leap Motion will (at its option) (1) repair or 
replace the product, or (2) refund the price paid, provided that 
the product is returned to the point of purchase or such other 
place as Leap Motion may direct with a copy of the sales receipt 
or dated itemized receipt. Shipping and handling charges may 
apply except where prohibited by applicable law. Leap Motion 
may, at its option, use new or refurbished or used parts in good 
working condition to repair or replace any product. Any 
replacement product will be warranted for the remainder of the 
original warranty period or thirty (30) days, whichever is longer 
or for any additional period of time that may be applicable in 
your jurisdiction.
This warranty does not cover problems or damage resulting 
from (1) accident, abuse, misapplication, or any unauthorized 
repair, modification or disassembly; (2) improper operation or 
maintenance, usage not in accordance with product 
instructions or connection to improper voltage supply; (3) use 
of cables or other equipment not supplied by Leap Motion; or 
(4) other causes that are not defects in material and 
workmanship except where such restriction is prohibited by 
applicable law. This warranty additionally does not cover 
products marked as “sample” or sold “AS IS”.
How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit 
the support section at www.leapmotion.com for technical 
assistance. Valid warranty claims are generally processed 
through the point of purchase during the first 30 days after 
purchase; however, this period of time may vary depending on 
where you purchased your product – please check with Leap 
Motion or the retailer where you purchased your product for 
details. Warranty claims that cannot be processed through the 
point of purchase and any other product related questions 
should be addressed directly to Leap Motion. The addresses 
and customer service contact information for Leap Motion can 
be found in the documentation accompanying your product 
and on the web at:  www.leapmotion.com/support
Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT, 
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES 
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE 
PRODUCT.  IN ADDITION, LEAP MOTION WILL NOT BE LIABLE 
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER 
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF 
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT 
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH  DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE 
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN 
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND 
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY 
OR IMPLIED.  Any recovery is limited to repair, replacement, or 
refund as described above.  Some jurisdictions do not allow the 
exclusion or limitation of special, indirect, incidental or 
consequential damages, so the above limitation or exclusion 
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE 
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS 
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH 
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION 
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES 
RESULTING FROM SUCH USE. 
Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP 
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY 
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY 
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED 
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS 
FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN 
DURATION TO THE DURATION OF THE WARRANTY PERIOD 
ABOVE. Some jurisdictions do not allow limitations on how 
long an implied warranty lasts, or do not allow exclusions or 
limitations on certain damages, including damages for death or 
personal injury caused by negligence, so the above limitation 
may not apply to you.  
National Statutory Rights
Consumers in some jurisdictions may have legal rights 
under applicable national legislation governing the sale of 
consumer goods. These rights are not affected by the 
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to 
make any modification, extension, or addition to this warranty.  
Your seller is solely responsible for any other warranties.
Service and Support
Your Leap Motion Controller does not contain any 
user-serviceable parts. If you need service, contact Leap Motion 
at one of the numbers below. Helpful information is also 
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges 
apply - please contact your telecom service provider for 
details).
The hours our customer support is available may be found at: 
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107 
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic
                            46-0006
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This Important Information Guide contains safety, handling, 
disposal, recycling and regulatory information, as well as the 
limited hardware warranty for your Leap Motion Controller.
Important Safety and Handling Information
High-risk activities 
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. 
Operating environment 
Operating your Leap Motion Controller outside these ranges 
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or 
where bright light sources or reflective surfaces (including 
exposed metal vents) are above the device, will impact 
performance. In order to improve performance, move to a less 
bright or reflective environment.
For best performance, maintain a clear field of view between 
your Leap Motion Controller and your hands and fingers. Loose 
sleeves, large or loose jewelry, and non-transparent objects or 
materials that are near the device, or between the device and 
your hands, or right above your hands, may impact 
performance. In addition, avoid wearing dark gloves, or using 
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may 
degrade the performance of your Leap Motion Controller.  
When cleaning the outside of the device, first unplug the cable. 
Then use a dry cloth to wipe the surface. Do not use 
detergents, abrasive cleaners or other cleaners, which may 
scratch the surface, and harm performance. Do not allow the 
device to become wet. 
Proper handling 
The surface of your Leap Motion Controller may become warm 
during normal use. The Leap Motion Controller complies with 
the user-accessible surface temperature limits defined by the 
International Standard for Safety of Information Technology 
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is 
comfortable to use.  Center your controller in front of your 
keyboard or laptop. Adjust your chair or work surface so that 
your elbows are near your side and your forearms are roughly 
parallel to the floor.  Your chair may need to be slightly higher 
or your work surface slightly lower than usual.
You should sit at such a height so that your forearms extend at 
roughly a right angle from your body to a position slightly 
above your Leap Motion Controller, with your wrist and hands 
in roughly a straight line. Your hands should be just above the 
device, and your shoulders should be relaxed. You can rest your 
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the 
controller again, change your arm posture. If you have 
persistent or recurrent discomfort after use, stop use and see a 
physician.
Disposal and Recycling Information
This symbol on the product (and on its packaging) is in 
accordance with the European Union's Waste Electrical and 
Electronic Equipment (WEEE) Directive. The symbol indicates 
that this product must be recycled/disposed of separately from 
other household waste. It is the end user’s responsibility to 
dispose of this product by taking it to a designated WEEE 
collection facility for the proper collection and recycling of the 
waste equipment. The separate collection and recycling of 
waste equipment will help to conserve natural resources and 
protect human health and the environment.  For more 
information about recycling, please contact your local 
environmental office, an electrical/electronic waste disposal 
company or the store where you purchased the product. 
Device Information
To get information about your Leap Motion Controller, use the 
“About” box in your Leap Motion software. It shows you what 
software is installed, the serial number, and more. 
Compliance
FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE 
USE.
This device complies with Part 15 of the FCC Rules. Operation is 
subject to the following two conditions: 1) this device may not 
cause harmful interference, and 2) this device must accept any 
interference received, including interference that may cause 
undesired operation. 
This equipment has been tested and found to comply with the 
limits for a Class B digital device, pursuant to part 15 of the FCC 
Rules. These limits are designed to provide reasonable 
protection against harmful interference in a residential 
installation. This equipment generates, uses and can radiate 
radio frequency energy. And, if not installed and used in 
accordance with the instructions, may cause harmful 
interference to radio communications. However, there is no 
guarantee that interference will not occur in a particular 
installation. If this equipment does cause harmful interference 
to radio or television reception, which can be determined by 
turning the equipment off and on, the user is encouraged to try 
to correct the interference by one or more of the following 
measures:
-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different 
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for 
help.
Warning: Where shielded interface cables or accessories have 
been provided with the product or specified additional 
components or accessories elsewhere defined to be used with 
the installation of the product, they must be used in order to 
ensure compliance with FCC limits. Changes or modifications to 
the product not expressly approved by Leap Motion, Inc. could 
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with 
Canadian ICES – 003. 
Déclaration IC: Cet appareil numérique de catégorie B est 
conforme à la norme canadienne NMB-003.
European Compliance Statement
A copy of the EU Declaration of Conformity is available at: 
www.leapmotion.com/legal
Read all safety information and operating instructions 
below before using your Leap Motion Controller to 
avoid injury. For user instructions for the Leap Motion 
Controller and the latest version of this Important 
Information Guide visit:  leapmotion.com/support
Software License Agreement
Use of the Leap Motion Controller constitutes acceptance of 
the Leap Motion and third-party software license terms found 
at:  www.leapmotion.com/legal
Leap Motion Hardware Limited Warranty
Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap 
Motion hardware product against material defects in materials 
and workmanship for a period of one year from the date of 
purchase (“Warranty Period”) by the original end user 
purchaser (“you”). Except where prohibited by applicable law, 
this warranty is nontransferable and is limited to the original 
purchaser. This warranty gives you specific legal rights, and you 
may also have other rights that vary under local laws.
Software distributed by Leap Motion with or without the Leap 
Motion brand name (including, but not limited to, the software 
that interacts with or that is pre-installed in the product) is not 
covered under this limited warranty. Refer to the licensing 
agreement accompanying the software for details of your 
rights with respect to its use. Leap Motion does not warrant 
that the operation of the product will be uninterrupted or 
error-free. Leap Motion is not responsible for damage arising 
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during 
the Warranty Period, Leap Motion will (at its option) (1) repair or 
replace the product, or (2) refund the price paid, provided that 
the product is returned to the point of purchase or such other 
place as Leap Motion may direct with a copy of the sales receipt 
or dated itemized receipt. Shipping and handling charges may 
apply except where prohibited by applicable law. Leap Motion 
may, at its option, use new or refurbished or used parts in good 
working condition to repair or replace any product. Any 
replacement product will be warranted for the remainder of the 
original warranty period or thirty (30) days, whichever is longer 
or for any additional period of time that may be applicable in 
your jurisdiction.
This warranty does not cover problems or damage resulting 
from (1) accident, abuse, misapplication, or any unauthorized 
repair, modification or disassembly; (2) improper operation or 
maintenance, usage not in accordance with product 
instructions or connection to improper voltage supply; (3) use 
of cables or other equipment not supplied by Leap Motion; or 
(4) other causes that are not defects in material and 
workmanship except where such restriction is prohibited by 
applicable law. This warranty additionally does not cover 
products marked as “sample” or sold “AS IS”.
How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit 
the support section at www.leapmotion.com for technical 
assistance. Valid warranty claims are generally processed 
through the point of purchase during the first 30 days after 
purchase; however, this period of time may vary depending on 
where you purchased your product – please check with Leap 
Motion or the retailer where you purchased your product for 
details. Warranty claims that cannot be processed through the 
point of purchase and any other product related questions 
should be addressed directly to Leap Motion. The addresses 
and customer service contact information for Leap Motion can 
be found in the documentation accompanying your product 
and on the web at:  www.leapmotion.com/support
Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT, 
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES 
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE 
PRODUCT.  IN ADDITION, LEAP MOTION WILL NOT BE LIABLE 
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER 
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF 
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT 
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH  DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE 
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN 
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND 
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY 
OR IMPLIED.  Any recovery is limited to repair, replacement, or 
refund as described above.  Some jurisdictions do not allow the 
exclusion or limitation of special, indirect, incidental or 
consequential damages, so the above limitation or exclusion 
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE 
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS 
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH 
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION 
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES 
RESULTING FROM SUCH USE. 
Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP 
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY 
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY 
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED 
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS 
FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN 
DURATION TO THE DURATION OF THE WARRANTY PERIOD 
ABOVE. Some jurisdictions do not allow limitations on how 
long an implied warranty lasts, or do not allow exclusions or 
limitations on certain damages, including damages for death or 
personal injury caused by negligence, so the above limitation 
may not apply to you.  
National Statutory Rights
Consumers in some jurisdictions may have legal rights 
under applicable national legislation governing the sale of 
consumer goods. These rights are not affected by the 
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to 
make any modification, extension, or addition to this warranty.  
Your seller is solely responsible for any other warranties.
Service and Support
Your Leap Motion Controller does not contain any 
user-serviceable parts. If you need service, contact Leap Motion 
at one of the numbers below. Helpful information is also 
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges 
apply - please contact your telecom service provider for 
details).
The hours our customer support is available may be found at: 
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107 
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic
                            46-0006
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This Important Information Guide contains safety, handling, 
disposal, recycling and regulatory information, as well as the 
limited hardware warranty for your Leap Motion Controller.
Important Safety and Handling Information
High-risk activities 
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. 
Operating environment 
Operating your Leap Motion Controller outside these ranges 
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or 
where bright light sources or reflective surfaces (including 
exposed metal vents) are above the device, will impact 
performance. In order to improve performance, move to a less 
bright or reflective environment.
For best performance, maintain a clear field of view between 
your Leap Motion Controller and your hands and fingers. Loose 
sleeves, large or loose jewelry, and non-transparent objects or 
materials that are near the device, or between the device and 
your hands, or right above your hands, may impact 
performance. In addition, avoid wearing dark gloves, or using 
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may 
degrade the performance of your Leap Motion Controller.  
When cleaning the outside of the device, first unplug the cable. 
Then use a dry cloth to wipe the surface. Do not use 
detergents, abrasive cleaners or other cleaners, which may 
scratch the surface, and harm performance. Do not allow the 
device to become wet. 
Proper handling 
The surface of your Leap Motion Controller may become warm 
during normal use. The Leap Motion Controller complies with 
the user-accessible surface temperature limits defined by the 
International Standard for Safety of Information Technology 
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is 
comfortable to use.  Center your controller in front of your 
keyboard or laptop. Adjust your chair or work surface so that 
your elbows are near your side and your forearms are roughly 
parallel to the floor.  Your chair may need to be slightly higher 
or your work surface slightly lower than usual.
You should sit at such a height so that your forearms extend at 
roughly a right angle from your body to a position slightly 
above your Leap Motion Controller, with your wrist and hands 
in roughly a straight line. Your hands should be just above the 
device, and your shoulders should be relaxed. You can rest your 
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the 
controller again, change your arm posture. If you have 
persistent or recurrent discomfort after use, stop use and see a 
physician.
Disposal and Recycling Information
This symbol on the product (and on its packaging) is in 
accordance with the European Union's Waste Electrical and 
Electronic Equipment (WEEE) Directive. The symbol indicates 
that this product must be recycled/disposed of separately from 
other household waste. It is the end user’s responsibility to 
dispose of this product by taking it to a designated WEEE 
collection facility for the proper collection and recycling of the 
waste equipment. The separate collection and recycling of 
waste equipment will help to conserve natural resources and 
protect human health and the environment.  For more 
information about recycling, please contact your local 
environmental office, an electrical/electronic waste disposal 
company or the store where you purchased the product. 
Device Information
To get information about your Leap Motion Controller, use the 
“About” box in your Leap Motion software. It shows you what 
software is installed, the serial number, and more. 
Compliance
FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE 
USE.
This device complies with Part 15 of the FCC Rules. Operation is 
subject to the following two conditions: 1) this device may not 
cause harmful interference, and 2) this device must accept any 
interference received, including interference that may cause 
undesired operation. 
This equipment has been tested and found to comply with the 
limits for a Class B digital device, pursuant to part 15 of the FCC 
Rules. These limits are designed to provide reasonable 
protection against harmful interference in a residential 
installation. This equipment generates, uses and can radiate 
radio frequency energy. And, if not installed and used in 
accordance with the instructions, may cause harmful 
interference to radio communications. However, there is no 
guarantee that interference will not occur in a particular 
installation. If this equipment does cause harmful interference 
to radio or television reception, which can be determined by 
turning the equipment off and on, the user is encouraged to try 
to correct the interference by one or more of the following 
measures:
-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different 
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for 
help.
Warning: Where shielded interface cables or accessories have 
been provided with the product or specified additional 
components or accessories elsewhere defined to be used with 
the installation of the product, they must be used in order to 
ensure compliance with FCC limits. Changes or modifications to 
the product not expressly approved by Leap Motion, Inc. could 
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with 
Canadian ICES – 003. 
Déclaration IC: Cet appareil numérique de catégorie B est 
conforme à la norme canadienne NMB-003.
European Compliance Statement
A copy of the EU Declaration of Conformity is available at: 
www.leapmotion.com/legal
Read all safety information and operating instructions 
below before using your Leap Motion Controller to 
avoid injury. For user instructions for the Leap Motion 
Controller and the latest version of this Important 
Information Guide visit:  leapmotion.com/support
Software License Agreement
Use of the Leap Motion Controller constitutes acceptance of 
the Leap Motion and third-party software license terms found 
at:  www.leapmotion.com/legal
Leap Motion Hardware Limited Warranty
Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap 
Motion hardware product against material defects in materials 
and workmanship for a period of one year from the date of 
purchase (“Warranty Period”) by the original end user 
purchaser (“you”). Except where prohibited by applicable law, 
this warranty is nontransferable and is limited to the original 
purchaser. This warranty gives you specific legal rights, and you 
may also have other rights that vary under local laws.
Software distributed by Leap Motion with or without the Leap 
Motion brand name (including, but not limited to, the software 
that interacts with or that is pre-installed in the product) is not 
covered under this limited warranty. Refer to the licensing 
agreement accompanying the software for details of your 
rights with respect to its use. Leap Motion does not warrant 
that the operation of the product will be uninterrupted or 
error-free. Leap Motion is not responsible for damage arising 
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during 
the Warranty Period, Leap Motion will (at its option) (1) repair or 
replace the product, or (2) refund the price paid, provided that 
the product is returned to the point of purchase or such other 
place as Leap Motion may direct with a copy of the sales receipt 
or dated itemized receipt. Shipping and handling charges may 
apply except where prohibited by applicable law. Leap Motion 
may, at its option, use new or refurbished or used parts in good 
working condition to repair or replace any product. Any 
replacement product will be warranted for the remainder of the 
original warranty period or thirty (30) days, whichever is longer 
or for any additional period of time that may be applicable in 
your jurisdiction.
This warranty does not cover problems or damage resulting 
from (1) accident, abuse, misapplication, or any unauthorized 
repair, modification or disassembly; (2) improper operation or 
maintenance, usage not in accordance with product 
instructions or connection to improper voltage supply; (3) use 
of cables or other equipment not supplied by Leap Motion; or 
(4) other causes that are not defects in material and 
workmanship except where such restriction is prohibited by 
applicable law. This warranty additionally does not cover 
products marked as “sample” or sold “AS IS”.
How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit 
the support section at www.leapmotion.com for technical 
assistance. Valid warranty claims are generally processed 
through the point of purchase during the first 30 days after 
purchase; however, this period of time may vary depending on 
where you purchased your product – please check with Leap 
Motion or the retailer where you purchased your product for 
details. Warranty claims that cannot be processed through the 
point of purchase and any other product related questions 
should be addressed directly to Leap Motion. The addresses 
and customer service contact information for Leap Motion can 
be found in the documentation accompanying your product 
and on the web at:  www.leapmotion.com/support
Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT, 
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES 
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE 
PRODUCT.  IN ADDITION, LEAP MOTION WILL NOT BE LIABLE 
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER 
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF 
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT 
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH  DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE 
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN 
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND 
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY 
OR IMPLIED.  Any recovery is limited to repair, replacement, or 
refund as described above.  Some jurisdictions do not allow the 
exclusion or limitation of special, indirect, incidental or 
consequential damages, so the above limitation or exclusion 
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER 
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR 
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED 
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT 
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO 
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE 
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS 
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH 
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION 
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES 
RESULTING FROM SUCH USE. 
Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP 
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY 
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY 
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED 
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS 
FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN 
DURATION TO THE DURATION OF THE WARRANTY PERIOD 
ABOVE. Some jurisdictions do not allow limitations on how 
long an implied warranty lasts, or do not allow exclusions or 
limitations on certain damages, including damages for death or 
personal injury caused by negligence, so the above limitation 
may not apply to you.  
National Statutory Rights
Consumers in some jurisdictions may have legal rights 
under applicable national legislation governing the sale of 
consumer goods. These rights are not affected by the 
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to 
make any modification, extension, or addition to this warranty.  
Your seller is solely responsible for any other warranties.
Service and Support
Your Leap Motion Controller does not contain any 
user-serviceable parts. If you need service, contact Leap Motion 
at one of the numbers below. Helpful information is also 
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges 
apply - please contact your telecom service provider for 
details).
The hours our customer support is available may be found at: 
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107 
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic
                            46-0006
Leap Motion Controller
Important Information Guide
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2.b Tremorometer 510(k) Summary 
i 510k Summary 
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I3 Device Tracking Forms 
3.a Leap Motion  
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3.b Tremorometer 
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I4 Miscellaneous  
4.a Mini-Mental Status Exam 
 
 
 
 
 
Mini-Mental State Examination (MMSE)
Patient’s Name:                                                                                 Date:                          
Instructions: Score one point for each correct response within each question or activity.
Maximum
Score
Patient’s
Score
Questions
5 “What is the year?  Season?  Date?  Day?  Month?”
5 “Where are we now?  State?  County?  Town/city?  Hospital?  Floor?”
3
The examiner names three unrelated objects clearly and slowly, then
the instructor asks the patient to name all three of them. The patient’s
response is used for scoring. The examiner repeats them until patient
learns all of them, if possible.
5
“I would like you to count backward from 100 by sevens.” (93, 86, 79,
72, 65, …)
Alternative: “Spell WORLD backwards.” (D-L-R-O-W)
3 “Earlier I told you the names of three things.  Can you tell me what
those were?”
2 Show the patient two simple objects, such as a wristwatch and a pencil,
and ask the patient to name them.
1 “Repeat the phrase: ‘No ifs, ands, or buts.’”
3 “Take the paper in your right hand, fold it in half, and put it on the floor.”
(The examiner gives the patient a piece of blank paper.)
1 “Please read this and do what it says.” (Written instruction is “Close
your eyes.”)
1 “Make up and write a sentence about anything.” (This sentence must
contain a noun and a verb.)
1
“Please copy this picture.”  (The examiner gives the patient a blank
piece of paper and asks him/her to draw the symbol below.  All 10
angles must be present and two must intersect.)
30 TOTAL
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Interpretation of the MMSE:
Method Score Interpretation
Single Cutoff <24 Abnormal
Range
<21
>25
Increased odds of dementia
Decreased odds of dementia
Education
21
<23
<24
Abnormal for 8th grade education
Abnormal for high school education
Abnormal for college education
Severity
24-30
18-23
0-17
No cognitive impairment
Mild cognitive impairment
Severe cognitive impairment
Interpretation of MMSE Scores:
Score Degree of
Impairment
Formal Psychometric
Assessment
Day-to-Day Functioning
25-30 Questionably
significant
If clinical signs of cognitive impairment
are present, formal assessment of
cognition may be valuable.
May have clinically significant but mild
deficits.  Likely to affect only most
demanding activities of daily living.
20-25 Mild
Formal assessment may be helpful to
better determine pattern and extent of
deficits.
Significant effect.  May require some
supervision, support and assistance.
10-20 Moderate Formal assessment may be helpful if
there are specific clinical indications.
Clear impairment.  May require 24-hour
supervision.
0-10 Severe Patient not likely to be testable.
Marked impairment.  Likely to require
24-hour supervision and assistance
with ADL.
Source:
• Folstein MF, Folstein SE, McHugh PR: “Mini-mental state: A practical method for grading the cognitive
state of patients for the clinician.”  J Psychiatr Res 1975;12:189-198.
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